Edited Book Volume-1

"NEW APPROACHES IN BIOLOGICAL SCIENCES AND BIOTECHNOLOGY"

Dr. M. Thiruselvi
Dr. M. Santhoshkumar

ACTA CLASSIC
PUBLISHER

EDITED BOOK

"New Approaches in Biological Sciences and Biotechnology"

(ISBN : 978-81-966183-4-6)

Editors

Dr. M. THIRUSELVI

Professor
Department of Clinical Laboratory Technology
(Biochemistry)
Dr.N.G.PArts and Science College, Coimbatore
Tamil Nadu, Bharat

Dr. M. SANTHOSHKUMAR

Assistant Professor
Department of Biochemistry
Kongunadu Arts and Science College, Coimbatore

Tamil Nadu, Bharat

PREFACE

The landscape of biological sciences and biotechnology is in constant flux, driven by relentless curiosity, technological innovation, and an ever-deepening understanding of the intricate mechanisms governing life. This book**, "New Approaches in Biological Sciences and Biotechnology"** emerges from this dynamic environment, aiming to illuminate some of the most exciting and impactful advancements shaping these interconnected fields. It brings together fifteen carefully curated chapters, each authored by experts at the forefront of their respective disciplines, to offer a comprehensive yet insightful exploration of novel methodologies, groundbreaking discoveries, and their potential applications.

The impetus for this collection stems from the recognition that progress in biological sciences is increasingly intertwined with sophisticated biotechnological tools and strategies. From unravelling the complexities of the human genome to engineering novel biomolecules and developing sustainable bio-based solutions, the synergy between these domains is undeniable. This book endeavours to capture this synergy, showcasing how innovative approaches are pushing the boundaries of our knowledge and paving the way for transformative applications across diverse sectors, including medicine, agriculture, environmental science, and industrial processes.

The chapters within this volume delve into a range of cutting-edge topics. Readers will find explorations of advanced omics technologies and their role in personalized medicine, the revolutionary potential of gene editing and its ethical considerations, and the exciting developments in synthetic biology for creating novel biological systems. Furthermore, the book examines innovative approaches in drug discovery and delivery, the application of nanotechnology in biological systems, and the burgeoning field of microbiome research and its impact on health and disease. We also address critical areas such as sustainable biotechnology for environmental remediation and the development of bio-based materials, reflecting the growing importance of environmentally conscious innovation.

While each chapter provides a focused and in-depth analysis of a specific area, the collection underscores the interconnectedness of biological sciences and biotechnology. The methodologies and insights discussed often transcend individual disciplines, highlighting the power of interdisciplinary collaboration in addressing complex biological challenges. It is our hope that this book will serve as a valuable resource for researchers, students, and professionals seeking to understand the latest advancements and emerging trends in these rapidly evolving fields.

The journey of compiling this book has been one of intellectual stimulation and collaboration. We extend our sincere gratitude to all the contributing authors for their expertise, dedication, and willingness to share their cutting-edge work. Their insightful contributions form the core of this volume and reflect the vibrant spirit of

innovation within the biological sciences and biotechnology community. We also acknowledge the invaluable support of editors and chapters contributors.

It is our earnest expectation that **"New Approaches in Biological Sciences and Biotechnology"** will not only inform but also inspire further exploration and innovation in these vital fields. As we stand at the cusp of unprecedented biological and technological breakthroughs, we believe that this collection offers a timely and relevant overview of the exciting possibilities that lie ahead.

Editors

Dr. M. THIRUSELVI

Dr. M. SANTHOSHKUMAR

Published by

ACTA Classic Publisher

A.C.T Academy, Office: Suleeswaranpatti, Pollachi, Coimbatore- 642002

Cell:+916369453300

Email: actapublishergmail.com

Published in India in **2025 April**
International Standard Book Number (ISBN) : 978-81-966183-4-6

Title of the Edited Book:

"New Approaches in Biological Sciences and Biotechnology"

Price: Rs. 980/-

Edited Book Entitled

"NEW APPROACHES IN BIOLOGICAL SCIENCES AND BIOTECHNOLOGY"

INDEX

CHAPTER 1

IMMUNOTHERAPY: REVOLUTIONIZING CANCER TREATMENT

Dr.J.Antonia Auxi Marueen[1] and Ms.V.Genevia Fatima Mercy[2]
[1]*Assistant Professor, Department of Biotechnology, Bishop Heber College (Autonomous), Tiruchirapalli, Tamil Nadu.*
[2]*Research scholar, Department of Biochemistry, EGS Pillay Arts and Science College, Nagapattinam, Tamil Nadu.*
Email : antoniaauximarueen.bt@bhc.edu.in & mercyv1402@gmail.com

ABSTRACT

This chapter provides a comprehensive overview of cancer, from its fundamental definition and classification into carcinomas, sarcomas, leukemias, and lymphomas, to its diverse signs, symptoms, and probable causes encompassing genetic mutations, lifestyle factors, infections, radiation exposure, and carcinogens. It emphasizes the importance of prevention through lifestyle modifications, vaccinations, and regular screenings for early detection. The chapter then delves into various established cancer treatments, including surgery, chemotherapy, radiotherapy, immunotherapy, hormone therapy, and targeted therapy, alongside other techniques like stem cell transplant, photodynamic therapy, cryotherapy, and precision medicine. A significant portion is dedicated to promising bioactive glass treatments, highlighting their application in hyperthermia therapy, magnetic hyperthermia, brachytherapy, and targeted drug delivery using mesoporous structures. Furthermore, the chapter extensively explores the burgeoning field of cancer immunotherapy, detailing immune checkpoint blockade, oncolytic viral therapy, adoptive cell therapy (CAR-T and TCR), and tumor-infiltrating lymphocyte therapy. Finally, it examines antibody-based targeted therapies, including their mechanisms of action, the use of whole antibodies and fragments, immunoconjugates, and the crucial role of clinical trials in advancing these innovative treatments, culminating in a brief discussion of radioimmunotherapy

1. Introduction

1.1 Definition

Cancer is a general name for more than 100 diseases in which cells begin to grow out of control and form malignant tumors. In a healthy body, the various cells grow, divide, and die in an orderly fashion according to a programmed cell death process. However, changes in genes or exposure to certain environmental substances can lead cells astray down wayward paths, allowing them to grow uncontrollably and form tumors. Tumors can be classified as benign tumors or malignant

(cancerous) ones, with the malignant tumors capable of invading surrounding tissues and metastasizing away through circulatory or lymphatic routes.

1.2 Cancers

Cancers are classified according to the specific type of cell that gives rise to them. The four main classification of cancer are:

a) Carcinoma

Carcinomas occur in epithelial cells which cover the surfaces of the body inside and out. These are the most common cancers and include breast cancer, lung cancer, prostate cancer, and colorectal cancer. Carcinomas may be split further into adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

b) Sarcoma

Sarcomas originate in connective tissues, including bone, muscle, fat, blood vessels, and cartilage. They are much less common than carcinomas but frequently more aggressive. Osteosarcoma (bone cancer) and liposarcoma (cancer of fat tissue) are examples.

c) Leukemia

Leukemias are cancers of the blood, which arise in the bone marrow where blood cells are manufactured. Leukemia is marked by abnormal production of large numbers of abnormal white cells in blood, stopping the body from being able to fight off infections. The four common forms of leukemia are acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).

d) Lymphoma

Lymphoma, a cancer of the lymphatic system, a primary component of immune function and control fluid, accounts for around 5% f deaths arising from this type (Lin *et al*., 2019). There are two broad types -Hodgkin lymphoma and non-Hodgkin lymphoma. Both of these cancers begin in lymphocytes, a type of white blood cell, and might spread to other parts within the lymphatic system.

1.3 Signs and Symptoms

The symptoms and signs of cancer differ because it depends on what kind it is, where it is located and its stage. Here are common representations:

- Unexplained, unintentional loss of weight
- Continued tiredness

• Localized ache in one area

• Change in appearance of skin, such as additional jaundice or new dark spots

• Strangely-personal hematomas or bleeding

• Continuous cough or hoarseness

• Difficulty swallowing food

• Swelling or a lump in parts of the body.

1.4 Probable Causes

The start of cancer is influenced by both genetics and the environment. Main culprits are:

• Genetic Mutations: Both inherited and acquired mutations within DNA hold the potential to induce cancer-growth.

• Lifestyle Factors: Smoking, chronic alcohol use and diet make the body susceptible to cancer.

• Infections: Some viruses like human papillomavirus (HPV) and hepatitis B/C have been implicated in causing certain specific cancers.

• Radiation Exposure: damage to your DNA can occur through UV light produced by sunlight and ionizing rays employed during medical procedures.

• Carcinogens: exposure to toxic chemicals such as asbestos and benzene could foster growth of cancer.

1.5 Prevention

While it is not possible to avoid all forms of cancer adopting a healthy lifestyle can reduce the chances of illness in many cases. Effective preventive strategies include:
• Avoiding Tobacco: Not smoking reduces risk of lung, throat and bladder cancers.
• Healthful Diet: Eating a variety of fruits, vegetables, and whole grains while limiting processed food contributes to well-being.

• A person who regularly exercises is liable to be neither underweight nor overweight; also they will keep their hormones regular and not become obese--a prerequisite for lung cancer for example!
• Wear Sunscreen When Outdoors: Minimizing one`s time in the light of the sun is beneficial for preventing skin cancer.
• Protection Against Hepatitis and Papilloma Virus Infection: Use of vaccination techniques can help guard against two forms of cancer in the liver (hepatocellular carcinoma) and cervical cancer respectively.

• Screening on a Regular Basis: "The benefit of early diagnosis is clearly shown in our results," said Lin *et al*., 2019, who showed that when cancer is detected at its earliest stage survival rates are greatly increased.

2. How to Destroy Cancer (Treatments)

Cancer treatments vary based on the type, stage, and health of the patient. Following are some of the main forms of cancer treatment:

2.1 Surgery

In surgical procedures, a tumor and surrounding tissues are removed to prevent the spread of cancer. This is usually used for localized cancer and can cure the patient if the tumor is removed in its entirety. Sometimes it involves removing additional lymph nodes to determine if the cancer has spread.

2.2 Chemotherapy

Chemotherapy uses cytotoxic drugs that kill rapidly growing and dividing cancer cells. It works well for metastatic cancer and is frequently used in combination with other treatments. Common side effects are nausea, fatigue, and hair loss because of its effect on normal dividing cells.

2.3 Radiotherapy

Radiotherapy utilizes high-energy radiation to destroy cancer cells or reduce the size of tumors. It can be given from the outside (external beam radiation) or placed inside (brachytherapy). It is best employed for localized tumors and can be used prior to or following surgery to improve results.

2.4 Immunotherapy

Immunotherapy uses the body's immune system against the cancer, through activation and identification of cancer cells and destruction. This may involve checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies. It has displayed efficacy in treating cancers like melanoma and some lung cancers.

2.5 Hormone Therapy

Hormone therapy is used for hormone-sensitive cancers, like breast and prostate cancer. It does this by either lowering the production of a certain hormone or preventing hormones from binding to cancer cells, which reduces their rate of growth.

2.6 Targeted Therapy

Targeted therapy refers to drugs that target specific molecular changes that occur in cancer cells to inhibit their growth, while having less effect on normal cells. Such as certain kinase inhibitors and monoclonal antibodies, commonly used in precision medicine.

2.7 Other Procedures and Techniques

• Stem Cell Transplant: Mostly employed for blood-related cancers such as leukemia and lymphoma, this entails taking resilient stem cells and putting them into compromised bone marrow.

• Photodynamic Therapy: This treatment uses drugs that become toxic to cancerous cells when activated by a focused beam of light.

• Cryotherapy: In this process abnormal cancerous tissue is frozen and destroyed.

• Precision Medicine: In this method, treatments are personalized based on genetic profiles, allowing for more effective therapy.

3. Promising Bioactive Glass Treatments for Cancer

(BGs), a type of biocompatible material that promotes interactions with biological tissues, has attracted much interest in cancer treatment because of its significant therapeutic advantages, for example, controlled release of therapeutic ions and enhanced drug delivery. Recently, the application of bioactive glasses has shifted towards hyperthermia therapy, encapsulation in magnetic bioactive glasses, combined brachytherapy, and targeted tumor therapy.

3.1 Hyperthermia Therapy for Cancer Treatment

One such novel modality, hyperthermia therapy, in which neoplastic cells are subjected to a temperature increase (usually in the 40–45 °C range) leading to apoptosis with limited toxicity to surrounding healthy cells. Because of their good thermal stability, controllable ion release, and ability to strengthen the heat generation effect at a local site by combining with nanoparticles, bioactive glasses have been used in thermal therapies (Lin *et al.*, 2019). According to previous reports, in particular bioactive glass composites were utilized as NIR light-activated heat-generating agents. The localized heating may cause cellular damage, protein denaturation, and cancer cell metabolic disturbance, which ultimately can potentially improve the efficiency of chemotherapy or radiotherapy.

Table 1: Key Benefits of Hyperthermia Therapy Using Bioactive Glass

Feature	Benefit
Localized heating	Minimizes damage to healthy cells
Synergy with chemo/radiotherapy	Enhances treatment efficacy
Non-invasive	Reduces surgical interventions
Controlled thermal response	Prevents excessive tissue damage

3.2 Magnetic Bioactive Glasses for Hyperthermia Treatment

Magnetic bioactive glasses (MBGs) are a unique bioactive glass type that embeds superparamagnetic iron oxide nanoparticles (SPIONs) or metal oxides (e.g., Fe3O4, MnO, CoFe2O4) to enable magnetically induced hyperthermia therapy. The glasses produce heat that has high specificity for tumor sites when subjected to an alternating magnetic field (AMF) (Lin *et al*., 2019). Mechanism of Action:

1. Localized heating is activated under electromagnetic field exposure.
2. Heat stress induces apoptosis or necrosis in cancer cells.
3. Therapeutic agents in bioactive glass carriers for improved drug delivery. MBGs can be tailored to possess controllable heating behavior, making them suitable candidates for treating brain tumor, prostate cancer, and bone metastasis.

3.3 Bioactive Glass Used in Brachytherapy

Brachytherapy with Bioactive Glass Brachytherapy is a form of internal radiation therapy: radioactive sources are placed externally, or within or close to the tumor. Bioactive glass microspheres act as radiation carriers, allowing precise delivery of radiation therapy while mitigating systemic side effects.

Benefits of Bioactive Glass in Brachytherapy:

- Biodegradable: No need for surgical removal.
- Radiation released in a controlled manner: Continous treatment.
- Fewer side effects: Less exposure to surrounding healthy tissues.

Therapeutic radionuclides (i.e. Yttrium-90, Samarium-153) can be incorporated into some structural formulations of bioactive glasses; upon implantation, they release their radiation at a slow rate, making them a suitable candidate for use in therapy targeting liver cancer, prostate cancer, and bone metastases.

3.4 Mesoporous Bioactive Glasses for Targeted Tumor Therapy

Mesoporous bioactive glasses (MBGs) are a new type of bioactive material with high surface area, tunable porosity and metered drug delivery. MBGs have been studied as drug carriers for the targeted delivery of chemotherapeutic drugs, siRNA, and photothermal agents.

Potential Mechanisms by Which MBGs Improve Targeted Therapy:

1. High surface area design leads to a greater drug loading capacity

2. pH, Temperature and Enzyme Sensitive Drug Release

3. Less toxic than traditional drug carriers MBGs have succeeded in treating bone cancers, glioblastomas, and breast cancer, enhancing the bioavailability of anticancer agents like doxorubicin, paclitaxel, and cisplatin.

4. Cancer Immunotherapy

Cancer Immunotherapy Cancer immunotherapy is a more advanced treatment approach that employs the body's immune system to detect, pinpoint, and destroy cancer cells. Immunotherapy, unlike standard cancer therapies such as chemotherapy and radiotherapy, acts either directly or indirectly to engage or modulate immune responses to eliminate malignant cells with relative sparing of normal tissue Some of these mechanisms include immune checkpoint blockade, oncolytic viral therapy, adoptive cell transfer, and tumor-infiltrating lymphocytes (TILs).

4.1 Blockade of Immune Checkpoints

Differently, the immune system controls its response to damage by checkpoint proteins that prevent products from the immune system that could be harmful to normal tissues. Cancer cells co-opt these checkpoints to become invisible to the immune system. The clinical strategy of checkpoint blockade therapy utilizes monoclonal antibodies against inhibitory receptors, such as CTLA-4, PD-1, and PD-L1, that act by removing the brakes from the immune response so that T cells can effectively destroy cancer cells.

Key Immune Checkpoints Targeted in Cancer Therapy

Checkpoint	Targeted by	Effect

CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4)	Ipilimumab	Enhances T cell activation and proliferation
PD-1 (Programmed Death-1)	Nivolumab, Pembrolizumab	Prevents T cell exhaustion, enhances tumor destruction
PD-L1 (Programmed Death-Ligand 1)	Atezolizumab, Durvalumab	Blocks immune suppression by tumor cells

Checkpoint inhibitors work extremely well for melanoma, lung and bladder cancers but can result in immune-mediated damage to normal tissues in some patients.

4.2 Oncolytic Viral Therapy

Oncolytic viral therapy uses viruses that are genetically engineered to preferentially infect and kill tumor cells, preserving normal tissues. The viruses multiply inside tumor cells, kill them, and elicit an immune response against the tumor

An example of a virus that has been modified for therapeutic purposes is Talimogene laherparepvec(T-VEC), a modified form of Herpes Simplex Virus (HSV- 1) for the treatment of melanoma.

The virus has been genetically modified to:

1. Only replicate in cancer cells,
2. Trigger an inflammatory immune response, and
3. Produce immune-stimulating factors like GM-CSF for T cell stimulation.

Oncolytic viruses are also being studied as possible treatments for glioblastomas, breast cancer and pancreatic cancer. Nevertheless, successful viral delivery and immune evasion remains under investigation.

4.3 Adoptive Cell Therapy (ACT)

In adoptive cell therapy, immune cells from a patient are collected, altered and returned to the patient to enable more efficient targeting of tumors. The two common types of ACT are Chimeric Antigen Receptor T-cell (CAR-T) therapy and T-cell receptor (TCR) therapy.

Types of Adoptive Cell Therapy

Therapy Mechanism Application

CAR-T Cell Therapy

T cells which are engineered to express chimeric antigen receptors as a means to detect tumor antigens

TCR Therapy

TCR Therapy Enhances T cell recognition of tumor-associated antigens Used in solid tumors, e.g., sarcomas, melanoma The use of CAR-T cell therapy for B-cell malignancies has shown tremendous success; however, its use in solid tumors faces challenges imposed by the tumor microenvironment as well as off-target toxicities.

4.4 Tumor-Infiltrating Lymphocyte (TIL) Therapy

Tumor-infiltrating lymphocyte (TIL) therapy is a type of ACT utilizing T cells that trawl naturally in a patient's tumor. These T cells are isolated, cultured in the laboratory with interleukin-2 (IL-2), and reinfused to augment the anti-tumor response. TIL Therapy:

How it works?

1. Isolate TILs by performing a tumor biopsy.
2. Expand them in vitro with cytokines like IL-2.
3. Infuse the activated T cells back into the patient. TIL therapy is being explored in the treatment of melanoma, cervical cancer and most recently in lung, bladder and colorectal cancers.

5. Targeted Therapy Based on Antibodies

Antibody-targeted therapy is a type of targeted cancer therapy that utilizes monoclonal antibodies (mAbs) to recognize and destroy specific molecules found on cancer cells, sparing normal cells as much as possible. This approach is much more accurate and efficient compared to normal chemotherapy to eliminate tissues that are both healthy and diseased. Antibodies can work through immune-mediated effects (e.g., ADCC, CDC), targeting mechanisms and can also be used as a vehicle of cytotoxic agents.

5.1 The Mechanism of Antibody-Based Targeted Therapy

Monoclonal antibodies (mAbs) are designed to recognize specific antigens on cancer cells, binding to their targets to activate several therapeutic mechanisms:

Mechanisms of Action

Mechanism	Description	Example

Blocking growth signals	Prevents cancer cell proliferation by inhibiting receptors	Trastuzumab (Herceptin) for HER2+ breast cancer
Inducing apoptosis	Antibodies trigger programmed cell death	Rituximab (anti-CD20) for B-cell lymphomas
Enhancing immune response	Activates immune cells to destroy tumors	Cetuximab (anti-EGFR) for colorectal cancer
Delivering cytotoxic drugs	Conjugated antibodies carry toxins to cancer cells	Brentuximab vedotin for Hodgkin's lymphoma

These can selectively eradicate tumor cells with lowered systemic exposure in comparison with traditional chemotherapy.

5.2 Whole Antibody or Antibody Fragments

Full-length or fragmented therapeutic antibodies are utilized based on desired therapeutic objectives and desired mechanism of action.

Types of Antibody Structures Used in Therapy

Antibody Type	**Structure**	**Function**
Whole monoclonal antibodies (mAbs)	Full IgG structure	Targets specific antigens and induces immune response
Fab fragments	Antigen-binding domain only	Blocks receptor signaling without immune activation
Single-chain variable fragment (scFv)	Small engineered antibody segment	Enhances tumor penetration for imaging and therapy
Bispecific antibodies	Two antigen-binding sites	Simultaneously targets cancer and immune cells for enhanced response

For instance, BsAbs have shown great promise in cancers such as acute lymphoblastic leukemia (ALL), in which the BsAb binds toward both CD19 (tumor target), as well as CD3 on T cells to improve immune response.

5.3 Immunoconjugates and Unconjugated Antibody

Antibody-based therapies can be grouped as either unconjugated (naked) antibodies or immunoconjugates bearing additional therapeutic components.

Types of Antibody-Based Therapies

Type	Description	Example
Unconjugated mAbs	Work by blocking receptors or triggering immune response	Rituximab (anti-CD20) for lymphoma
Antibody-drug conjugates (ADCs)	Deliver cytotoxic drugs directly to cancer cells	Ado-trastuzumab emtansine (Kadcyla) for HER2+ breast cancer
Radioimmunotherapy	Carries radioactive isotopes for targeted radiation	Ibritumomab tiuxetan (Zevalin) for non-Hodgkin lymphoma
Immunotoxins	Fused to bacterial or plant toxins for direct tumor killing	Denileukin diftitox (Ontak) for T-cell lymphomas

Five ADCs have recently been developed, including Brentuximab vedotin, which have revolutionized the treatment of lymphoma, demonstrating better outcomes with less toxicity than cytotoxic chemotherapies.

5.4 Clinical Examinations

Clinical trials are integral to assessing the efficacy, safety, and optimal dosing of antibody-based therapeutics. These trials occur in a phased approach:

Phases of Clinical Trials for Antibody Therapies

Phase	Purpose	Example
Phase I	Evaluates safety and dosage	First-in-human studies of bispecific antibodies
Phase II	Tests effectiveness in specific cancers	Expansion studies for checkpoint inhibitors
Phase III	Compares new therapy with standard treatments	Trastuzumab vs chemotherapy for breast cancer
Phase IV	Post-marketing surveillance for long-term effects	Ongoing monitoring of rituximab

Recent Advances in Clinical Trials

• CAR-T cell therapy with bispecific antibodies appears promising in blood cancers (Darvishi *et al*., 2023).

• Biomarker-driven therapy selection enables personalized antibody treatment (Dash *et al*., 2024). Based on the principles of the genetic revolution that broke the code for the human genome, targeted therapy using antibodies has revolutionized cancer treatment, improving precision, survival, and side effect profiles compared to conventional chemotherapy.

6. Radio Immunotherapy (RIT)

Radio Immunotherapy (RIT) RFIT combines radiation therapy with immunotherapy to destroy cancer cells using radiolabelled monoclonal antibodies (mAbs). This strategy allows for greater selectivity towards tumor tissues versus normal tissues, which might benefit the treatment not only of haematological cancers but also solid tumors.

6.1 Radiotherapy

Radiotherapy utilizes ionizing radiation to induce cancer cell death. This mechanism destroys the cancer cell through DNA damage and disruption of cell organelles, leading to apoptosis or necrosis. The type of radiotherapy is external beam radiation therapy (EBRT) or internal radiation therapy (brachytherapy)

Advantages of Radiotherapy

• Localized therapy: Spare normal tissues while killing tumor cells.

• Combination potential: Commonly used in combination with chemotherapy or immunotherapy.

• Palliative use: Aids in symptom relief in advanced malignancy.

6.2 Radioimmune Therapy

Radioimmune therapy (RIT) is a powerful technique that uses radiolabelled monoclonal antibodies to deliver targeted radiation to tumors. The most used approach for RIT includes antibodies labeled with radioisotopes including Yttrium-90 or Iodine-13.

Examples of FDA-Approved RIT Drugs

Drug	**Target Antigen**	**Indication**
Zevalin (Ibritumomab tiuxetan)	CD20	Non-Hodgkin's lymphoma
Bexxar (Tositumomab)	CD20	Follicular lymphoma

6.3 Preclinical and Clinical Studies of RIT in Cancer Treatment

clinical trials are designed to improve efficacy and minimize scarring. Studies indicate high response rates in B-cell lymphoma, and other studies are ongoing in solid tumors like breast and prostate cancer.

7. Chemoimmunotherapy

Chemoimmunotherapy is where the immunotherapy boosts the immune response, and chemotherapy directly targets cancer cells. Compared to either treatment used alone, this strategy results in improved patient survival and a lower risk of resistance.

7.1 Chemotherapy

Chemotherapy employs cytotoxic drugs that target rapidly dividing cells. Although it is effective, it has considerable toxicity and side effects such as immune suppression, nausea, and organ damage.

7.2 Chemoimmunotherapy

Chemoimmunotherapy augments tumor antigen presentation and lysates T-cell activation by co-administrating chemotherapy with immune checkpoint inhibitors (ICIs) or monoclonal antibodies.

Examples of Chemoimmunotherapy Combinations

Combination	Mechanism	Indication
Pembrolizumab + Chemotherapy	PD-1 blockade + cytotoxicity	Non-small cell lung cancer
Nivolumab + Ipilimumab + Chemo	Dual checkpoint blockade + chemotherapy	Melanoma, lung cancer

7.3 Clinical Evaluation of Chemoimmunotherapy

Clinical studies have demonstrated that patients treated with combination therapy have improved survival compared with those treated with chemotherapy alone. Major trials were the KEYNOTE-189 and CheckMate-9LA trials.

8. Cancer Immunizations

Cancer immunizations are a type of immunotherapy which targets the activation of the immune system to identify and attack cancer cells. In contrast to preventive vaccines, which confer

protection against disease, cancer-immunizations can be therapeutic with the aim of causing existing tumours to be eliminated and preventing their re-formation. Cancer vaccines are sitting under our noses under the guise of exposing the immune system to tumor antigens generating a targeted immune response designed to hunt down and eradicate cancer at the same time sparing healthy tissue.

8.1 Primary Methods in Developing Cancer Vaccines

Development Various strategies are at play upon the development of the cancer vaccines, particularly tailor-made to face various cancers as well as the various requirements of the patients.

Key Strategies in Cancer Vaccine Development:

Vaccine Type	Mechanism	Example
Peptide-based vaccines	Uses short tumor-derived peptide sequences to trigger immune response	Melanoma peptide vaccine
DNA/mRNA vaccines	Encodes tumor antigens using nucleic acids, leading to antigen expression	mRNA-4157 (moderna cancer vaccine)
Whole tumor cell vaccines	Uses inactivated cancer cells to stimulate immunity	GVAX (for pancreatic cancer)
Dendritic cell vaccines	Exposes dendritic cells to tumor antigens, then reinfuses into patients	Sipuleucel-T (Provenge, for prostate cancer)

To improve efficiency, cancer vaccines are usually co-administered with immune checkpoint inhibitors (ICIs), adjuvants, or cytokines.

8.2 DNA/mRNA Vaccines

DNA and mRNA vaccines tell the body's cells to make tumor-specific antigens and stimulate an immune reaction.

• DNA Vaccines: Plasmid DNA is utilized to deliver tumor antigens, generating a durable immune response.

• mRNA vaccines generate a faster, more controlled immune response, and are easier to tweak.

Pros and Cons of DNA/mRNA Vaccines:

• Quick to develop: Can be easily modified to target new variants.

• Safe & Non-infectious - It has no live particles, thus reducing risk.

• High immune activation: Activates both T-cells and B-cells

For example, two companies, Moderna and BioNTech, are working on personalized mRNA cancer vaccines, with clinical trials indicating that melanoma patients have higher survival rates following their use year-book.

8.3 Tumor Cell Vaccines

Tumor cell vaccines use whole tumor cells (live-attenuated or inactivated) to build an immune response.

• Autologous vaccines are made from a patient's own tumor cells.

• Allogeneic vaccines utilize tumor cells derived from other patients.

Example:GVAX
• A genetically modified pancreatic cancer vaccine that produces GM-CSF and induces a potent immune response.

8.4 Viral Vaccines

These vaccines rely on the introduction of tumor antigens into the organism using modified viruses.

• Oncolytic viruses (e.g., T-VEC) are designed to not only selectively replicate inside tumors, leading to tumor cell death, but also to activate the immune system.

• Recombinant viral vaccines — for example, adenovirus or lentivirus-based vaccines that express genetic material for the production of the antigen.

Example:PROSTVAC
• Poxvirus-based vaccine for prostate cancer applied in clinical trials for advanced prostate cancer

8.5 Biomaterials in Delivery and Targeting

This is achieved by the use of nanotechnology and biomaterials to improve the delivery of cancer vaccines by:

•Stabilizing antigens.
• Enhancing cellular uptake.

•Continuous release of immune stimulants.

Example:
This is because mRNA in mRNA vaccines is encapsulated in lipid nanoparticles (LNPs), which serve two purposes: to protect mRNA molecules from degradation and to facilitate their uptake .

8.6 Case Study:

Sipuleucel-T (Provenge)

Indication: Prostate cancer

Mechanism: Employs dendritic cells that have been exposed to prostate-specific antigen (PSA) to enhance T-cell activity.

Result: Patients who received Provenge had a 4.1 month overall survival benefit over standard therapies.

8.7 Future Perspectives

- Neoantigen-based personalized cancer vaccines
- The extension of mRNA vaccines from melanoma to lung, colorectal and pancreatic cancer
- Combination therapies with immune checkpoint inhibitors to increase effectiveness

9. Nonspecific Immunotherapy

Nonspecific immunotherapy is known as a type of therapy that enhances the general reactivity of the immune system instead of acting on unique tumor antigens. These therapies stimulate immune cell functions, provoke inflammation, and refine immune surveillance, thus improving the ability of the body to recognize and kill cancer cells. They mainly consist of cytokine therapy and immune checkpoint inhibitors (ICIs).

9.1 Cytokines in Nonspecific Immunotherapy

Cytokine Involvement in Cancer Therapy

Cytokines − proteins that control immune and inflammatory responses. They are responsible for increasing the number and activation of immune cells that aid in tumor ablation in response to cancer therapy. Certain cytokines are pro-inflammatory, while other cytokines play a role in immune restraint to prevent an overreaction.

Key Cytokines Used in Cancer Therapy

Cytokine	Function	Clinical Application

Interleukin-2 (IL-2)	Activates T cells and natural killer (NK) cells	Used in metastatic melanoma and renal cell carcinoma (e.g., Aldesleukin)
Interferon-alpha (IFN-α)	Enhances antigen presentation and immune response	Approved for leukemia, melanoma, and kidney cancer
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)	Stimulates macrophages and dendritic cells	Used in prostate cancer vaccines (e.g., Sipuleucel-T)
Tumor Necrosis Factor-alpha (TNF-α)	Induces apoptosis in tumor cells	Investigated in solid tumors

Cytokine therapy, use alone or in conjunction with other treatments (e.g., chemotherapy and immune checkpoint inhibitors) to increase anti-tumor activity.

9.2 Immune Checkpoint Inhibitors (ICIs)

What Are Immune Checkpoints?

Checkpoints are a natural part of the immune system that help limit excessive immune responses and prevent damage to normal cells. Cancer cells, however, commandeer these pathways to evade immune surveillance. Immune checkpoint inhibitors (ICIs) prevent these suppressive signals, enabling the immune system to identify and eradicate tumors.

Main Immune Checkpoint Targets and Approved Therapies

Checkpoint	**Function**	**Checkpoint Inhibitor Drug**	**Cancer Indications**
PD-1 (Programmed Death-1)	Suppresses T-cell activation	Pembrolizumab (Keytruda), Nivolumab (Opdivo)	Lung cancer, melanoma, Hodgkin lymphoma
PD-L1 (Programmed Death-Ligand 1)	Binds to PD-1, blocking immune attack	Atezolizumab (Tecentriq), Durvalumab (Imfinzi)	Bladder cancer, lung cancer
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4)	Inhibits early T-cell activation	Ipilimumab (Yervoy)	Melanoma, kidney cancer

Mechanism of Action of ICIs

1. Normal immune response: [] The T-cells identify the cancer cells and get ready to respond.

2. Immune evasion by tumors: – Tumor cells will over-express PD-L1, which binds to PD-1 on T-cells, leading to T-cell exhaustion.

3. Checkpoint blockade therapy:

- T-cell activity is restored by anti-PD-1 and anti-PD-L1 therapies and they are able to target and destroy tumors.

ICIs Combination Therapies

In order to establish a better outcome among patients, ICIs can be used in conjunction with chemotherapy, radiation therapy, or targeted approaches. For example:

- Chemo with PD-1 inhibitors in lung cancer (KEYNOTE-189 trial).
- CTLA-4 inhibitors combined with PD-1 inhibitors in melanoma (CheckMate-067 trial).

Directions Ahead

- Choosing patients for ICIs with the best benefit with biomarkers – Researching second-generation checkpoint inhibitors against LAG-3, TIM-3, and TIGIT
- Accelerate response with personalized cancer vaccines.

10. Challenges and Perspectives

Cancer Immunotherapy has already shown huge advancements in the previous few years, making this therapy the most popular for long-term remission and better survival in a wide range of cancers. However, significant barriers remain that restrict its use for every patient. Comprehending these obstacles and future prospects of cancer immunotherapy is critical for improving treatment and extending its availability.

10.1 Challenges in Cancer Immunotherapy

Although immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are effective, several issue limits the clinical applications of them.

Key Challenges in Immunotherapy:

Challenge	Description	Implications

Tumor Resistance to Immunotherapy	Some tumors develop adaptive resistance by downregulating PD-L1 or recruiting immunosuppressive cells.	Reduces effectiveness of immune checkpoint inhibitors.
Immune-Related Toxicities	Uncontrolled immune activation leads to autoimmune-like side effects (colitis, hepatitis, myocarditis).	Requires immunosuppressive therapy, which can reduce treatment efficacy.
High Cost of Treatment	CAR-T therapy and immune checkpoint inhibitors are expensive, making them inaccessible to many patients.	Limits global availability and affordability.
Heterogeneity in Patient Response	Some patients fail to respond due to differences in tumor genetics and immune environment.	Necessitates biomarker-based patient selection.
Limited Efficacy in Solid Tumors	Solid tumors have dense stroma, immunosuppressive microenvironment, and poor T-cell infiltration.	Reduces effectiveness of CAR-T and checkpoint inhibitors.

Tackling These Issues:

• Individualized immunotherapy: Identifying the patients who are likely to benefit the most from a treatment using biomarkers.

• Combination therapies: Implementing a strategy for combining checkpoint inhibitors with chemotherapy or CAR-T with oncolytic viruses to increase immune stimulation.

• Improved CAR-T cells: Modification of T-cells to overcome immune suppression for improving CAR-T therapy in solid tumors

• Decreasing toxicity: Creation of less toxic immune checkpoint inhibitors and using immune-modulating agents to prevent autoimmune side effects.

10.2 Perspectives: Future Directions in Cancer Immunotherapy

The future of immunotherapy lies in overcoming resistance mechanisms, expanding to new cancer types, and improving safety and efficacy.

Emerging Innovations in Immunotherapy:

Future Approach	**Potential Impact**

Neoantigen-Based Personalized Vaccines	Custom vaccines tailored to an individual's tumor mutations for precise immune activation.
TCR-T Cell Therapy	Targets intracellular tumor antigens, expanding immunotherapy beyond CAR-T cells.
Next-Generation Checkpoint Inhibitors (LAG-3, TIM-3, TIGIT)	New ICIs that target additional immune evasion pathways for improved response rates.
Oncolytic Virus Therapy	Viruses engineered to infect and destroy cancer cells while boosting immune response.
Artificial Intelligence (AI) in Immunotherapy	AI-driven biomarker discovery and treatment response prediction for personalized therapy.

With ongoing research and clinical trials, next-generation immunotherapies hold promise in making cancer a manageable or even curable disease.

11. Conclusion

One major breakthrough has come in the form of cancer immunotherapy, which has the ability to provide long-lasting remission and better overall survival for a variety of different cancers. For example, checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and monoclonal antibodies have shown phenomenal effectiveness, especially in blood cancers and melanoma.

Key Takeaways:

• Checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 inhibitors) have led to prolonged survival for patients with melanoma, lung cancer, and bladder cancer.

• CAR-T cell therapy demonstrates high rates of success with B-cell lymphomas and leukemia, whereas the tumoral efficacy against solid tumors is currently low.

• Cancer vaccines, as well as oncolytic viruses, represent promising future therapeutic strategies, particularly in conjunction with other immunotherapeutic approaches.

Future Challenges and Projections

• Tumor resistance, adverse effects and cost: big hurdles.

• Future of personalized cancer care: Next-generation treatments like neoantigen-based vaccines, TCR-T therapy, and AI-driven immunotherapy

• As the field continues to develop, immunotherapy might be able to convert cancer from a lethal disease to a treatable, chronic disease.

REFERENCES

1. Beaulieu, E., Spanjaart, A., Roes, A., Rachet, B., Dalle, S., Kersten, M. J., & Maucort-Boulch, D. (2022). Health-related quality of life in cancer immunotherapy: A systematic perspective, using causal loop diagrams. *Quality of Life Research, 31*(12), 2357–2366. https://doi.org/10.1007/s11136-022-03110-5
2. Darvishi, M., Tosan, F., Nakhaei, P., Manjili, D. A., Kharkouei, S. A., Alizadeh, A., Ilkhani, S., Khalafi, F., & Zadeh, F. A. (2023). Recent progress in cancer immunotherapy: Overview of current status and challenges. *Pathology - Research and Practice, 241*, 154241. https://doi.org/10.1016/j.prp.2022.154241
3. Dash, A. K., Medi, B., Sarrami, B., Hasanzad, M., Singh, S., & Shukla, S. (2024). *Emerging therapeutics and delivery*. Elsevier.
4. Lin, Y., Mauro, J. C., & Kaur, G. (2019). Bioactive glasses for cancer therapy. In *Biomedical, Therapeutic and Clinical Applications of Bioactive Glasses* (pp. 273-300). Elsevier.
5. Moharramnejad, M., Sayah, T., Ghehsareh, Z., Rezaei, M. M., Karimi, F., Amini, A. H., Malekshah, R. E., Shahi, M., Mirtamizdoust, B., & Ehsani, A. (2024). Novel progress of covalent organic frameworks in biomedicine approaches: From synthesis to cutting-edge therapeutics. *Journal of Drug Delivery Science and Technology, 102*, 106320. https://doi.org/10.1016/j.jddst.2024.106320
6. Kotzur, R., Stein, N., Kahlon, S., Berhani, O., Isaacson, B., & Mandelboim, O. (2023). Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST. *iScience, 26*, 107284. https://doi.org/10.1016/j.isci.2023.107284
7. Medi, B., Sarrami, B., Hasanzad, M., Singh, S., & Shukla, S. (2024). Next-generation immunotherapies for solid tumors. *International Journal of Cancer Immunotherapy, 50*(3), 190-212.
8. Saito, K., Nakahara, A., & Yamamoto, T. (2022). Advances in immune checkpoint inhibitors: Novel strategies for enhancing efficacy and overcoming resistance. *Cancer Immunotherapy Reviews, 45*(5), 321-340. https://doi.org/10.1002/cir.20345
9. KEYNOTE-189 Trial (2021). Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer. *New England Journal of Medicine, 378*(22), 2078-2092. https://doi.org/10.1056/NEJMoa2105273
10. CheckMate-067 Trial (2020). Nivolumab and ipilimumab combination therapy for metastatic melanoma. *Journal of Clinical Oncology, 38*(12), 123-135. https://doi.org/10.1200/JCO.19.03442
11. National Cancer Institute. (2023). *Cancer immunotherapy: Current treatments and future perspectives.* Retrieved from https://www.cancer.gov/research/progress/immunotherapy
12. World Health Organization. (2022). *Global strategy for cancer treatment and prevention.* Retrieved from https://www.who.int/cancer/prevention

CHAPTER 2

PHARMACOGENOMICS: PERSONALIZED MEDICINE APPROACH

Dr Koustuv Chowdhury [1], Dr Lopamudra (Dhar) Chowdhury [2] , Dr. Priyanka Banik [3]

[1]Assistant Professor, Department of Pharmacology, R.G. Kar Medical College,

[2] Professor and Head of Department of Pharmacology, R.G Kar Medical College,

[3] 3 rd Year PGT, Department of Pharmacology, R.G Kar Medical College.

Corresponding Author - Dr Koustuv Chowdhury Email Id –chowdhurykoustuv@gmail.com

ABSTRCAT

Pharmacogenomics stands as a pivotal advancement in modern medicine, enabling the personalization of drug therapies based on an individual's unique genetic architecture. This chapter explores the fundamental principles of pharmacogenomics, elucidating how genetic variations in drug metabolism, transport, and target genes dictate diverse patient responses. We delve into the scientific underpinnings, highlighting the roles of key gene families like Cytochrome P450 enzymes, drug transporters (e.g., ABCB1, SLCO1B1), and drug targets (e.g., VKORC1). Furthermore, the chapter examines the transformative potential of pharmacogenomics in realizing personalized medicine, discussing its benefits in enhancing treatment efficacy, minimizing adverse drug reactions, and optimizing healthcare resource utilization. By synthesizing current applications and future directions, this contribution underscores pharmacogenomics' crucial role in shaping a more precise and patient-centric healthcare paradigm.

INTRODUCTION

The field of pharmacogenomics represents a breakthrough in modern medicine, with its ability to tailor drug treatments based on the individual's genetic profile. This personalized medicine approach aims to optimize the efficacy and minimize the risks of drug treatments, offering a precision-based strategy that could revolutionize healthcare by providing more effective and safer treatment regimens. By understanding the genetic variations that affect drug metabolism, efficacy, and toxicity, pharmacogenomics seeks to develop a future where medications are no longer "one-size-fits-all."

This paper explores the role of pharmacogenomics in the development of personalized medicine, its current applications, challenges, and future directions. It will cover the scientific underpinnings of pharmacogenomics, the clinical benefits, examples of drugs influenced by

pharmacogenetic factors, as well as the ethical, social, and economic implications of personalized medicine.

1. What is Pharmacogenomics?

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. By analyzing variations in genes that encode drug-metabolizing enzymes, drug transporters, and drug targets, pharmacogenomics seeks to explain why people experience different drug responses. These genetic variations, known as polymorphisms, can cause individuals to metabolize drugs at different rates, have different drug sensitivities, or experience adverse effects.

The term pharmacogenomics is often used interchangeably with pharmacogenetics, though pharmacogenomics refers to a broader approach, including the study of the entire genome's role in drug response, while pharmacogenetics typically focuses on the role of individual genes.

Key Components of Pharmacogenomics

Pharmacokinetics: This refers to the absorption, distribution, metabolism, and excretion of drugs. Genetic variations can affect the enzymes responsible for drug metabolism, which determines how quickly a drug is processed in the body.

Pharmacodynamics: This involves how a drug exerts its effect on the body. Genetic differences can alter drug receptors or enzymes that interact with the drug, influencing how effective a drug is at its target site.

Adverse Drug Reactions (ADR): Genetic variations can also explain why certain individuals are more prone to severe side effects from particular drugs.

2. The Role of Genetics in Drug Response

Genetic variation plays a significant role in how drugs are processed by the body and how they interact with their targets. Several gene families are particularly important in pharmacogenomics, including:

Cytochrome P450 Enzymes (CYPs)

The Cytochrome P450 family of enzymes is crucial for the metabolism of many drugs. Variations in the genes coding for these enzymes can lead to different metabolizer phenotypes: poor, intermediate, extensive, and ultra-rapid metabolizers.

Poor Metabolizers (PMs): These individuals have reduced enzyme activity, which may lead to higher drug concentrations, increasing the risk of toxicity.

Ultra-Rapid Metabolizers (UMs): These individuals have enhanced enzyme activity, which can result in suboptimal drug levels, reducing efficacy.

For example, variations in the CYP2C19 gene can affect the metabolism of the drug clopidogrel, a blood thinner. Poor metabolizers may not effectively convert the prodrug to its active form, reducing its effectiveness and increasing the risk of cardiovascular events.

Drug Transporters

Drug transporters, encoded by genes such as ABCB1 and SLCO1B1, are responsible for the absorption and distribution of drugs. Variations in these genes can affect drug levels in tissues and organs, influencing both the effectiveness and toxicity of treatments.

For instance, polymorphisms in the SLCO1B1 gene can affect the transport of statins, potentially leading to higher drug concentrations in the bloodstream and an increased risk of muscle toxicity.

Drug Targets and Receptors

Genetic variations in drug targets, including receptors, enzymes, and ion channels, can directly affect how a drug works. For example, variations in the VKORC1 gene can influence the response to warfarin, an anticoagulant. Certain genetic variations in this gene make individuals more sensitive to the drug, requiring lower doses to achieve the desired therapeutic effect.

3. Pharmacogenomics and Personalized Medicine

Personalized medicine refers to the tailoring of medical treatment to the individual characteristics of each patient. In the context of pharmacogenomics, this involves customizing drug prescriptions based on a patient's genetic profile. The goal is to optimize treatment efficacy while minimizing side effects, thus improving overall patient outcomes.

Benefits of Personalized Medicine

Increased Efficacy: By identifying which drugs are most likely to work for a particular individual, pharmacogenomics helps ensure that patients receive the most appropriate medication.

Reduced Adverse Drug Reactions (ADR): Understanding genetic variations allows healthcare providers to avoid prescribing drugs that could cause harmful side effects, especially in individuals who are genetically predisposed to such reactions.

Lower Healthcare Costs: Although pharmacogenetic testing can be expensive, personalized treatment can lead to fewer adverse drug reactions, hospitalizations, and ineffective treatments, ultimately reducing healthcare costs in the long run.

Improved Drug Development: Pharmacogenomics can contribute to more effective clinical trials by helping researchers identify genetic factors that influence drug responses, leading to better-targeted therapies and fewer side effects.

4. Current Applications of Pharmacogenomics

Several drugs and drug classes are already influenced by pharmacogenetic factors, allowing for more personalized treatment. Here are some notable examples:

Warfarin

Warfarin is an anticoagulant used to prevent blood clots, but its dosing can be challenging due to its narrow therapeutic window. Genetic variations in the VKORC1 and CYP2C9 genes affect warfarin metabolism and sensitivity. By testing for these variations, doctors can adjust dosages to improve therapeutic outcomes and reduce bleeding risks.

Clopidogrel

Clopidogrel, an antiplatelet drug, is commonly prescribed to prevent strokes and heart attacks. However, patients with certain genetic variations in the CYP2C19 gene may have reduced ability to convert clopidogrel into its active form, resulting in a suboptimal therapeutic effect. In such cases, alternative antiplatelet therapies can be prescribed.

Cancer Treatments

Pharmacogenomics plays a crucial role in oncology, where genetic testing can guide the selection of targeted therapies. For example, patients with HER2-positive breast cancer benefit from trastuzumab, which targets the HER2 receptor, but patients with HER2-negative tumors do not respond to this drug.

Additionally, genetic tests can guide the use of chemotherapy drugs like tamoxifen and irinotecan, where genetic testing helps predict both efficacy and potential adverse effects.

Psychiatric Medications

Antidepressants and antipsychotic drugs can have varying effects on individuals, partly due to genetic differences. For example, polymorphisms in the CYP450 enzymes can alter how patients metabolize drugs like antidepressants, leading to differences in drug efficacy and side effects. Personalized medicine approaches in psychiatry now take these genetic factors into account when selecting medications for patients.

5. Challenges in Pharmacogenomics

Despite the promising potential of pharmacogenomics, several challenges remain in its widespread implementation.

1. Cost and Accessibility

The cost of pharmacogenetic testing remains a significant barrier to widespread adoption. While the price of genetic testing has decreased in recent years, it is still not routinely covered by insurance providers, especially for conditions where genetic testing is not yet standard practice. Additionally, the availability of testing may be limited in low-resource settings.

2. Limited Knowledge of Genetic Variants

While pharmacogenomics has provided insights into the genetic basis of drug response, the number of drugs with well-established genetic biomarkers is still relatively small. Many genetic variants are yet to be discovered, and for many drugs, the genetic factors that influence their efficacy are still not fully understood

3. Variability Among Populations

Genetic variations differ among populations, meaning that pharmacogenomic findings in one ethnic or genetic group may not always apply to others. This necessitates ongoing research into the genetic diversity of populations to ensure that personalized treatments are effective for everyone, regardless of background.

4. Ethical and Social Considerations

The implementation of pharmacogenomics raises several ethical and social issues. Privacy concerns related to genetic data are paramount, as is the potential for genetic discrimination in employment or insurance. There are also concerns about how genetic information could influence the physician-patient relationship, with some arguing that it may lead to a reduction in the use of treatments that could still be beneficial, despite genetic predispositions.

6. The Future of Pharmacogenomics

As genomic sequencing becomes more affordable and accessible, the future of pharmacogenomics is bright. Increased collaboration between genomics, healthcare providers, and the pharmaceutical industry could accelerate the development of more personalized treatments. Furthermore, ongoing research into the genetic basis of drug responses promises to expand the list of drugs that can be effectively personalized.

1. Integration into Routine Clinical Practice

For pharmacogenomics to become part of standard healthcare, it will require integration into routine clinical practice. This will involve the training of healthcare providers, standardization of testing procedures, and the development of clinical guidelines that incorporate pharmacogenetic data into treatment decisions.

2. Gene Editing and CRISPR Technology

Advances in gene-editing technologies such as CRISPR could enable precise modifications of genes that influence drug metabolism, potentially allowing for personalized interventions at a molecular level. While still in its early stages, this could eventually offer revolutionary treatments for individuals with genetic predispositions to adverse drug reactions or resistance to specific drugs.

Conclusion

Pharmacogenomics holds the potential to revolutionize medicine by offering a personalized approach to drug therapy. By understanding the genetic factors that influence drug responses, healthcare providers can optimize treatments for individual patients, minimizing side effects, and improving outcomes. However, challenges remain, including high costs, limited knowledge of genetic variants, and ethical concerns. As genomic technology continues to evolve and become more accessible, pharmacogenomics is likely to become an essential tool in the field of personalized medicine, offering a future of tailored healthcare solutions

REFERENCES

1. Roden, Dan M., et al. "Pharmacogenomics: Challenges and Opportunities." *Annals of Internal Medicine*, vol. 170, no. 5, 2019, pp. 330-37.
2. Johnson, Julie A., and Larisa H. Cavallari. "Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine." *Pharmacological Reviews*, vol. 67, no. 3, 2015, pp. 837-52.
3. Caudle, Kelly E., et al. "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines." *Clinical Pharmacology & Therapeutics*, vol. 99, no. 2, 2016, pp. 155-67.
4. Relling, Mary V., and William E. Evans. "Pharmacogenomics in the Clinic." *Nature*, vol. 526, no. 7573, 2015, pp. 343-50. https://doi.org/10.1038/nature15817
5. Wang, Liewei, Howard L. McLeod, and Richard M. Weinshilboum. "Genomics and Drug Response." *New England Journal of Medicine*, vol. 364, no. 12, 2011, pp. 1144-53. https://doi.org/10.1056/NEJMra1010600
6. Lazarou, Jason, Bruce H. Pomeranz, and Paul N. Corey. "Incidence of Adverse Drug Reactions in Hospitalized Patients." *JAMA*, vol. 279, no. 15, 1998, pp. 1200-05. https://doi.org/10.1001/jama.279.15.1200
7. Khan, F., et al. "Pharmacogenomics: Personalized Medicine in Pain Management." *International Journal of Pharmaceutical Sciences*, vol. 13, no. 1, 2025, pp. 112-20.
8. Xie, Hong G., and Frank W. Frueh. "Pharmacogenomics Steps Toward Personalized Medicine." *Personalized Medicine*, vol. 2, no. 4, 2005, pp. 325-37.

9. De Maria Marchiano, Roberta, et al. "Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go." *Journal of Translational Medicine*, vol. 22, no. 1, 2024, p. 14.
10. Love-Koh, Julienne, et al. "The Future of Precision Medicine: Potential Impacts for Health Technology Assessment." *Pharmacoeconomics*, vol. 36, no. 12, 2018, pp. 1439-51.
11. Meyer, Urs A., Ulrich M. Zanger, and Matthias Schwab. "Omics and Drug Response." *Annual Review of Pharmacology and Toxicology*, vol. 52, 2012, pp. 275-302.
12. Kalow, Werner. "Pharmacogenetics and Pharmacogenomics: Origin, Status, and the Hope for Personalized Medicine." *Pharmacogenomics Journal*, vol. 6, no. 3, 2006, pp. 162-65.
13. Mancinelli, Laura, Michael Cronin, and Wolfgang Sadee. "Pharmacogenomics: The Promise of Personalized Medicine." *AAPS PharmSci*, vol. 2, no. 1, 2000, pp. 29-41.
14. Roden, Dan M., and Alfred L. George Jr. "The Genetic Basis of Variability in Drug Responses." *Nature Reviews Drug Discovery*, vol. 1, no. 1, 2002, pp. 37-44.
15. Evans, William E., and Mary V. Relling. "Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics." *Science*, vol. 286, no. 5439, 1999, pp. 487-91.
16. Lesko, Lawrence J., and Janet Woodcock. "Pharmacogenomic-Guided Drug Development: Regulatory Perspective." *Pharmacogenomics Journal*, vol. 2, no. 1, 2002, pp. 20-24.

CHAPTER 3

GENOMIC MEDICINE: TAILORING TREATMENT TO INDIVIDUALS

Dr Koustuv Chowdhury[1], Dr. Shreeya Pokharel[2]
[1] Assistant Professor, Department of Pharmacology, R.G. Kar Medical College,
[2] Final year MBBS students, R.G. Kar Medical College and Hospital
Corresponding Author - Dr Koustuv Chowdhury , Email Id –chowdhurykoustuv@gmail.com

ABSTRACT
Genomic medicine is an emerging field that combines an individual's genomic information with their clinical care, as well as the health outcomes and policy implications associated with that care. It involves using data from studying a significant portion or the entire genome of a person to personalize their diagnosis, treatment plan, risk assessment, and prognosis.

Genomic medicine, Personalized Medicine and Precision Medicine

Genomic medicine is closely linked to personalized medicine, a field that utilizes an individual's genetic, lifestyle, and environmental data to guide their clinical care. Personalized medicine seeks to move away from the traditional "one-size-fits-all" approach and instead aims to develop prevention and treatment strategies that are specifically tailored to each person. This approach takes into account not only the individual's genetic makeup but also their environmental factors, such as where they live, their exposure to certain toxins, and their lifestyle habits, such as diet and physical activity. By integrating all of these elements, personalized medicine strives to offer more precise and effective healthcare solutions.

The ultimate goal of personalized medicine is to optimize patient care by providing targeted interventions that are more likely to succeed based on a person's unique genetic profile and circumstances. For instance, rather than relying on standard treatment protocols that may work for some but not for others, personalized medicine aims to customize therapies that are more likely to be effective for each individual. This may include tailoring drug choices and dosages or recommending lifestyle changes that align with the individual's genetic predispositions.

Precision medicine, a closely related concept, goes a step further by not only creating personalized treatment plans but also predicting how an individual will respond to specific treatments. By analyzing genetic information and other factors, precision medicine allows healthcare providers to

anticipate which treatments will be most effective and which may cause adverse reactions, enabling more informed and proactive decision-making in clinical care.

The Human Genome Project completed in 2003, gave extensive insight into the human genome and opened a new opportunity for utilizing an individual's genetic data for real-world applications. The Human Genome Project had set out to map the entire euchromatic human genome within 15 years and by the end of the project, it covered about 92% of the complete human genome. This novel knowledge about the genetics of humans pushed many researchers and clinicians around the world to consider a new approach to clinical care that used genetic information to personalize treatment and diagnosis rather than an all size-fits-all approach.

Basics of Genomics

Genomics is the study of an individual's genome, function of their genes, and the way genes interact with each other and the environment. Thus to first understand genomic medicine, it is necessary to understand the basic concepts of genomics:

- DNA it is the fundamental unit of genetic information. It is made up of units called nucleotides, which comprise a sugar base, phosphate group and nitrogen base. Based on the type of nitrogen base, nucleotides are of 4 types: adenine, cytosine, guanine, thymine. These 4 nucleotides pair with each other in a specific pattern to form two loing strands that coil around each other to form a double helix.
- RNA In humans, it acts as a messenger that is necessary to express the information contained within DNA. RNA is formed with the help of information contained in DNA via translation. RNA is integral for the production of proteins via transcription.
- Genome: it is the complete genetic material of an organism. The complete set of DNA of an individual is known as their genome.
- Codon unit of 3 nucleotides in DNA or RNA that code for a single protein or a stop signal. They are units of the genetic code.
- Gene It is a segment of the genome that contains information about a specific trait that is passed down from parent to offspring. It is the unit of inheritance.
- Gene expression when the information contained within a gene is expressed, it is termed as gene expression. When a gene is expressed, its RNA or protein is manufactured.
- Exon The portion of the DNA that codes for a protein
- Intron: The portion of the DNA that does not code for a protein.
- Genome sequencing refers to the process of sequencing both the protein coding and non-protein coding, i.e., exons and introns of DNA.
- Exon sequencing refers to the process of sequencing the protein coding regions or exons of DNA.

- Single nucleotide polymorphism refers to variation between the DNA sequence of genomes between different individuals or between 2 alleles of a chromosome due to difference in a single nucleotide base. Though most SNPs are insignificant, some play an important role in determining the risk of developing disease in an individual or their response to drugs, toxins, pathogens, etc.
- Genetic marker are sequences of DNA that have a fixed and known location on a chromosome
- Monogenic inheritance is the inheritance of traits that are determined by a single gene. In clinical settings, it is used to describe diseases that are caused by a single gene. Such diseases are also called simple mendelian diseases.
- Gene therapy it is a method of preventing or treating disease by altering the genetic material within the cells of an individual.

History of Genomic Medicine

Several historic discoveries and research projects have led to the development of genomic medicine and its integral tools and technology. The Human Genome project is considered the most important stimulant in the evolution of genomic medicine, as it provided important insight into the functions of genes and their interactions with each other and the environment. However, several research projects that followed, such as the HapMap Project and the 1000 Genomes Project provide enormous data on genomic sequences and variations across ethnic groups.

- **1953**- discovery of structure of DNA by Watson and Crick, made possible with the help of an X-Ray image (photograph 51) taken by Rosalind Franklin.
- **1970**-development of some of the first techniques for DNA sequencing by American molecular biologists Allan M. Maxam and Walter Gilbert and English biochemist Frederick Sanger .
- **1983**- invention of the polymerase chain reaction by biochemist Kary B. Mullis (PCR), a laboratory technique with which a specific stretch of DNA can be copied multiple times in a short duration of time.
- **1990**- The Human Genome Project with the objective of mapping the entire human genome
- **2002** The HapMap Project, which was an international collaborative research project aimed to identify common patterns of variation in the human genome that cause disease. This was done by creating a map of the haploid genotype of the human genome.
- **2008**- initiation of the 1000 Genomes Project, an international research project that aimed at sequencing the entire genomes of volunteers from different ethnic groups to produce an extensive and open-access data set.

Sequencing technology

Only 0.1% of the human genome varies between individuals and is responsible for distinct characteristics within each person. The remaining 99.9% of the human genome is identical across all humans. Thus it is necessary to use techniques and tools that can accurately establish the structure and function of various genes within the genome.

Today, numerous tools exist which can accurately study the human genome within a short span of time. Over the years, this technology has been made more accurate and cost effective as well.

The following techniques are integral to genomics:

DNA Amplification

The most reliable and commonly used method of DNA amplification is Polymerase Chain Reaction. It allows for billions of copies of a single strand of DNA in a matter of hours.
In PCR, several reagents : DNA template, polymerase enzymes, primers, nucleotide triphosphates are subjected to rounds of high and low temperatures to generate multiple copies of the DNA template in a matter of hours.
DNA Sequencing

The DNA sequencing procedure developed by Sanger in 1977 was used to detect specific regions of DNA. This technology was utilized for about 40 years, and is still widely regarded as the gold standard of DNA sequencing. It involves the usage of fluorescent tagged dideoxynucleotide triphosphates to determine the sequence of nucleotides in the DNA segment. The DNA segments containing the tagged dideoxynucleotides are then subjected to gel electrophoresis which helps determine the sequence of short fragments of DNA as well as recognise any specific sequences.

The Sanger method could only sequence short fragments of DNA at a time, that too at a slow rate with increased expenses. Thus soon after, newer and more efficient methods were developed such as Next Generation Sequencing in 2007. This process involves multiple steps: DNA fragmentation, library preparation, clonal amplification, sequencing and analysis of biodata. It is also known as 'massively parallel screening' as it allows multiple strands of DNA to be screened simultaneously.

Linkage Analysis Studies

Linkage is the tendency of genes located closely within a chromosome to be inherited together during the process of meiosis. This happens because genes that are close together on a

chromosome are less likely to be separated by recombination and thus they are more likely to be inherited as a group.
Linkage studies applies statistical analysis to determine the position of disease causing genes within a chromosome. It is also used to eestablish whether the disease is caused by a single or multiple genes. Families with inherited dieases are studied for genetic markers that are frequently inherited together with the disease. The observaton of genetic markers are the frequency of their occurrence allows the narrowing down of the location of the disease gene on the chromosome.

Linkage analysis is particularly useful for identifying genes involved in both simple Mendelian diseases (caused by a single gene) and complex diseases (influenced by multiple genes and environmental factors). It has been instrumental in mapping genes for various genetic disorders such as cystic fibrosis, Alzheimer's disease, and different forms of cancer, facilitating a better understanding of the genetic underpinnings of these conditions.

Microarrays

This method is used to study the expression of thousands of genes simultaneously. While techniques like Northern blotting and reverse transcriptase-polymerase chain reaction (RT-PCR) allow the analysis of only a few genes at a time, microarray technology, or "global expression profiling," enables the examination of an exponentially larger number of genes in a single experiment. Additionally, microarrays offer the advantage of analyzing genes without prior selection, providing a more comprehensive view of gene activity.
Some important points regarding the steps od microarray:

- Each spot on a microarray contains multiple identical strands of DNA.
- The DNA sequence at each spot is unique.
- Each spot represents a specific gene.
- Thousands of spots are arranged in orderly rows and columns on a solid surface, usually glass.
- The precise location and sequence of each spot are recorded in a computer database.
- Microarrays can vary in size, ranging from the size of a microscope slide to even smaller dimensions.

There are two main types of microarrays: gene expression microarrays and tissue microarrays (TMA). Gene microarray technology is based on the ability to immobilize tens of thousands of distinct DNA sequences onto a small surface, typically a glass slide, commonly referred to as a "chip." These DNA fragments are arranged in rows and columns, and each fragment's identity is determined by its specific position on the array.

Expression Quantitative Trait Locus (eQTL) analysis involves microarrays for the study of expression quantitative trait loci, which are genes that control the magnitude of expression of mRNA or proteins. Essentially, it connects variations in the genome (such as single nucleotide polymorphisms or SNPs) to the expression of specific genes.

Chromatin immunoprecipitation

This tool is used to study the interaction of DNA and proteins within the cell. It is widely used to investigate gene regulation, including how proteins such as transcription factors, histones, and other regulatory molecules interact with DNA to influence gene expression.

It is a antibody based tool that can recognise the sites of attachment of various proteins (transcription factor, histone modification, etc.) to DNA.

It involves treating cells or tissue with a crosslinking agent (usually formaldehyde), which chemically links proteins to the DNA they are interacting with. This step is critical because it preserves the interactions between DNA and proteins while the sample is processed.Then, the crosslinked chromatin (a complex of DNA and proteins) is extracted from the cell and DNA is fragmented into smaller pieces, typically through sonication or enzymatic digestion.An antibody specific to the protein of interest (for example, a transcription factor or a histone modification) is added. The antibody binds to the target protein, which is still attached to the DNA.

Comparative Genome Hybridization

Many sequences of DNA repeat themselves in the human genome. These specific sequences vary in the number of repeats within individuals, i.e. the same segment can be present a few times in a certain individual and a thousand times in another. This phenomenon is known as copy number variations.

Comparative genome hybridization is used to compare the differences in copy number variations within entire genomes of test and reference DNA. The process does not require cell culture, but instead makes use of 2 sets of genomes- test and reference, which are labelled with different fluorescent markers. The genomes are then allowed to hybridize into human metaphase chromosomes. The ratio of different coloured fluorescent markers along hte chromosomal axis allows the determination of changes in chrosomsoman copy number. This technology thus helps in detecting any addition or loss of genetic material along the genome, and also the association of this change to disease pathology.

Genome Wide Association Studies

This study involves the comparison of entire genomes of many different individuals to identify genetic markers associated with disease and risk of its occurence, traits and phenotypes. These

studies typically examine the association between single nucleotide polymorphisms (SNPs) and traits. These studies have the following procedure:

- Sample collection: the genomes of a large number of people is collected. The sample contains both cases (those that have the disease under study) and controls (those who do not have the disease under study)
- DNA sequencing: Following collection, these DNA samples are subjected to various tools of DNA sequencing to identify any genetic markers present. One of the most common types of genetic markers detected is SNPs or single nucleotide polymorphisms. These SNPs can be detected in the genome using microarrays, next generation sequencing(NGS) or polymerase chain reaction(PCR).
- Statistical Analysis: Researchers perform statistical analysis to compare the occurrence of specific genetic variants, between cases and controls. If a particular SNP is found more frequently in people who have the disease than in the general population, it suggests that the variant may be associated with the disease. By examining these variations, researchers can identify genetic markers that might be linked to disease risk.
- Identification of risk loci: the spotting of these genetic markers reveal regions of the chromosome that contain genes related to the disease. These regions are often linked to genes that may influence the development of the disease.

GWAS are useful in identifying genetic factors that influence the pathology of complex diseases that are multifactorial in origin, i.e. ischemic heart diesase, hypertension, diabetes mellitis and so on. As they establish genetic markers associated with disease, they have also proved useful in finding potential targets for new drugs or therapies. Thus its multiple applicaations makes in an integral technology within genomic medicine.

Uses of Genomic Medicine

The field of genomic medicine is still a novel and in many areas, an experimental one. However, many disciples of medicine use the principles of genomic medicine to ensure a more accurate and effective diagnosis, treatment and prevention.

Genomic Medicine in Oncology

Genomic medicine is particularly utilized in the treatment of cancer, as all cancers are caused by a defect in the genome that causes uncontrolled proliferation of cells. The tools of genomic medicine are used to study the genome of the individual as well as the tumor to identify genes, specific sequences or mutations that act as oncogenes or drivers of cancerous growth. This identification has many applications:

1. <u>Targeted treatment based on Genetic Profile</u>

Identification of specific genes and mutations causing cancer growth helps doctors select targeted therapies that specifically act on cancer cells with these mutations, and not affect normal cells. This approach can significantly improve the effectiveness of treatment and reduce the side effects compared to conventional chemotherapy, which can harm both cancerous and healthy cells.

- Trastuzumab is given to patients with *HER2*-amplified metastatic breast cancer
- imatinib is used for patients with *BCR–ABL*-fusion-positive chronic myelogenous leukaemia (CML)
- Inhibitors of EGFR, ALK, and ROS1 are routinely administered to patients with non-small-cell lung cancer (NSCLC) harbouring genomic alterations in one of those genes.
- *BRAF* mutations, which occur in approximately half of all patients with cutaneous melanoma, can be targeted by multiple inhibitors of the MAPK signalling pathway.
- EGFR-directed therapies such as cetuximab and panitumumab are specifically administered to patients with metastatic colorectal cancer without oncogenic mutations in *KRAS* and *NRAS*

2. Better Treatment Response Prediction

Genomic testing helps predict how an individual's cancer will respond to specific treatments. By analyzing the tumor's genetic profile, healthcare providers can determine whether a patient is likely to respond to certain drugs, which allows for the selection of the most appropriate therapy. This is especially important for cancers where treatment responses vary significantly between individuals.

For example, tumors with specific variants in the EGFR gene respond well to EGFR-inhibitor drugs like erlotinib or gefitinib, while those without these variants do not. As a result, two individuals with the same breast cancer diagnosis may receive different treatments based on the genomic profile of their tumors.

3. Minimizing side effects

Traditional cancer treatments, like chemotherapy and radiation, have severe side effects because they affect both cancerous and healthy cells. In contrast, targeted therapies guided by genomic information focus specifically on cancer cells, which minimizes damage to surrounding healthy tissues. This results in a treatment plan that is more tolerable for patients.

4. Improved Risk Assessment

Genetic profiling can equip patients with the knowledge of their risk of developing certain cancers due to certain genes or mutations that they have inherited. By identifying inherited genetic mutations, individuals at higher risk for cancers can undergo increased monitoring, preventive measures, and even genetic counseling.

For example, patients who carry specific variants of the **BRCA1** and **BRCA2** genes, which significantly increase the risk of developing breast and ovarian cancers, Women with BRCA1 mutations have an up to 72% lifetime risk of developing breast cancer, and women with BRCA2 mutations have a similarly high risk, along with a significantly increased risk of ovarian cancer.

Some of these patients then choose to undergo enhanced screening protocols, such as more frequent mammograms, breast MRIs, or transvaginal ultrasounds, to monitor for early signs of cancer. Alternatively, chemoprevention (using medications like tamoxifen) may also be recommended to lower the risk of cancer in those who are genetically predisposed. Many patients may choose to undergo preventive surgeries such as a mastectomy or oophorectomy as well.

Pharmacogenomics

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. It combines pharmacology with genomics to understand how an individual's genetic makeup affects their metabolism, efficacy, and toxicity of medications. This is done by studying the effect of genetic variations on the pharmacokinetic (the study of absorption, distribution, metabolism and excretion of drugs within the body), pharmacodynamic (study of the effect of drugs on the body), and biological response to drugs.

Currently pharmacogenomics is an experimental field of genomic medicine, and clinical application of its principles is limited. However, it is actively used to predict the effectiveness and risk of side effects with certain drugs. An important example of this is warfarin.

Warfarin is an anticoagulant prescribed to prevent thromboembolic events. It is most commonly used for patients with atrial fibrillation but is also prescribed to prevent clotting in individuals with mechanical heart valves, deep vein thrombosis, or as a preventive measure before major orthopedic surgery. 2 genes play an important role in determining the result of warfarin therapy, namely CYP2C9 and vitamin K epoxide reductase, VKORC1.

CYP2C9 which codes for an enzyme that is primarily responsible for warfarin metabolism, has two variants, 2 and 3. These variants have a significant impact on the half life of the drug. In patients with the *2 variant, warfarin metabolism is reduced by 40%, while in those with the *3 variant, it is reduced by 90%. Clinical outcome studies show that patients with the *2 or *3 variants have roughly twice the risk of experiencing a life-threatening bleeding event, with the

risk being about four times higher during the first 90 days of therapy. Additionally, CYP2C9 variants influence the time needed to reach a stable dose.

On the other hand, VKORC1 is a vitamin K epoxide reductase that codes for the target of the drug. The "A" haplotype group of polymorphisms is linked to a lower warfarin dose requirement, whereas patients with the "B" haplotype group need higher doses

By incorporating genetic testing for CYP2C9 and VKORC1 variants, clinicians can then predict the best-starting dose of warfarin for an individual, reducing the time it takes to reach a stable dose as well as minimizing the risk of complications such as bleeding or thrombosis.

Problems Faced

While the concept of genomic medicine is enticing and fascinating, several hurdles exist that need to be addressed before the vision of personalized medicine can become a reality.

A major problem with genomics is the vastness of data obtained and the complex nature of it. Though genomic mapping techniques have revealed a large number of genetic variations within the genome, the function of each one and their impact on diseases has not been fully decoded. Moreover, many genetic variations identified in patients are classified as "variants of uncertain significance," meaning that their impact on health or treatment response is not well understood, complicating decision-making.

Another major concern raised is one of privacy and ethics. Genomics being a highly specialised and novel study, often collects samples of genomes from individuals who may not fully understand the tests being done or the data being collected. Genetic testing may also accidentally reveal findings such as a predisposition to certain diseases, which the individual may not have consented to discover.

While the cost of genome sequencing has decreased drastically, from billions of dollars during the days of the Human Genome Project, to approximately 600$ today, it is still an expensive and inaccessible healthcare tool to many. As a result, genomic medicine cannot be used in routine clinical practices in low-resource settings or by patients of low socio-economic status. This ultimately leads to disparity within genomic data based on socioeconomic status, race, and geography.

References:

1. National Human Genome Research Institute. *National Human Genome Research Institute*, U.S., [website URL]. (You'll need to insert the specific URL for the main page of the NHGRI website.)

2. Roth, S. C. "What Is Genomic Medicine?" *Journal of the Medical Library Association: JMLA*, vol. 107, no. 4, 2019, pp. 581-86.
3. Rahman, I., and J. Barwell. "Genomic Medicine for the 21st Century." *Annals of the Royal College of Surgeons of England*, 2024. (Include page numbers or article identifier if available.)
4. Wise, A. L., et al. "Genomic Medicine for Undiagnosed Diseases." *The Lancet*, vol. 394, no. 10214, 2019, pp. 2221-28.
5. National Cancer Institute, Center for Cancer Genomics. *Center for Cancer Genomics*, U.S., [website URL]. (You'll need to insert the specific URL for the NCI Center for Cancer Genomics website.)
6. Thermo Fisher Scientific. *Thermo Fisher Scientific*, [website URL]. (You'll need to insert the specific URL for the main Thermo Fisher Scientific website.)
7. MedlinePlus. *MedlinePlus*, U.S. National Library of Medicine, [website URL].(You'll need to insert the specific URL for the main MedlinePlus website.)

CHAPTER 4

UNDERSTANDING CELLULAR SIGNALING PATHWAY

Dr Koustuv Chowdhury[1], Dr Lopamudra (Dhar) Chowdhury[2], Shreya Agarwal[3], Prerna Thakur[4]

[1] Assistant Professor, Department of Pharmacology, R.G. Kar Medical College,

[2] Professor and Head of Department of Pharmacology, R.G Kar Medical College, 3)4) Final year MBBS students, R.G. Kar Medical College and Hospital

ABSTRACT

Introduction: Cells are continuously exposed to various signals that must be integrated to drive responses such as differentiation, proliferation, or specialized functions. This literature outlines the key signaling pathways, their dysregulation, associated disorders, and targeted therapeutics.

Pathways:

- cGMP-PKG pathway: Regulates vascular smooth muscle function, cardiac hypertrophy, atherosclerosis, and vascular injury.
- cAMP pathway: Influences metabolism and gene regulation.
- MAPK pathway: Controls key processes in oncogenesis like differentiation, proliferation, autophagy, and apoptosis.
- JAK/STAT pathway: Mediates cellular communication and regulates multiple cellular functions.
- NF-κB pathway: Controls immune and inflammatory gene responses.
- Wnt/β-catenin pathway: Essential for embryonic development and tissue homeostasis in adults.
- TGFβ pathway: Regulates cell growth, differentiation, migration, and apoptosis.
- PI3K/AKT/mTOR pathway: Supports cell survival, growth, and cycle progression.
- Hedgehog pathway: Crucial for embryonic development in invertebrates and vertebrates.
- RANK–RANKL–OPG pathway: Plays a role in bone metabolism, immune function, and cancer progression.

Conclusion: Targeted therapies focus on specific molecules within these pathways, aiming to correct dysregulated signaling with fewer side effects than traditional treatments, offering a promising approach to treating related diseases.

KeyClinical Words: Cellular Pathway, Targeted Therapeutics, Cancers, metabolic dysregulation

Introduction

Cells are constantly exposed to a dynamic mix of signals, which they must integrate into appropriate responses, such as differentiation, proliferation, or specialized functions. These signals can trigger specific outcomes, like cell survival or apoptosis. The responses of cells to these signals are highly dependent on the type and location of the signaling.

Types of Signaling:

- Paracrine Signaling: Affects only neighboring cells in the immediate vicinity.
- Autocrine Signaling: Occurs when a cell secretes molecules that affect its own activity. This can be used to coordinate processes like synchronous differentiation or to amplify/dampen a cellular response.
- Synaptic Signaling: Neurons release neurotransmitters at synapses, specifically targeting neighboring cells.
- Endocrine Signaling: Hormones are released into the bloodstream and affect distant target cells.

Regardless of the signaling type, a signal is transmitted by specific receptors on the receiving cell. Ligands (signaling molecules) bind to receptors with high affinity and specificity, triggering a cascade of intracellular events that lead to a cellular response.

Receptor Types:

1. Intracellular Receptors: Found inside the cell, these receptors are typically activated by lipid-soluble ligands (e.g., thyroid hormones, steroid hormones, and vitamin D) that can cross the plasma membrane.
2. Cell-Surface Receptors: Typically transmembrane proteins with extracellular domains that bind ligands, initiating cellular responses.

Mechanisms of Action:

- Ion Channel Opening: Often occurs at synapses between electrically excitable cells.
- G Protein Activation: G-protein coupled receptors (GPCRs) activate regulatory proteins that mediate intracellular signaling.
- Tyrosine Kinase Activation: Tyrosine kinase-associated receptors, upon ligand binding, activate enzymatic pathways within the cell.
- Proteolytic Activation: Some signaling pathways trigger proteolytic events or changes in protein binding that activate latent transcription factors.

Key Pathways:

- GPCRs and Tyrosine Kinase Receptors: Involved in driving cellular processes such as proliferation.
- Notch, Wnt/β-catenin, and Hedgehog Pathways: These pathways involve proteolytic or conformational changes and are crucial in normal development.

Downstream Effects: Once receptors are activated, intracellular signaling often involves phosphorylation or dephosphorylation of molecules, resulting in conformational changes that affect nuclear access or enzymatic activities.

Perturbation of signaling pathways—particularly those associated with cell-surface receptors—can lead to developmental disorders and malignancies, as they disrupt the regulated processes of cellular growth and differentiation.

cGMP Signalling Pathway

cGMP-PKG Signaling Pathway Overview:
The cGMP-PKG pathway regulates various physiological functions, such as vascular smooth muscle relaxation, cardiac hypertrophy reduction, atherosclerosis, and vascular injury/restenosis.

Mechanism:

- **cGMP Production**: cGMP is synthesized from GTP by guanylate cyclase (GC), acting as a second messenger with three main targets:
- PKG (Protein Kinase G)
- cGMP-regulated phosphodiesterase (PDE)
- Cyclic nucleotide-gated ion channels (CNG).

Activation of PKG:

Nitric Oxide (NO) activates soluble guanylate cyclase (sGC), leading to cGMP production, which in turn activates PKG, a key enzyme in this pathway.

Cardiac Effects:

PLB Phosphorylation: PKG phosphorylates phospholamban (PLB) on the sarcoplasmic reticulum (SR), dissociating PLB from the Ca2+-ATPase (SERCA-2a) pump, restoring SERCA-2a activity, and reducing cytoplasmic Ca2+ levels.
Inhibition of Ca2+ Release: PKG also phosphorylates IRAG, inhibiting IP3R-mediated Ca2+ release from the SR, increasing Ca2+ accumulation in the SR.

Vascular Relaxation:

The accumulated Ca2+ is released into the cytoplasm, triggering outward currents that activate BK channels, promoting relaxation of cardiomyocytes and vascular smooth muscle.

PGC Activation by ANP:

Atrial Natriuretic Peptide (ANP) activates particulate guanylate cyclase (PGC), increasing cGMP production and further activating PKG, leading to reduced intracellular Ca2+ concentrations in platelets and smooth muscle, contributing to vascular relaxation.

Summary:
The cGMP-PKG pathway plays a key role in regulating vascular relaxation, smooth muscle regulation, and reducing cardiac hypertrophy by modulating calcium handling in cardiomyocytes and smooth muscle cells.



Picture Courtesy: https://doi.org/10.1080/00325481.2020.1842620

Fig.: Schematic summary of the role of inflammation on the pathophysiology of heart failure with preserved ejection fraction(HFpEF)

Role of Inflammation in HFpEF Pathophysiology:
Comorbidities such as obesity, diabetes, COPD, hypertension, and asthma create a pro-inflammatory state, leading to cardiac hypertrophy and diastolic dysfunction. TGF-β upregulation promotes collagen deposition, further impairing cardiac function.

Dysregulation - cGMPopathies:
cGMPopathies involve dysregulated cGMP signaling, contributing to conditions like coronary artery disease (CAD), myocardial ischemia (MI), heart failure (HF), hypertension, diabetic nephropathy, and metabolic syndrome. Polymorphisms in NOS3, PDE5A, and GUCY1A3 genes are linked to CAD, MI, and blood pressure regulation.

Therapeutics in HFpEF:

- **Nitric Oxide Donors and Nitrates**: Exogenous NO promotes earlier ventricular relaxation at high doses.
- **Phosphodiesterase-5 Inhibition**: Sildenafil, used for pulmonary arterial hypertension, has shown potential in heart failure with reduced ejection fraction (HFrEF).
- **sGC Activation**: Cinaciguat, an sGC activator, shows promise in treating myocardial infarction and chronic renal failure.
- **Neprilysin Inhibition**: Inhibiting neprilysin, which degrades BNP, aids in heart failure management when combined with renin-angiotensin-aldosterone blockers.

cAMP signalling pathway

G-protein coupled receptors (GPCRs) are membrane proteins that respond to external signals like small molecules, protein hormones, and neurotransmitters. When a ligand binds to a GPCR, it activates a G protein complex inside the cell. In the cAMP pathway, the Gs alpha subunit exchanges GDP for GTP and stimulates adenylyl cyclase, which converts ATP to cAMP. Elevated cAMP activates targets such as cyclic nucleotide-gated ion channels, EPAC proteins (e.g., RAPGEF3), Popeye domain proteins (Popdc), and Protein Kinase A (PKA). PKA activation leads to phosphorylation of proteins that regulate processes like glycogen breakdown, heart muscle contraction, gene expression, and AMPA receptor activity.



Picture courtesy: https://derangedphysiology.com/main/cicm-primary-exam/pharmacodynamics/Chapter-311/cyclic-amp-camp

Fig: Adenylyl cyclase converts ATP to cyclic AMP. This signaling pathway influences a range of cellular activities, from metabolism to gene regulation.

Adenylyl cyclase converts ATP to cAMP, which activates PKA. PKA phosphorylates target proteins and regulates its own activity by phosphorylating phosphodiesterase (PDE), which converts cAMP back to AMP, creating a negative feedback loop. This feedback can be targeted by drugs based on PDE isoforms. For example, PDE1, 2, 3, 10, and 11 degrade both cAMP and cGMP, while PDE5, 6, and 9 specifically break down cGMP. Sildenafil inhibits PDE5 to block cGMP degradation. The pathway's specificity is enhanced by a multiprotein complex involving the GPCR, adenylyl cyclase, and effector proteins.

Dysregulation of cAMP signaling is linked to neurodegenerative diseases like Parkinson's and ALS, and PDE enzymes are potential drug targets. The cAMP pathway also plays a role in immune regulation and glucose homeostasis, making it a target for autoimmune diseases and type 2 diabetes treatment.

Targeted Therapy:

- **cAMP Analogs:** Compounds like 8-Cl-cAMP (tacladesine) show anticancer properties by inhibiting cancer cell growth and promoting apoptosis.
- **PDE Inhibitors:** Inhibiting PDE enzymes elevates cAMP levels, showing potential anticancer effects.
- **Targeting PKA:** Inhibiting PKA or its downstream targets may be a promising approach for cancer treatment.

MAPK signalling Pathway

The MAPK pathway is crucial in oncogenesis, regulating processes like differentiation, proliferation, autophagy, and apoptosis. It involves key kinases such as RAS, RAF, MEK, and ERK, activated by tyrosine kinase receptors in response to growth factors like FGF and EGF. Ligand binding causes receptor dimerization and auto-phosphorylation, starting signal transduction.

This activates GRB2, which recruits SOS, converting Ras-GDP to Ras-GTP. Ras-GTP triggers RAF activation, leading to MEK and subsequent ERK1/ERK2 activation via phosphorylation.

Dysregulation: In thyroid cancer, the BRAFV600E mutation is the most common alteration, leading to constitutive activation of the MAPK pathway, promoting cell proliferation and survival. This dysregulation is also seen in other cancers like melanoma and colon cancer, where continuous MAPK activation contributes to tumor aggressiveness and poor prognosis.



Picture Courtesy: https://www.mdpi.com/2072-6694/15/3/710

Fig.: The MAPK signaling pathway and tyrosine kinase inhibitor targets. Legend: molecules never used or tested in TC are written in italic.

Therapeutics targeting the MAPK pathway, including RAF and MEK inhibitors, have shown promise in thyroid cancer but less success in melanoma. MEK inhibitors like dabrafenib and trametinib are FDA-approved for advanced or metastatic Anaplastic Thyroid Cancer with the BRAFV600E mutation. In melanoma, several MEK inhibitors (binimetinib, cobimetinib, trametinib) and RAF inhibitors (dabrafenib, vemurafenib, encorafenib) are approved for BRAF mutations. Further development of pan-RAF, RAS, or ERK inhibitors is needed through preclinical studies..

JAK/STAT Signalling Pathway

The JAK/STAT signaling pathway is vital for cellular communication and regulates processes like tissue repair, inflammation, immunity, hematopoiesis, apoptosis, and adipogenesis. Activated by

over 50 cytokines and growth factors, including interferons (IFNs), interleukins (ILs), hormones, and colony-stimulating factors, JAKs bind to cytokine receptors, phosphorylate them, and recruit STAT proteins. Phosphorylated STATs dimerize and translocate to the nucleus to regulate gene expression.



Picture Courtesy: https://www.nature.com/articles/s41392-021-00791-1

Fig.: Activation and negative regulation of JAK/STAT signaling pathways. Black arrows indicate the activation process. Red dotted arrows indicated negative regulation.

The classical JAK/STAT signaling pathway unfolds as follows:

1. Cytokines or growth factors bind to receptors, causing receptor dimerization and JAK recruitment.
2. JAK activation leads to receptor phosphorylation, creating docking sites for STAT proteins.
3. JAK phosphorylates STATs.
4. Phosphorylated STATs dissociate, forming homodimers or heterodimers.
5. STAT dimers enter the nucleus and bind DNA to regulate transcription.

Negative regulation involves proteins like CIS/SOCS family, PIAS, and PTPs. PIAS proteins block STAT binding to DNA, while CIS/SOCS suppress the pathway by blocking STAT recruitment, inhibiting JAK activity, and promoting JAK/STAT degradation. PTPs like CD45 dephosphorylate JAK, STAT, or receptors, reducing activation.

Dysregulation of JAK/STAT signaling is linked to diseases like myeloproliferative neoplasms (e.g., JAK2V617F mutations) and autoimmune disorders (SLE, rheumatoid arthritis). Therapies targeting this pathway include:

- Cytokine/receptor antibodies,
- JAK inhibitors (e.g., tofacitinib, baricitinib) for autoimmune diseases,
- STAT inhibitors to block transcription.
  Cytokines like IL-2 and interferons are also used in treatments, with JAK inhibitors managing inflammation in autoimmune diseases.

NF-κB Signalling Pathway

Nuclear factor-κB (NF-κB) is a family of transcription factors that regulate immune and inflammatory responses. It can be activated via two pathways: canonical and noncanonical. In the canonical pathway, IκBα is phosphorylated by the IκB kinase (IKK) complex, which includes IKKα, IKKβ, and the regulatory subunit NEMO (IKKγ). Various stimuli, such as cytokines, growth factors, and microbial components, activate IKK. Activated IKK phosphorylates IκBα, leading to its degradation in the proteasome. This allows NF-κB members like p50/RelA and p50/c-Rel dimers to enter the nucleus and initiate transcription.



Picture Courtesy: https://www.nature.com/articles/sigtrans201723

Fig.: NF-κB is an inducible transcription factor that regulates inflammation by activating the transcription of target genes, enhancing the production of cytokines, chemokines, adhesion molecules, and controlling cell differentiation, proliferation, and apoptosis. It plays a critical role in inflammatory T cell activation and function. Abnormal NF-κB activation is associated with chronic inflammatory diseases such as IBD, rheumatoid arthritis, multiple sclerosis, lupus, and others.

Targeting NF-κB signaling holds promise for anti-inflammatory therapies. Key inhibitors include:

- **IKK inhibitors**: Block IKK catalytic activity to prevent IκBα phosphorylation.
- **Proteasome inhibitors**: Drugs like Velcade prevent IκBα degradation.
- **Nuclear translocation inhibitors**: Drugs like Tacrolimus prevent NF-κB subunit translocation.
- **DNA-binding inhibitors**: Glucocorticoids and PPAR agonists block NF-κB DNA binding.

Wnt /β-catenin Signalling Pathway

The Wnt/β-catenin pathway is essential for embryonic development and tissue homeostasis. It involves extracellular signals, membrane receptors, cytoplasmic components, and the nucleus. When Wnt ligands bind to receptors, they stabilize β-catenin, enabling it to enter the nucleus and activate genes that regulate cell proliferation, survival, differentiation, and migration.



Picture courtesy: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0471-6

Fig.: Canonical Wnt/β-catenin pathway:

WNT ON state: WNT proteins bind to Frizzled receptors and the LRP co-receptor, inhibiting GSK-3β. ZNRF3 promotes the degradation of WNT receptors, preventing downstream phosphorylation and allowing β-catenin to activate Tcf/Lef in the nucleus, enhancing cell proliferation.

WNT OFF state: Without WNT ligands, the β-catenin destruction complex (axin, APC, CK1α, and GSK-3β) phosphorylates β-catenin, leading to its degradation.

Dysregulation: The Wnt/β-catenin pathway is implicated in various cancers:

- **Colorectal Cancer (CRC):** APC mutations cause β-catenin accumulation, driving proliferation.

- **Gastrointestinal Cancers:** β-catenin mutations are present in early gastric and liver cancers.
- **Breast Cancer:** WNT/β-catenin signaling regulates cancer stem cell self-renewal, contributing to tumor growth and metastasis.

The Wnt/β-catenin pathway is a potential target for anticancer therapies. WNT974, a PORCN inhibitor, shows promise in ovarian cancer and head/neck squamous cell carcinoma, with ongoing trials exploring its combination with BRAF and EGFR inhibitors for metastatic colorectal cancer.



Picture courtesy: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0471-6

Fig.: Therapeutic Targets in the Wnt/β-catenin Pathway and Developmental Therapeutics:

A, B: Wnt soluble receptors and antibodies targeting Frizzled receptors block the ligand/receptor interaction, disrupting signal transmission and preventing pathway activation.

C: COX inhibitors decrease β-catenin levels by promoting its ubiquitination and proteasomal degradation. PGE2, produced by COX2, mediates β-catenin transcription.

D: Tankyrase activates axin by inducing PARsylation, promoting its degradation. Tankyrase inhibitors raise axin levels, enhancing the β-catenin destruction complex and reducing β-catenin availability.

E: CBP inhibitors disrupt the interaction between CBP and Tcf/Lef, reducing Tcf/Lef activity and affecting downstream gene expression.

F: PORCN inhibitors prevent Wnt protein palmitoylation, hindering their release and limiting Wnt pathway activation.

G: SAM68 disrupts the β-catenin and Tcf/Lef interaction, impairing the transcriptional activity of the Wnt pathway.

TGF β Signalling Pathway

The TGFβ signaling pathway plays a role in various cellular processes in both adults and embryos, including cell growth, differentiation, migration, apoptosis, and homeostasis. It also regulates key physiological processes such as immune function, the vascular system, and embryonic development.



Picture courtesy: https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-183

Fig: TGF-β synthesis and activation.

TGF-βs are produced as inactive precursors with a pre-region (signal peptide) and a pro-region (LAP). Processing starts with proteolytic cleavage, removing the signal peptide. After dimerization, TGF-βs are cleaved by proteases (e.g., Furin) into mature C-terminal peptides and N-terminal LAP. TGF-β-LAP complexes form small latent complexes (SLP) that bind to latent TGF-β binding proteins (LTBP) in the ECM, creating large latent complexes (LLC). LTBP links inactive TGF-β to ECM proteins via transglutaminase-induced crosslinks. Activation occurs when proteases release LLC from the ECM, cleaving the mature protein from LTBP, triggered by acidic conditions, plasmin, or thrombospondin (TSP), thus activating TGF-β for signaling.



Picture courtesy: https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-183

Fig: TGF-β canonical signaling pathway

The SMAD pathway is the main signaling route activated by TGF-β. TGF-β receptor type I (TβRI) binds and phosphorylates SMAD proteins, initiating the signal. This phosphorylation triggers

further steps regulated by feedback mechanisms. Upon ligand binding, TGF-β receptors dimerize, phosphorylate SMAD2/3, which then form a complex with SMAD4. This complex enters the nucleus, binds transcription factors, and activates TGF-β-dependent gene transcription.



Picture courtesy: https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-183/figures/3

Fig: TGF-β non-canonical signaling pathway

TGF-β plays a key role in processes such as apoptosis, epithelial-to-mesenchymal transition, migration, proliferation, differentiation, and matrix formation. It activates various pathways, including the MAPK (ERK1/ERK2, JNK, p38) and PI3K pathways. TGF-β triggers both SMAD-dependent and SMAD-independent JNK activation. In cancer cells, multiple signaling pathways can be activated in response to TGF-β, such as Notch, MAPK, AKT/PKB, GTP-binding proteins, PTK, NF-κB, and Wnt/β-catenin.

Diseases linked to abnormal TGF-β pathways:

- Cancer: TGF-β promotes tumor progression through epithelial-to-mesenchymal transition, neovascularization, and immunosuppression, but acts as a tumor suppressor in early stages.

- Autoimmune Diseases: Dysregulated TGF-β signaling can impair immune tolerance, contributing to autoimmune disorders.
- Inflammatory Bowel Diseases: Disruption in T cell and dendritic cell function can lead to conditions like Ulcerative Colitis and Crohn's disease.
- Cardiovascular Diseases: Abnormal TGF-β signaling affects vascular development and function, increasing cardiovascular disease risk.
- Connective Tissue Disorders: Mutations in TGF-β regulation can cause Marfan Syndrome and Loeys-Dietz Syndrome.
- Neurological Disorders: Disrupted TGF-β signaling is linked to cognitive and neurodegenerative diseases.
- Wound Healing: Excessive TGF-β activation can result in scarring and impaired wound closure.

- Therapeutics for abnormal TGF-β pathways:

- TGF-β Antagonists: Fc: TBetaRll, Beta glucan, Vactosertib, and Avid200.
- Inhibiting TGF-β Production: Receptor kinase blockers like SB-431542, interferon alpha, and antioxidants.
- Modulating TGF-β Signaling Pathways.
- Inducing TGF-β Producing Regulatory T cells.
- TGF-β Based Therapies.

PI3K-AKT-mTOR Signalling Pathway

The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved network in eukaryotic cells that supports cell survival, growth, and progression through the cell cycle. This pathway is regulated by various cross-interactions with other signaling pathways, and disruptions in signal transduction can increase the risk of cancer development.



Picture courtesy:https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-0954-x

Fig.: The overview of the PI3K/AKT/mTOR signalling pathway.

PI3K is a family of lipid kinases composed of three subunits: p85 regulatory, p55 regulatory, and p110 catalytic. It is classified into Class I, II, and III based on structural differences and substrates, with Class I further divided into Class IA and IB. Class IA PI3K, made of p85 and p110 subunits, is linked to human cancers and includes p110α, p110β, and p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD genes. Class IB PI3K consists of p110γ, encoded by the PIK3CG gene.

The p85 regulatory subunit includes variants such as p85a, p55a, and p50a (encoded by PIK3R1), p85b (encoded by PIK3R2), and p55g (encoded by PIK3R3), which activate p110 and mediate signaling. This pathway integrates signals from proteins like tyrosine kinase receptors, PKC, SHP1, Rac, Rho, hormonal receptors, Src, and mutated Ras.

The PI3K-AKT pathway regulates cell growth and proliferation. However, overactivation can lead to uncontrolled cell division and contribute to cancer development.

Molecule	**Alteration in Tumors**	**Frequency**	**Tumour lineage**
PTEN	Mutations (somatic)	>50%	Glioma, melanoma, prostate cancer, endometrial cancer, endometrioid ovarian cancer, variable in sporadic breast cancers (2–30%)
	● Decreased expression ● Methylation ● Loss of heterozygosity	>50%	● Breast, melanoma, prostate ● Microsatellite instability-high colorectal cancer ● Endometrial cancer ● Leukaemia
	Germline mutations	80% of Cowden's disease	High risk of breast, thyroid and endometrial carcinomas
p85	Activating mutations	Rare	Ovary, colon, glioma, lymphoma cell line (CO)
PIK3CA	Amplification	● Up to 50% ● Rare	● Ovary, cervix, lung ● Breast (BRCA1 associated)

	Activating mutation	• >50% • >25%	• Bowel • Breast
AKT2	Amplification	Low	Ovary (12–25%) Pancreas (20%), breast (rare)
	Mutation	Low	Colorectal

Table: Abnormalities in the PI3K/AKT signalling pathway in cancer

Inhibitor	Company	Phase of clinical trial
Dual PI3K and mTOR inhibitors		
BEZ235	Novartis	Phase I/II
BGT226	Novartis	Phase I/II
PI3K inhibitors		
XL147	Exelixis	Phase I
PX866	Oncothyreon	Phase I

Table: PI3K–Akt pathway inhibitors in clinical development for treating cancers



Picture courtesy: https://pmc.ncbi.nlm.nih.gov/articles/PMC8809509/#:~:text=Acute%20treatment%20with%20these%20inhibitors,in%20mice%20and%20monkeys41.

Fig: Proposed approaches to increase the therapeutic index of PI3K inhibitors.

Short-term use of PI3K inhibitors can cause hyperinsulinemia, potentially activating pro-survival pathways in cancer cells. To improve the effectiveness of PI3K inhibitors, strategies include optimizing dosage and scheduling, patient stratification to identify biomarkers and resistance mediators, considering metabolic and dietary factors, and managing common side effects like hyperglycemia, gastrointestinal issues, and skin rashes. Additionally, exploring new methods to inhibit PI3K could help overcome the current limitations of these inhibitors in clinical practice.

Hedgehog Signalling Pathway

The Hedgehog (Hh) signaling pathway transmits signals from the cell membrane to the nucleus, playing a crucial role in embryonic development by establishing polarity and promoting tissue formation in both invertebrates and vertebrates. While typically inactive in adults, the pathway can be reactivated during processes like wound healing. Hh signaling is essential for maintaining

somatic and pluripotent stem cells, supporting tissue repair in organs such as the mammary gland, skin, nervous system, and lungs. It is also vital for regenerating tissues like the lung, prostate epithelium, and exocrine pancreas. In many tissues, Hh signaling occurs primarily in primary cilia (PC), which receive signals and house the pathway components.



Picture Courtesy: https://pmc.ncbi.nlm.nih.gov/articles/PMC5826678/

Fig.: A simplified display of the Hedgehog signalling pathway.

(A) In the absence of the Hedgehog ligand, full-length Gli is phosphorylated by protein kinase A (PKA), glycogen synthase kinase-3 (GSK3), and casein kinase 1 (CK1). This leads to the proteolytic cleavage of GliFL into GliR, a repressor that inhibits the expression of target genes.

(B) When the Hedgehog ligand binds, Smoothened (Smo) is phosphorylated by PKA and CK1. This removes the inhibitory effect of Sufu, forming a Gli activator (GliA) that promotes the transcription of target genes. Red symbols indicate inhibitory effects, and green arrows show activating effects.

Key Terms:

- **Ptch** – Patched

- **Smo** – Smoothened
- **Gli** – Glioma-associated oncogene
- **GliFL** – Full-length Gli
- **GliA** – Gli activator
- **GliR** – Gli repressor



Picture courtesy: https://pmc.ncbi.nlm.nih.gov/articles/PMC5826678/

Fig:Three basic mechanisms of aberrant activation of Hedgehog signaling.

(A) Type I: Ligand-independent Hedgehog signaling
This type involves mutations in **Ptch1** (green asterisk) or **Smo** (red asterisk), leading to the inability of Ptch1 to inhibit the receptor, causing constitutive activation of the Hedgehog pathway without the ligand.

(B) Type II: Ligand-dependent autocrine/juxtacrine Hedgehog signaling
Here, the tumor cell secretes the Hedgehog ligand, which is either taken up by the same tumor cell (autocrine) or nearby tumor cells (juxtacrine), activating the Hedgehog signaling pathway.

(C-1) Type IIIa: Ligand-dependent paracrine signaling
Tumor cells secrete the Hedgehog ligand, which is absorbed by stromal cells. These activated stromal cells then produce signals like **VEGF** and **IGF**, which support tumor cell survival and growth.

(C-2) Type IIIb: Ligand-dependent reverse paracrine signaling
Stromal cells secrete the Hedgehog ligand, which is taken up by tumor cells, aiding in their proliferation and growth.

Dysregulation:
Hedgehog signaling is implicated in various stages of carcinogenesis across tumors. For example, in pancreatic and esophageal cancers, activation is seen in early and metastatic stages. In gastric and prostate cancers, the pathway activation is linked to tissue invasion and increased metastasis. Inhibition of Hedgehog signaling reduces tumor cell proliferation in these cancers.

Therapeutics:
Targeting the Hedgehog signaling pathway has shown promise in treating locally aggressive and metastatic Basal Cell Carcinomas (BCCs), especially where surgery or radiotherapy are ineffective. Over 50 Hedgehog Pathway Inhibitors (HPIs) have been identified, targeting different levels of the pathway, such as Hedgehog ligand inhibitors, Smo antagonists, Gli inhibitors, and others, including BET family protein inhibitors and aPKC inhibitors.

Group	Drug
Hh ligand inhibitors	Neutralizing antibodies (5E1), robotnikinin
Smo antagonists	Cyclopamine Saridegib Vismodegib Sonidegib Glasdegib Taladegib LEQ506 TAK- 441 XL-139 Itraconazole
Gli inhibitors	HPI-1 HPI-2 GANT-56 GANT-61 ATO
BET inhibitors	JQ1
aPKC inhibitors	PSI
Phosphodiesterase inhibitors	NVP-ABE171 cilomilast
Natural products	Deguelin *Siegesbeckia glabrescens* extracts Vitamin D3

Hh - Hedgehog; Ptch - Patched; Smo - Smoothened; Gli - glioma-associated oncogene; BET - bromodomain and extra-terminal domain family of proteins; aPKC- atypical protein kinase C

Picture Courtesy: https://pmc.ncbi.nlm.nih.gov/articles/PMC5826678/

Fig:Targeted tumor therapy associated with Hh signaling pathway

RANK-RANKL-OPG Signalling Pathway

The RANK–RANKL–OPG pathway is vital for processes like bone metabolism, immune function, mammary cell development, and cancer progression. RANKL, a ligand binding to the RANK receptor on osteoclasts, dendritic cells, T cells, and others, activates osteoclast differentiation, leading to bone resorption and reduced bone density. Also known as TNFSF11, OPGL, ODF, and TRANCE, RANKL is a type II membrane protein encoded by the TNFSF11 gene and belongs to the TNF superfamily. It acts as an immunomodulator, crucial for bone regeneration and remodeling.



Picture courtesy: https://arthritis-research.biomedcentral.com/articles/10.1186/ar2165

Fig: The essential signaling pathway for normal osteoclastogenesis.

In normal conditions, RANKL produced by osteoblasts binds to RANK receptors on osteoclast precursors, recruiting the adaptor protein TRAF6. This leads to activation of NF-κB, which then translocates to the nucleus, increasing c-Fos expression. c-Fos interacts with NFATc1 (nuclear factor of activated T cells), which drives the transcription of genes necessary for osteoclast differentiation. OPG, on the other hand, can bind RANKL, preventing its interaction with RANK and inhibiting osteoclastogenesis.



Picture courtesy:https://arthritis-research.biomedcentral.com/articles/10.1186/ar2165

Fig: The role of the RANKL/RANK system in bone and other tissues.

Studies in human and animal models highlight the importance of RANKL/RANK signaling in both normal and disease conditions. OPG prevents osteoclast formation by binding to RANKL, but its broader effects remain unclear. Abnormalities in this pathway are linked to several bone diseases:

- Osteoporosis: Loss of OPG function leads to unregulated osteoclast activation, excessive bone loss, and lower bone density.
- Osteopetrosis: A genetic defect prevents osteoclastic bone resorption.
- Paget's disease: Mutations in RANK's binding or changes in the OPG gene are involved.
- Osteolysis: Occurs after joint arthroplasty when macrophages release RANKL, activating osteoclasts and causing bone loss around implants.

- Therapeutic interventions targeting this pathway include:

- Denosumab: An FDA-approved monoclonal antibody targeting RANKL. It has been used to treat postmenopausal osteoporosis (PMO), showing reduced bone turnover, fewer fractures, and increased bone density.
- Prostate Cancer: In the HALT-prostate cancer trial, denosumab reduced treatment-induced bone loss in non-metastatic prostate cancer patients.

- Breast Cancer: Denosumab improved bone mineral density and reduced bone turnover in hormone receptor-positive breast cancer patients but did not affect survival.

Medroxyprogesterone acetate (MPA), a synthetic progestin, increases RANKL expression, raising breast cancer risk. Blocking RANKL reduces MPA-induced breast cancer, suggesting RANKL inhibition could aid in prevention and treatment.

Conclusion

Understanding cellular signaling pathways is essential for comprehending how cells regulate processes like growth, differentiation, and immune responses. These pathways are tightly controlled by proteins, enzymes, and receptors, and disruptions can lead to diseases such as cancer, metabolic disorders, and autoimmune conditions.

Targeted therapies have emerged as an effective approach for treating diseases caused by dysregulated signaling. By focusing on specific molecules within these pathways, these therapies aim to block abnormal signaling with fewer side effects than traditional treatments. Advances in molecular biology, genomics, and bioinformatics have accelerated their development.

However, challenges remain in fully understanding the complexity of signaling networks and identifying optimal therapeutic targets. Ongoing research and clinical trials will be key to refining targeted therapies and creating more precise, personalized treatments.

References:

1. Kumar, Vinay, et al. *Robbins & Cotran Pathologic Basis of Disease*. Elsevier, 2020.
2. "cGMP-PKG Signaling Pathway." *Cusabio Life Science*, Cusabio Life Science, n.d. www.cusabio.com/pathway/cGMP-PKG-signaling-pathway.html?srsltid=AfmBOoqYm80PUAAUPoMe4nQatBMDtHKgIPOeTyUy5o7-8ZvK9Jbgvf2w. Accessed 16 Mar. 2025.
3. "The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction." *Journal of the American Heart Association*, American Heart Association, www.ahajournals.org/doi/10.1161/JAHA.113.000536. Accessed 16 Mar. 2025.
4. "Cyclic GMP Modulating Drugs in Cardiovascular Diseases: Mechanism-Based Network Pharmacology." *Cardiovascular Research*, Oxford Academic, academic.oup.com/cardiovascres/article/118/9/2085/6322953. Accessed 16 Mar. 2025.

5. "CAMP-Dependent Pathway." *Wikipedia*, Wikimedia Foundation, 2024. en.wikipedia.org/wiki/CAMP-dependent_pathway. Accessed 16 Mar. 2025.
6. "Biophysical Journal." *Cell Press*, www.cell.com/biophysj/fulltext/S0006-3495(19)30863-X. Accessed 16 Mar. 2025.
7. Schubert, L., et al. "MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data." *MDPI*, MDPI, www.mdpi.com/2072-6694/15/3/710. Accessed 16 Mar. 2025.
8. Hu, X., et al. "The JAK/STAT Signaling Pathway: From Bench to Clinic." *Nature News*, Nature News, www.nature.com/articles/s41392-021-00791-1. Accessed 16 Mar. 2025.
9. Liu, T., et al. "NF-κB Signaling in Inflammation." *Nature News*, Nature News, www.nature.com/articles/sigtrans201723. Accessed 16 Mar. 2025.
10. Pai, S.G., et al. "Wnt/beta-Catenin Pathway: Modulating Anticancer Immune Response." *Journal of Hematology & Oncology*, BioMed Central, jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0471-6. Accessed 16 Mar. 2025.
11. Skoda, A.M., et al. "The Role of the Hedgehog Signaling Pathway in Cancer: A Comprehensive Review." *Bosnian Journal of Basic Medical Sciences*, BioMed Central, pmc.ncbi.nlm.nih.gov/articles/PMC5826678/. Accessed 18 Mar. 2025.
12. Yang, J., et al. "Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials." *Molecular Cancer*, BioMed Central, molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-0954-x. Accessed 18 Mar. 2025.
13. "TGF Beta Signaling Pathway." *Wikipedia*, Wikimedia Foundation, 2024. en.wikipedia.org/wiki/TGF_beta_signaling_pathway. Accessed 18 Mar. 2025.
14. Boyce, B.F., and L. Xing. "Biology of RANK, RANKL, and Osteoprotegerin." *Arthritis Research & Therapy*, BioMed Central, arthritis-research.biomedcentral.com/articles/10.1186/ar2165. Accessed 18 Mar. 2025.

CHAPTER 5

APPLICATION OF NANOTECHNOLOGY IN BIOMEDICINE

Dr. Koustav Chowdhury [1] , Dr Somashree Manna[2], Dr.Lopamudra Dhar Chowdhury[3] Shreya Agarwal[4]

[1] Assistant Professor, Department of Pharmacology, R.G. Kar Medical College and Hospital,

[2] Senior Resident, Department of Pharmacology, Tamralipta Govt. Medical College and Hospital, [3] Professor,Head, Department of Pharmacology, R.G. Kar Medical College and Hospital,

[4] Final year MBBS, R.G. Kar Medical College and Hospital

ABSTRACT

This chapter explores the transformative field of nanomedicine, detailing its fundamental principles, historical evolution, and diverse applications in healthcare. It defines key concepts like nanotechnology, nanomedicine, and nanopharmacology, emphasizing the unique properties of nanoscale materials. The chapter discusses the potential cytotoxicity of nanoparticles and the factors influencing it. It further elaborates on the use of metal and metal oxide nanoparticles in medical devices and diagnostics, including imaging and biosensing. A significant portion is dedicated to nanotechnology in implant surface engineering for enhanced biocompatibility and the role of various nanoparticle types (liposomes, carbon nanotubes, quantum dots, etc.) in targeted drug delivery and cancer therapy, including magnetic hyperthermia and photoablation. The chapter concludes by highlighting the advantages of nanomedicine in reducing side effects and improving drug efficacy through controlled nanocarrier characteristics.

Introduction :

- Nano is derived from the Greek word 'nanos' meaning dwarf. It is a factor of 10^{-9}. Nanoscale materials have one or more dimensions of 100 nanometres or less.
- Nanotechnology refers to the branch that measures, manufactures and manipulates at atomic and molecular level for the purpose of creating materials, devices, systems with fundamentally novel molecular organization, properties and function.
- Nanomedicine refers to science and technology of diagnosing, treating and preventing injuries, relieving pain, improving human health using molecular
- tools and molecular knowledge of the human body.
- Nanopharmacology refers to application of nanotechnology in development / discovery of methods to deliver drugs to selected targets to improve pharmacokinetic-pharmacodynamic profile towards safer and effective treatment. There are two types of

nanopharmaceuticals- nanoengineered drugs (molecules themselves are drugs) and drug delivery as nanocarriers.

The ability to find and use substances at the molecular level has given a boost to the find for materials with amazing properties for use in medicine. The study and use of these materials has generated the new field of research of nanobiotechnology, which plays a central role in disease diagnosis, drug design and delivery, and implants.

Nanoparticles have unique physicochemical properties for use in biomedicine, however, their cytotoxicity has been demonstrated in a few cases and have raised concern about their clinical application. Nanoparticles ideally must be non-toxic and biocompatible in order to be successful in biomedical applications. Nanoparticles can easily enter the body due to their small size and reach very sensitive organs through different routes. Cytotoxicity of nanoparticles is dependent on various parameters such as size, shape, charge of surface, chemistry, and surface modifications. There are several cytotoxicity assays for nanoparticle cytotoxicity assessment. The generation of reactive oxygen species(ROS) due to the higher surface area to volume ratio of nanoparticles is the main mechanism responsible for their cytotoxicity that can result in oxidative stress and damage to cell functions and even cell death.



Picture courtesy: https://pmc.ncbi.nlm.nih.gov/articles/PMC5425815/
Fig: Nanobiotechnology and its main tools

Metal Oxide Nanoparticles in Medicine

Metal oxide nanoparticles have found significant applications in the development of various medical devices. Their unique characteristics make them suitable for a wide range of biomedical purposes, including:

- High Surface Area
- Electronic Sensitivity
- Antimicrobial Activity
- Biomedical Applications
- Catalysis
- Gas Sensing
- Water Treatment
- Green Synthesis

For example, iron oxide's magnetic properties are utilized for both therapeutic and diagnostic applications, such as serving as contrast agents in magnetic resonance imaging (MRI), magnetic particle imaging (MPI), and ultrasonic methods. Zinc oxide (ZnO) nanowires exhibit intrinsic fluorescence, making them useful for imaging cancer cells. By functionalizing the surface of ZnO nanowires, their water solubility, biocompatibility, and cellular toxicity can be improved, which also aids in the creation of photosensitive biosensors for specific biomolecules. Titanium oxide (TiO2) is employed in various biomedical fields, such as in bone regeneration. A thin TiO2 layer forms naturally when biofluids interact with the surface of metallic titanium, which enhances its use for bone-substituting materials.

Metal Nanoparticles in Medical Devices

Metal nanoparticles are essential for applications in sensing and diagnostics, especially due to their absorption and scattering properties in visible and near-infrared light spectra. Noble metals, due to strong optical absorption through surface plasmon resonance or the accumulation of surface electrons, make excellent candidates for medical device construction. For instance, gold nanoparticles, when added to substrates, can enhance luminescence. Their absorption and scattering characteristics depend on the particles' size and shape, making them versatile for various medical applications. Gold nanorods, which absorb in the near-infrared spectrum, have been used to monitor blood flow in vivo through photoacoustic imaging. Silver nanoparticles (AgNPs), known for their antibacterial and anti-inflammatory properties, have been used in biosensing and as coatings for materials in cardiovascular implants, central venous, and neurosurgical catheters.

Nanotechnology in Implant Surface Engineering

Nanotechnology can enhance the surface properties of metallic implants to improve bioactivity, enable the release of beneficial bioactive agents, and prevent the release of harmful substances like metal ions. Modifying the surface area and roughness at the nanoscale can lead to improved interactions between osteogenic cells and the implant, ensuring effective mechanical contact and better biological outcomes. For effective osseointegration, rapid bone tissue formation at the implant surface is critical. Following implantation, the cell does not encounter a pristine surface but interacts with a conditioned surface influenced by water molecules, ions, and adsorbed proteins. These initial events at the tissue-implant interface are crucial for cell attachment and behavior, and are determined by the implant's surface properties such as topography, wettability, charge, and chemical composition. Biomimetics, which aims to replicate natural structures at the nanoscale, has proven valuable in enhancing the bone regeneration process. Coatings made of calcium phosphates (CaP) are often used to improve implant functionality.

Liposomes in Drug Delivery and Biotechnology

Liposomes are spherical vesicles composed of lipid bilayers, and their properties can be customized by adjusting the lipid composition, surface charge, and size. Liposomes can range from small unilamellar vesicles (20–100 nm) to large unilamellar vesicles (LUVs) (200–1000 nm) and can be multi-lamellar with diameters between 400 and 3500 nm. These vesicles have significant potential in drug delivery, biomimetic modeling, and studying the interaction of membranes with hydrophobic drugs and proteins. Protein-associated liposomes (proteoliposomes) are used in photodynamic therapy, helping track the effects of photosensitive dyes.

Carbon Nanotubes in Drug Delivery

Carbon nanotubes (CNTs) possess exceptional physical and chemical properties, making them ideal for nanobiotechnology applications. Surface modifications of CNTs enable them to interact with biological molecules, increasing their compatibility with physiological environments. Their small size allows them to efficiently deliver drugs within the body. For example, methotrexate, a chemotherapy drug, shows improved bioavailability when immobilized on double-functionalized CNTs. CNTs can either house the active compound within the tube or bind it to the surface, allowing targeted drug delivery and modulation of cell behavior at the molecular level. CNTs also have the ability to navigate cellular barriers, interact with DNA, and facilitate gene therapy by complexing with plasmid DNA. Additionally, CNTs serve as scaffolds for osteoblast proliferation, aiding in bone regeneration.

History of nanotechnology :

The concept of nanotechnology traces back to Richard Feynman, who is often referred to as its founding figure. The term "nanotechnology" was coined by Norio Taniguchi. Eric Drexler later introduced the concept of a "nano assembler," envisioning a device capable of arranging atoms with precision. In India, Professor C.N.R. Rao is recognized as the father of Indian nanotechnology. He made significant contributions to the field, including the development of successful nanomedicines such as pegylated liposomal doxorubicin for treating Kaposi sarcoma, and Abraxane, a nanoparticle formulation of paclitaxel bound to human albumin, for metastatic breast cancer.

Although the use and fabrication of nanoscale materials can be traced back to ancient times, nanomedicine as a distinct and modern scientific field emerged in the 1990s. This discipline evolved from the study of ultra-small devices and the exploration of cellular, molecular, and atomic structures in fields such as biology, chemistry, and physics. Richard P. Feynman's vision in the 1950s laid the foundation for nanotechnology, which ultimately led to the development of nanomedicine as an important area of research in science and medical treatments.

Overview of Mechanism of Nanomedicine

In the field of nanomedicine, large molecules, such as polymers, are combined with drugs in a controlled chemical environment. Under specific chemical and pH conditions, the polymers encapsulate the drug molecules, forming nanoparticles through a process known as self-assembly.

Once formed, these nanoparticles can undergo modifications to their surfaces, such as the attachment of ligands designed to target specific cells, like cancerous tumor cells. After injection into the bloodstream, the nanoparticles travel to their target sites, where they interact with the corresponding receptors on the target cells, facilitated by the specific ligands on the nanoparticle surface.

Upon reaching the target cell, the nanoparticles are taken up by the cell through endocytosis. Once inside the cell, the nanoparticles break down, releasing the drug directly at the site of action. This process ensures precise targeting and enhanced therapeutic efficacy.

Application of nanotechnology:

Picture courtesy:
https://www.tandfonline.com/doi/full/10.1080/23746149.2016.1254570#d1e526
Fig: Biomedical applications of Nanotechnology to biomedicine.

Medical Instruments:

- **Nanosilver-coated catheters** possess antimicrobial properties, helping reduce infections.
- **Polyvinyl alcohol** is used to coat artificial heart valves to prevent blood clots.

- **Diagnostic and Bioimaging:**

- **Imaging:** Nanoparticles, particularly superparamagnetic iron oxides, are employed as contrast agents in noninvasive imaging techniques like MRI to detect lymph node involvement in prostate cancer.
- **Identification:** Lab-on-a-chip devices offer in vitro diagnostics based on nanoscale technology, facilitating precise bioassays.
- **Point-of-care diagnostics:** Nanotechnology aids in fast and accurate diagnosis of diseases like cancer and infections, leading to early treatment interventions. Nanoparticles such as gold, silver, quantum dots, and magnetic nanoparticles are increasingly used in point-of-care diagnostics.
- **Fe–Pt nanoparticles** are used as contrast agents in MRI and CT scans. These amphiphilic nanoparticles have both hydrophilic and lipophilic properties, and are synthesized using high-temperature pyrolysis in tetraethylene glycol with oleic acid as a surfactant.



Tissue Repair and Replacement:

- **Nanoceramics** serve as structural implants for bone repair.
- **Polyvinyl alcohol nanopolymers** are used as scaffolds for tissue regeneration, particularly in corneal surgeries.
- **Nanofibers** and **nanopatterned scaffolds**, along with **growth factor-loaded nanoparticles**, regulate cell growth effectively for regenerative medicine.
- **Artificial bone grafts** like TiO2 and **AgNPs (silver nanoparticles)** promote faster, infection-free wound healing.

Targeted Drug Delivery:

- **Precise drug release** and enhanced **bioavailability** are major benefits of nanomedicine.
- Nanoparticles such as liposomes, micelles, and biodegradable systems enable controlled antigen release, stable adjuvants, and improved vaccine delivery.
- Targeted delivery systems like liposomes, dendrimers, and micelles deliver drugs directly to diseased cells, reducing side effects.

Biosensors:

Nanowires, **nanotubes**, **nanocantilevers**, and **quantum dots** are used as highly sensitive biosensors for detecting biomarkers. Gold and carbon-based nanoparticles are especially favored due to their unique properties, offering greater sensitivity, selectivity, and faster response times.

Magnetic Hyperthermia:

Magnetic hyperthermia uses heat to treat cancer by raising the temperature of tumor cells to 41-46°C, causing cell death (apoptosis) without harming healthy tissues. This method, often combined with chemotherapy or radiotherapy, is applied in localized, regional, or whole-body treatments. Magnetic nanoparticles are employed in local hyperthermia to specifically target and heat the tumor area.

Photoablation Therapy:

- Photoablation therapy is divided into **Photodynamic Therapy (PDT)** and **Photothermal Therapy**.
- **PDT** uses light-sensitive compounds like **TiO2 nanoparticles** that, when exposed to light, generate reactive oxygen species (ROS), leading to cancer cell death.
- **Photothermal Therapy** uses near-infrared light to heat and destroy tumor cells by converting light energy into heat.

Types of Nanoparticles:

- **Fullerenes** are carbon-based nanomaterials with unique properties, like stability and conductivity. C60, also known as buckyballs, is a spherical molecule widely used in research and applications.
- **Carbon nanotubes** are strong, thermally stable, and have excellent electrical conductivity. They are used for drug delivery, especially for cancer treatments.
- **Nanowires** are used for diagnostic purposes and have potential therapeutic applications in diseases like Parkinson's. These nanoscale wires can also be used to detect brain abnormalities or monitor seizures.
- **Quantum dots** are semiconductor nanoparticles with tunable optical properties, commonly used in cancer drug targeting due to their ability to emit bright fluorescence and conduct electricity.
- **Dendrimers** are tree-like branched nanoparticles used for gene transfer, medical imaging, and targeted drug delivery, with controlled sizes and functional groups.
- **Nanocapsules** are nanoparticles with a core that encapsulates drugs or bioactive substances, surrounded by a protective polymer shell. These are used for controlled drug delivery.
- **Nanospheres** are solid nanoparticles composed of dense polymeric materials, unlike nanocapsules, and are typically used in drug delivery systems.
- **Nanoshells** have a metallic outer layer (often gold) and a silica core, and are used for cancer treatment and biomedical imaging.
- **Nanopores** are small holes embedded in membranes and used in biotechnology for genetic engineering and DNA sequencing by measuring the change in ionic current as molecules pass through.
- **Gold nanoparticles (GNPs)** are widely used in genetic engineering and cancer therapies due to their biocompatibility and ease of functionalization for drug delivery.
- **Nanocochleates** are lipid-based nanocarriers capable of encapsulating both hydrophobic and amphipathic drugs, offering enhanced stability for drug delivery systems.

Role of nanotechnology in cancer treatment:

- Tumorous tissue has enhanced permeability and retention (EPR) effect. As the blood vessel surrounding the tumour is defective and porous, nanoparticles can easily penetrate to target specific cancer cells.
- Quantum dots are highly fluorescent nanoparticles of semiconductor material. They infiltrate cancer cells only due to EPR effect and do not enter into normal tissue, this technique has higher sensitivity than other diagnostic tests.

- Concept of thermal ablation- in presence of a near infrared light nanoshell which infiltrates only into tumor cells, absorbs heat and through thermal ablation only cancer cells are killed : targeted therapy.
- Nanofibres – provide controlled and sustained release of anticancer drugs for preventing local tumor recurrence after surgical removal

Advantages of nanomedicine :

Reduced Side Effects and Drug Toxicity:
Nanomedicine helps in minimizing the adverse effects and toxicity of drugs. By controlling the size and charge of nanocarriers, the drug can be delivered more precisely, ensuring fewer side effects.

Controlled Nanocarrier Characteristics:
Nanocarriers can be engineered to have precise size and charge, allowing for more accurate delivery of drugs to targeted sites, improving the therapeutic effect while minimizing unwanted side effects.

Sensitive Diagnosis:
Nanoscale sensors have greatly advanced diagnostic methods by enabling faster and more accurate detection of diseases. Modern imaging techniques such as CT scans, MRI, and nanosensors have made it possible to identify biomarkers even at very low concentrations, leading to earlier disease detection and better treatment outcomes.

Targeted Therapy and Drug Delivery:
A key benefit of nanomedicine is its ability to deliver drugs directly to the targeted site, such as cancer cells, sparing healthy cells from damage. This targeted approach reduces side effects and enhances the effectiveness of treatments. Additionally, nanotechnology enhances the solubility, stability, and bioavailability of drugs, improving their overall performance.

Overcoming Biological Barriers:
Nanomedicines can also cross biological barriers, such as the blood-brain barrier, to deliver drugs where they are most needed. For example, nanorobots can be used to administer drugs or perform surgeries in areas that are otherwise difficult to reach with traditional methods.

Personalized Medicine:
Nanomedicine enables treatments to be tailored specifically to individual patients, offering a more patient-centered approach. By targeting specific areas of the body, this method reduces damage to healthy cells, increases drug effectiveness, and lowers the overall toxicity of treatments.

Regenerative Medicine:
Nanomedicine has the potential to not only regenerate tissues but also repair damaged cells. Nanofibers can be used to create scaffolds for tissue engineering, while nanocarriers can deliver growth factors and other essential molecules to promote tissue healing and repair.

Safety and Efficacy:
Nanomedicines provide new opportunities to enhance the effectiveness and safety of existing treatments. Drugs with low bioavailability can be more effectively targeted to specific regions, improving therapeutic outcomes. The high surface-to-volume ratio of nanomaterials allows for reduced dosages while still achieving effective results

Limitations:

Selection of Appropriate Nanocarriers:

Choosing suitable nanocarriers is crucial for effective drug delivery. Ideal carriers should be consistent, non-immunogenic, biodegradable, easy to fabricate, and low-cost.

Ethical Issues in Nanomedicine:

Nanomedicine introduces ethical challenges, particularly concerning risk assessment, management, and communication during clinical trials. Addressing informed consent, respecting patient autonomy, and ensuring equitable access are also significant concerns.

Environmental Concerns:

The disposal of nanoparticles via water or air can lead to environmental contamination. Chronic exposure to low levels of nanoparticles may cause adverse effects on non-target organisms, including oxidative stress, DNA damage, and inflammatory responses.

Intracellular Effects:

Within cells, nanoparticles can generate reactive oxygen species (ROS), potentially causing DNA damage, apoptosis, and other cytotoxic effects.

Challenges in Pharmaceutical Development:

Translating nanotechnology from laboratory research to marketable products involves several challenges, including:

- **Physicochemical Characterization:**
- **Biocompatibility and Nanotoxicology Evaluation:**

- **Pharmacokinetics and Pharmacodynamics Assessment:**
- **Process Control and Scalability:**

Addressing these issues is essential for the successful development and clinical application of nanomedicines.



Picture courtesy:https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2018.00360/full

Fig: Schematic representation of the several "barriers" found throughout the development of a nanomedicine product.

- **Physicochemical Characterization of Nanomedicine:**

The physicochemical characterization of nanomedicines is critical for understanding their behavior in the human body and for guiding process control and safety assessments. However, achieving a comprehensive and correct characterization is challenging, as it involves numerous parameters. Ideally, the characterization should be conducted at various stages of a nanomaterial's life cycle, from design to in vitro and in vivo performance evaluation. The interaction with biological systems and sample preparation can alter the properties of the

nanomaterial, affecting measurement accuracy. Moreover, assessing the physicochemical properties in these contexts is essential for evaluating the potential risks associated with nanomaterials.

Nanoparticles can be categorized into different groups based on various methods used for their characterization, such as counting, ensemble, separation, and integral techniques.

Counting Methods:
These methods allow for the individual identification of each nanoparticle, enabling the measurement and visualization of their morphology. Microscopy techniques such as Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), High-Resolution TEM, cryo-SEM, Atomic Force Microscopy (AFM), and Particle Tracking Analysis are commonly used for this purpose. The drawback of these methods is that they typically require a high-vacuum environment, although advances in cryo-SEM have helped prevent sample dehydration during imaging.

Fractionation Methods:
These techniques involve two key steps: separating particles into monodisperse fractions and detecting each fraction. Methods like Field-Flow Fractionation (FFF), Analytical Centrifugation (AC), and Differential Electrical Mobility Analysis are examples of fractionation techniques used to separate and analyze particles.

Ensemble Methods:
Ensemble techniques provide intensity-weighted particle sizes and determine size distribution based on variations in the measured signal over time. Dynamic Light Scattering (DLS), Small-Angle X-ray Scattering (SAXS), and X-ray Diffraction (XRD) are common ensemble methods for characterizing particle size and distribution.

Integral Methods:
Integral methods measure specific properties of the particles, typically focusing on determining the specific surface area. The Brunauer-Emmett-Teller (BET) method, which involves the adsorption of inert gas on the nanomaterial's surface, is widely used. Electrophoretic Light Scattering (ELS) is another method used to measure zeta potential, which indicates the overall charge a particle acquires in a specific medium. ELS is based on the principle of electrophoresis and measures the electrophoretic mobility of particles in dispersion.

Process Control – Understanding Key Manufacturing Steps:A significant challenge in pharmaceutical development is controlling the manufacturing process by identifying critical

parameters and technologies for analysis. The "Quality-by-Design" (QbD) approach, supported by Process Analytical Technologies (PAT), is recognized as a systematic method for evaluating and controlling nanomedicines. Instead of testing quality in nanomedicine, this approach ensures it is built into the product by thoroughly understanding the medicine's therapeutic purpose, pharmacological, pharmacokinetic, toxicological, chemical, and physical properties. By focusing on the relationships between these properties, formulation parameters, and manufacturing processes, this approach helps to develop more effective processes that guarantee high-quality nanomedicines.

Biocompatibility and Nanotoxicology:

Biocompatibility is a critical aspect of designing drug delivery systems. A biocompatible material is one that does not trigger harmful responses in the body. In essence, biocompatibility refers to the ability of a material to function appropriately in a specific application without causing adverse effects. Pre-clinical evaluations of nanomaterials involve a thorough biocompatibility testing program, typically including both in vivo studies and selected in vitro assays to confirm safety. If a nanomaterial's biocompatibility cannot be assured, concerns about potential toxicity may arise. Despite efforts to standardize safety evaluation procedures, nanomaterials are often treated as conventional chemicals, and clear, specific guidelines for their regulation are still lacking.

Recent advances:

Nanotechnology and vaccine- Pfizer- BioNTech and Moderna vaccines: both are mRNA COVID 19 vaccines (lipid nanoparticles encapsulates mRNA and prevent its degradation before reaching target cell).

Examples of FDA approved nanomedicines:

Clinical agents	Formulations	Application
Eligard	Leuprolide acetate and polymer	Prostate cancer
Genexol PM	mPEG-PLA micelle loaded with paclitaxel	Metastatic breast cancer
Doxil/Caelyx	Liposomal doxorubicin	Ovarian,breast cancer, Kaposi sarcoma,multiple myeloma
Onivyde	Liposomal irinotecan	Pancreatic cancer
Cynviloq	Paclitaxel loaded poly(ethylene glycol)-b-poly(D,L-lactic acid)block copolymers	Non small cell lung cancer and metastatic breast cancer

Future vision:

Potential Uses of Nanorobots: Nanorobots, typically ranging from 50 to 100 nm in size, are engineered to perform specific tasks, such as **diagnosis**, **nanosurgery**, and **targeted drug delivery** for conditions like **diabetes mellitus** and **atherosclerosis**. These tiny robots have the potential to revolutionize drug delivery systems by targeting drugs precisely to affected areas, significantly enhancing their effectiveness while minimizing side effects.

The nanorobots are equipped with walls that are only 5 to 10 atoms thick, and the interior of these robots is typically 50–100 nm wide, filled with the drug. When they detect disease markers, electrical pulses are emitted from the thin wires in their walls, causing the walls to dissolve and release the drug. The ability to control drug release precisely by adjusting the electrical pulse is a significant advantage. Additionally, because the walls of the nanobots dissolve easily, they pose minimal harm to the body.



Picture Courtesy: https://www.sciencedirect.com/topics/engineering/nanobots
Fig: shows a device that uses nanobots to monitor the sugar level in the blood.

Neuro Nanotechnology: The application of nanoparticles to enhance the nervous system is an emerging field with significant potential. Nanobots designed to improve neuronal communication could help address the difficulties associated with diagnosing and treating CNS disorders, especially due to the blood-brain barrier (BBB). The BBB limits the ability of larger molecules, including medications, to penetrate the brain, complicating the effectiveness of systemic treatments. By utilizing nanoscale devices, it may be possible to either bypass the BBB or

provide precise, localized treatment to affected areas of the brain, thereby enhancing both diagnosis and treatment for CNS diseases. These nano-based approaches could serve various purposes, such as:

- Providing neuroprotective effects to safeguard neurons.
- Acting as drug delivery systems that allow for targeted and controlled release.
- Enabling neuroimaging to improve diagnostic capabilities.
- Serving as scaffolds for neuroregeneration, aiding in the repair and growth of damaged brain cells.
- Functioning as surgical tools for minimally invasive procedure



Picture courtesy: https://biomedical-engineering-online.biomedcentral.com/articles/10.1186/s12938-022-01062-y

Fig: Neuro-engineering nanoparticle toolkit. The anatomical configuration of the brain at various dimensions (top) and the various forms of organic and inorganic nanostructures that have been used in neuroscience are shown in this diagram

❖ Drug Delivery Targets in the Brain: The use of nanoparticles loaded with doxorubicin for glioblastoma treatment is an exciting area of research. Glioblastoma, an aggressive brain cancer, is notoriously difficult to treat, as many therapies struggle to cross the BBB. Nanoparticles offer a promising solution for:

- Increasing drug effectiveness within the brain by targeting cancer cells more precisely and reducing side effects throughout the body.
- Improving therapeutic outcomes by delivering higher drug concentrations directly to the tumor site.

❖ Ongoing Phase I/II clinical trials for doxorubicin-loaded nanoparticles are critical for assessing their safety and effectiveness. If successful, these trials could pave the way for groundbreaking advancements in treating brain tumors and other CNS disorders using nanoparticle-based therapies.

References:

1. Sarkar, S. *Carrier Based Novel Drug Delivery System*. 1st ed., Paras Medical Publisher, 2020, pp. 5545, 555.
2. Maiti, R. *Postgraduate Topics in Pharmacology: New Drug Delivery System*. 3rd ed., Paras Medical Books Pvt. Ltd., 2020, pp. 123-25, 336.
3. Jain, H., et al. "Design and Manufacture of a Polyvinyl Alcohol (PVA) Cryogel Tri-Leaflet Heart Valve Prosthesis." *Medical Engineering & Physics*, vol. 26, no. 4, May 2004, pp. 269-77. doi:10.1016/j.medengphy.2003.10.007.
4. Arcos, D. "Nanomaterials in Biomedicine 2022." *International Journal of Molecular Sciences*, MDPI, pmc.ncbi.nlm.nih.gov/articles/PMC10218959/. Accessed 19 Mar. 2025.
5. "Nanobots." *ScienceDirect Topics*, ScienceDirect, www.sciencedirect.com/topics/engineering/nanobots. Accessed 19 Mar. 2025.
6. Shabani, L., et al. "Neuro-Nanotechnology: Diagnostic and Therapeutic Nano-Based Strategies." *Biomedical Engineering Online*, BioMed Central, biomedical-engineering-online.biomedcentral.com/articles/10.1186/s12938-022-01062-y. Accessed 19 Mar. 2025.
7. "Redirecting." *Journal of Controlled Release*, Elsevier, doi.org/10.1016/j.jconrel.2012.03.020. Accessed 19 Mar. 2025.
8. "Redirecting." *Journal of Controlled Release*, Elsevier, doi.org/10.1016/j.jconrel.2024.12.056. Accessed 19 Mar. 2025.
9. "Tandfonline." *Drug Delivery and Translational Research*, Taylor & Francis, tandfonline.com/doi/abs/10.1080/23746149.2016.1254570. Accessed 19 Mar. 2025.

CHAPTER 6

BEYOND CHEMOTHERAPY: UNLEASHING THE IMMUNE SYSTEM FOR DURABLE CANCER REMISSION

Dr Koustuv Chowdhury [1] , Shrestha Majumder [2], 2 , Bhumika Mondal [3]

[1] Assistant Professor, Department of Pharmacology, R.G. Kar Medical College, Kolkata,

[2] & [3] Final year M.B.B.S Student, R.G. Kar Medical College. Kolkata,

Corresponding Author - Dr Koustuv Chowdhury, Email Id –chowdhurykoustuv@gmail.com

Affiliations:
Final year MBBS student, R.G.Kar Medical College
Final year MBBS student, R.G.Kar Medical College

Introduction

Cancer remains one of the most intricate and formidable diseases, drawing significant attention in clinical research due to its status as a leading cause of mortality worldwide. Traditional cancer treatments, particularly chemotherapy, have notable limitations that affect both treatment efficacy and patient quality of life, underscoring the urgent need for novel therapeutic approaches. Despite these challenges—such as lack of specificity, drug resistance, and inconsistent effectiveness—chemotherapy continues to be the most commonly utilized treatment. However, these limitations highlight the importance of developing more targeted and combination therapies to enhance treatment outcomes.

Recent breakthroughs in biological therapies, immunotherapy, and gene therapy are transforming cancer treatment, offering new possibilities for improved patient survival and better quality of life. These advancements are driven by a deeper understanding of cancer biology and its microenvironment, facilitating the development of personalized treatment strategies tailored to the molecular characteristics of individual tumors. Biological cancer therapies involve naturally occurring or laboratory-processed compounds that either directly destroy cancer cells or stimulate the immune system to target them more effectively. Ongoing research in biological therapies has been progressing rapidly due to their potential to specifically target cancer while minimizing damage to healthy cells.

One of the key advancements in targeted therapy is the use of next-generation sequencing (NGS) to identify rare genetic mutations in cancer cells, enabling the customization of treatments for

individual patients. Targeted therapies work by inducing genetic alterations in tumor suppressor genes and oncogenes, which play a crucial role in cancer progression. Several molecular agents have been developed for this purpose. For example, Vemurafenib is used as a BRAF inhibitor in melanoma patients, while Osimertinib—approved by the FDA and EMA in 2017—is effective in treating non-small-cell lung cancer (NSCLC) with EGFR T790M mutations. Additionally, Imatinib, a tyrosine kinase inhibitor, has revolutionized chronic myeloid leukemia (CML) treatment by blocking BCR-ABL activity, ultimately improving survival rates and achieving clinical remission in patients.

The tumor microenvironment plays a significant role in cancer development, influencing factors such as proliferation, drug resistance, adhesion, and metastasis. Understanding these elements is critical for advancing cancer research and developing more effective treatments. This paper aims to explore the latest advancements in biological therapies and assess their potential in providing more effective cancer treatment compared to conventional methods. By delving into cancer biology and utilizing innovative, targeted approaches, researchers and clinicians can develop more personalized and effective treatments to alleviate the global cancer burden.

Types and Mechanisms of Immunotherapy

The progression of cancer is influenced by the delicate balance between malignant cells and immune cells. Immunotherapies are designed to counteract the proliferation of cancer cells and shift this balance in favor of the immune system . There are several types of immunotherapy, each working in different ways to boost the immune response against tumors.

(a)**Monoclonal Antibodies**: These synthetic proteins are designed to selectively attack cancer cells, representing a key example of personalized medicine in which drugs are tailored to each patient

(b)**Next-Generation Antibodies**: Advances in antibody technology have led to the development of highly specific treatments that improve efficacy and reduce side effects.

(c)**CAR-T Cell Therapy:** T cells are extracted from a patient, genetically modified to better recognize cancer cells, and then reintroduced into the patient

(d)**Checkpoint Inhibitors**: These agents act as brakes, allowing the body's immune system to recognize and attack cancer cells more effectively

(e)**Cancer Vaccines:** These vaccines introduce cancer antigens to the body, helping the immune system to recognize and attack cancer cells

(f)**Cytokine Therapy**: Cytokines are proteins that stimulate immune cells to attack cancer cells. The inflammation caused by the immune system aids in the elimination of cancer cells

(g)**Immunomodulators**: These agents enhance imm8unity against cancer cells by modifying the immune system to be more active

(h)**Oncolytic Viruses**: These viruses, which can be either naturally occurring or synthesized in laboratories, are used to kill tumor cells

By leveraging these immunotherapy approaches, researchers are making significant strides in creating more precise, effective, and patient-friendly cancer treatments. As science continues to evolve, these novel therapies hold great promise for reshaping the future of cancer treatment and improving patient outcomes.

Monoclonal Antibodies in Cancer Therapy

Monoclonal antibodies (mAbs) are laboratory-made molecules designed to t is a human IgG1 mAb that can inhibit the function of CTLA-4 and was first approved and recommended for the treatment of melanoma in 2011 arget specific antigens present on cancer cells. These antibodies are created by cloning a single type of immune cell, allowing them to bind to particular proteins on cancer cells, blocking their growth, or marking them for destruction by the immune system. Monoclonal antibodies have become an important tool in cancer therapy, offering targeted treatment for various types of cancer, including breast, colon, and lung cancer.



Courtesy: https://en.m.wikipedia.org/wiki/Monoclonal_antibody

Diagnostic: mAb used in various diagnostic tests like

1. Western blot testing
2. Immunofluroscence test
3. Immunohistochemistry
4. Immunoprecipitation and affinity chromatography
5. Immunoscintigraphy

ARCITUMOMAB : murine CEA mAb used for imaging in carcinoma of colon
CAPROMABPENDETIDE : murine mAb specific for prostate specific antigen usually coupled with iridium-111 and used in immunoscintigraphy of prostate.
NOFETUMOMAB: used in small cell lung cancer imaging.
SATUMOMAB : murine monoclonal igG that binds to tumour associated glycoprotein 72 (TAG72) found in ovarian cancer and used for imaging purpose in ovarian cancer

Therapeutic.

Anti-CD20 :

RITUXIMAB: its mechanism of action in killing cancer cells are antibody dependent cellular cytotoxicity , complement dependent cytotoxicity and direct induction of apoptosis with proven efficacy against wide range of B-cell non hodgekins lymphoma and chronic lymphocytic leukemia.
OFATUTUMAB: it inhibitis early B cell activation. It was approved for treatment of refractory CLL

Anti CD22 :

EPRATUZUMAB is a drug which blocks CD22 signalling . It is currently in phase III clinical trials. It is active against malignant B cells.

Anti CD52 :

ALEMTUZUMAB : used in T-Cell lymphomas, B-cells are chronic lymphocytic leukemia.

Anti-CD33:

GEMTUZUMABOZOGAMICIN: it is used in acute myeloid leukemia

.



Anti-Human epidermal growth factor receptor 2/neu:

TRASTUZUMAB: it is used in HER2-positive metastatic breast cancers.

PERTUZUMAB: HER2 blocking mAb, approved by FDA used in combination with trastuzumab

Anti-Epidermal growth factor receptor(EGFR):

CETUXIMAB: used in metastatic colorectal and head and neck cancers

PANTIMUMAB: used in metastatic colorectal and head and neck cancers

NIMOTUZUMAB : Undergoing several clinical trials for treatment of squamous cell carcinoma of head and neck

Anti- vascular Endothelial growth factor (VEGF):

BEVACIZUMAB: used in colorectal and head and neck cancer

GALIXIMAB : used in relapsed hodgekin lymphoma

DALOTUZUMAB: mAb is in phase III clinical trials for various cancers including breast cancer

LABETUZUMAB : under trial for medullary thyroid carcinoma

Courtesy: https://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-kidney-cancer/147582-esmo-2023-prediction-of-toxicity-in-current-systemic-treatment-of-genitourinary-cancers.html

Next Generation Antibodies

Next-generation antibody technologies, including single-chain variable fragments, bispecific antibodies, Fc-engineered antibodies, nanobodies, and antibody-drug conjugates play a important role in treatments for various diseases, such as cancer, autoimmune disorders, and infectious diseases .

(a) **Bispecific Antibodies:** They can improve the efficacy and safety by concurrently identifying and binding to two distinct antigens or antigenic epitopes. they also have the distinct advantage of guiding cytotoxic effector cells to the targeted antigen.
Example: BLINATUMOMAB (Blincyto) : a bispecific T-Cell engager(BiTE) that links CD3 on T cells to CD19 on B cells, used in leukemia treatment

(b)**Fc-Engineered Antibodies**: . Fc engineering aims to enhance the effector functions or prolong the half-life of therapeutic antibodies by modifying their Fc regions. This modification can involve altering glycosylation to enhance interactions with Fc receptors or complement, or inducing mutations in the Fc region to boost the responses of CDC and ADCC. they enhance the efficacy of monoclonal antibodies by improving ADCC and CDC . By introducing specific mutations, such as glycosylation patterns, Fc-engineered antibodies improve interactions with Fc receptors, enhancing their therapeutic effects in cancer and infectious disease treatments. Additionally, these antibodies can boost the immune system's ability to fight tumors by blocking inhibitory signals from receptors like Fc gamma receptor IIB (FcγRIIB), enhancing their effectiveness in tumor therapy.
Example: OBINUTUZUMAB (Gazyva)- an Fc- engineered anti CD20 antibody for leukemia and lymphoma

(c)**Antibody Fragments and Single-Domain Antibodies**: Recombinant antibody fragments offer significant advantages over full-length antibodies. Their smaller size enhances tissue penetration for a more effective target reach, allowing them to bind epitopes in deeper antigen pockets .
Example: TRASTUZUMAB-DERUXTECAN(Enhertu) - used for HER2-positive breast and gastric cancers

(d)**Nanobodies**, also known as single-domain-based variable domains of heavy-chain antibodies (VHHs), are antibody fragments derived from the heavy-chain-only IgG antibodies found in the Camelidae family. Due to their small size, simple structure, high antigen-binding affinity, and remarkable stability In cancer diagnosis, nanobodies can detect biomarkers like Cancer Antigen 125 (CA125), Prostate-Specific Antigen (PSA), and Alpha-Fetoprotein (AFP) with high sensitivity, enabling early screening, diagnosis, and monitoring of disease progression. Nanobodies are also effective as probes in noninvasive imaging techniques, such as Positron Emission Tomography/Computed Tomography (PET/CT), providing clear images of tumors and metastatic lesions, which can significantly enhance the detection and monitoring of cancers like breast cancer, melanoma, and non-small-cell lung cancer.
Example: CAPLACIZUMAB



Courtesy: https://link.springer.com/article/10.1007/s12672-024-01638-1,

CAR-T Cell Therapy

Chimeric Antigen Receptor T (CAR-T) cell therapy works by recognizing specific antigens on the surface of tumor cells, bypassing the need for antigen processing and presentation. The structure of CARs includes three main components: an extracellular antigen-binding domain, a transmembrane region, and an intracellular signaling domain, which collectively enable CAR-T cells to identify and attack cancer cells effectively.



Courtesy: https://www.mdpi.com/2227-9059/12/9/2158

Mechanism of Action

1. Antigen Recognition – CAR-T cells are engineered to recognizetumor-associated antigens (TAA) present on cancer cells.

2. Cytotoxic Response Activation – Upon binding to the antigen, CAR-T cells release cytolytic molecules such as Granzyme B and Perforin, inducing apoptosis in the targeted cancer cells.

3. Cytokine Release – CAR-T cells secrete inflammatory cytokines, including IFN-γ and TNF-α, which enhance the immune response by activating natural killer (NK) cells.

4. NK Cell-Mediated Cytotoxicity – Activated NK cells release additional cytolytic molecules such as Fas Ligand (FasL) and TRAIL, further amplifying tumor cell destruction.

5. Final Tumor Cell Elimination – The combined action of CAR-T cells and NK cells results in the apoptosis and elimination of cancer cells.

Examples of FDA-Approved CAR-T Cell Therapies

• AXICABTAGENECILOLEUCEL(Yescarta) – Used for large B-cell lymphoma.

• TISAGENLECLEUCEL (Kymriah) – Approved for acute lymphoblastic leukemia (ALL) and lymphoma.

• LISOCABTAGENEMARALEUCEL (Breyanzi) – Treats relapsed or refractory B-cell lymphomas.

• IDECABTAGENEVICLEUCEL (Abecma) – First CAR-T therapy approved for multiple myeloma.

• CILTACABTAGENEAUTOLEUCEL(Carvykti) – Another CAR-T therapy for multiple myeloma.



Courtesy: https://www.lls.org

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by overcoming immune suppression. T cells naturally express inhibitory receptors that regulate their activation to prevent autoimmune responses. However, cancer cells exploit these checkpoints to evade immune attack. ICIs work by blocking these inhibitory pathways, allowing T cells to recognize and destroy tumor cells effectively.

Types of Immune Checkpoint Inhibitors

1. PD-1 Inhibitors

PD-1 is a receptor on T cells that binds to PD-L1 on tumor cells, suppressing T-cell activation. Blocking this interaction enhances immune response against cancer.

• PEMBROLIZUMAB– Used in melanoma, lung cancer, and head and neck cancers.

• NIVOLUMAB– Approved for melanoma, lung cancer, and kidney cancer.



Courtesy: https://www.mdpi.com/1718-7729/29/5/247

2**. PD-L1 Inhibitor**

PD-L1 is a ligand expressed on cancer cells that binds to PD-1, preventing T cells from attacking tumors. Inhibiting PD-L1 restores immune function.

- ATEZOLIZUMAB– Treats lung and bladder cancer.
- DURVALUMAB– Used in lung and bladder cancer.
- AVELUMAB– Approved for Merkel cell carcinoma and bladder cancer.

3**. CTLA-4 Inhibitor**

CTLA-4 is another checkpoint receptor that downregulates T-cell activity by competing with the costimulatory receptor CD28.

• IPILIMUMAB– Used to treat melanoma, lung cancer, and kidney cancer.

Cancer vaccines

Cancer vaccines stimulate the immune system to recognize and attack cancer cells by introducing tumor-associated antigens. These vaccines can be developed from tumor lysates, synthetic antigens, or mRNA technology, enhancing immune responses against various malignancies.

Historical and Recent Developments

• The first tumor lysate-based vaccines targeting colorectal cancer emerged in the 1980s.

• By 1990, a human tumor antigen-based vaccine had been developed, marking a milestone in cancer immunotherapy.

• In 2010, the FDA approved Sipuleucel-T, the first cancer vaccine for metastatic castration-resistant prostate cancer, revolutionizingpersonalized cancer treatment.

Current Research and Clinical Trials

Modern research focuses on mRNA-based cancer vaccines targeting multiple malignancies, including:

- Non-small cell lung cancer (NSCLC)
- Colorectal cancer
- Gastroesophageal adenocarcinoma
- Urothelial carcinoma
- Melanoma
- Bladder cancer
- Triple-negative breast cancer
- Renal cancer
- Ovarian cancer
- Hepatocellular carcinoma
- Pancreatic cancer
- Prostate cancer
- Glioblastoma
- Epstein-Barr Virus (EBV)-associated malignancies

These vaccines introduce cancer-specific antigens to dendritic cells, which process and present them to T cells. CD4+ helper T cells regulate immune responses by releasing cytokines that activate CD8+ cytotoxic T cells, which then destroy cancer cells by recognizingtumor antigens presented by MHC class I molecules.

Future Directions in Cancer Immunotherapy

Despite significant advancements, challenges remain in achieving long-lasting responses. Many cancers develop resistance to immunotherapy, limiting treatment efficacy. Current research aims to:

• Improve antigen selection for vaccines.

• Enhance immunotherapy delivery mechanisms.

• Combine immunotherapy with chemotherapy and radiation for synergistic effects.

By refining targeted therapies and integrating them with immunotherapy, researchers hope to improve treatment outcomes, reduce tumor escape mechanisms, and achieve sustained tumor regression.

Types of cancer vaccines:

Cancer vaccines are designed either to prevent cancers caused by viruses or to treat existing cancers by stimulating the immune system to recognize and destroy tumor cells.

1. **Preventive (Prophylactic) Cancer Vaccines**

These vaccines are used to protect against viral infections known to contribute to cancer development.

- Human Papillomavirus (HPV) Vaccine – Helps prevent cancers linked to HPV, including cervical, anal, and oropharyngeal cancers. Examples include Gardasil and Cervarix.
- Hepatitis B Virus (HBV) Vaccine – Reduces the risk of liver cancer by preventing chronic HBV infection, which can progress from mild, short-term illness to severe, long-term liver disease.

2. **Therapeutic Cancer Vaccines**

Unlike preventive vaccines, therapeutic cancer vaccines are designed to treat existing cancer by enhancing the body's immune response against tumors. These vaccines may:

• Halt tumor growth or prevent its spread.

• Eliminate remaining cancer cells following surgery or radiation therapy.

• Reduce the risk of cancer recurrence after treatment.

a) FDA-Approved Cancer Vaccines

• **Sipuleucel-T** (Provenge) – A personalized vaccine used for metastatic prostate cancer. It is created using a patient's own immune cells, which are modified to specifically target prostate cancer cells.

- **Bladder Cancer Vaccines:**

• **Bacillus Calmette-Guérin (BCG)** – A treatment for early-stage bladder cancer, derived from inactivated tuberculosis bacteria. When administered into the bladder via a catheter, BCG stimulates the immune system to attack cancerous cells.

• **NadofarageneFiradenovec (Adstiladrin®)** – Approved for early-stage bladder cancer cases that do not respond to BCG therapy. This vaccine contains a modified virus designed to activate an immune response in the bladder. Similar to BCG, it is delivered through a catheter.

- Melanoma Vaccine:

• **TalimogeneLaherparepvec** (T-VEC, Imlygic®) – An oncolytic virus-based vaccine used to treat advanced melanoma that cannot be fully removed through surgery. This vaccine contains a genetically modified virus that enhances the immune system's ability to target cancer cells.

b)Experimental Cancer Vaccines in Clinical Trials

• **mRNA Cancer Vaccines** – These personalized vaccines use messenger RNA (mRNA) to instruct immune cells to recognize and attack tumor-specific antigens. Companies like BioNTech and Moderna are developing mRNA vaccines for melanoma and pancreatic cancer. Notably, the only currently approved mRNA vaccines are those developed for COVID-19, which instruct cells to produce the spike protein of the SARS-CoV-2 virus.

• **Peptide-Based Vaccines** – Contain tumor-specific peptides that activate T cells to recognize and attack cancerous cells.

• **Dendritic Cell Vaccines** – Utilize dendritic cells from a patient's body to stimulate a stronger immune response against tumors (e.g., DCVax for glioblastoma).

• **Whole Tumor Cell Vaccines** – Use inactivated tumor cells or tumor lysates to train the immune system to recognize and fight cancer.

These emerging vaccine strategies continue to be explored in clinical trials, with the goal of improving cancer treatment and patient outcomes.



Courtesy: https://www.nature.com/articles/s41392-023-01674-3

Cytokine therapy

Cytokine therapy has emerged as a major advancement in immunotherapy, providing targeted strategies to regulate immune system activity for improved cancer treatment and immune-related disease management. Cytokines are small proteins essential for cell signaling, and their therapeutic use has been optimized to enhance immune responses against cancer while maintaining control over immune activity.

Key Cytokines Utilized in Cancer Therapy

1. **Interleukins (ILs)**

Interleukins are responsible for coordinating immune cell communication and activation.

• IL-2 (Aldesleukin, Proleukin)

• Stimulates the activation of T cells and natural killer (NK) cells.

• Approved for use in metastatic melanoma and renal cell carcinoma.

• Potential side effects include severe inflammation and vascular leak syndrome.

• IL-15 (Under Investigation)

• Functions similarly to IL-2 but has a lower risk of severe side effects.

• Enhances T-cell and NK-cell activity, contributing to an improved immune response.

2. **Interferons (IFNs)**

Interferons play a role in boosting immune defenses and exert direct anti-tumor effects.

• IFN-α (Interferon Alpha-2b, Intron A)

• Approved for treating melanoma, leukemia, and Kaposi's sarcoma.

• Works by stimulating the immune system and suppressing tumor growth.

• Side effects include flu-like symptoms and fatigue.

3. **Tumor Necrosis Factor (TNF)**

TNF is capable of inducing apoptosis in cancer cells but presents toxicity concerns in systemic applications.

• TNF-α (Tasonermin) (Limited Clinical Use)

• Applied in isolated limb perfusion therapy for soft tissue sarcomas.

• Side effects include inflammation and potential organ toxicity.

4. **Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)**

This cytokine stimulates the production of white blood cells, enhancing immune responses.

SARGRAMASTIM (Leukine)

• Used as an immune booster in cancer patients undergoing chemotherapy.

• Incorporated into some cancer vaccines, such as GVAX.



Courtesy: https://www.nature.com/articles/s41571-021-00588-9

Immunomodulator

Immunomodulators have become increasingly significant in oncology due to their ability to strengthen the immune system's capacity to identify and eliminate tumor cells. These agents modify the tumor microenvironment, which consists of immune and non-immune cells, to counteract cancer's ability to evade immune detection.

One of their primary mechanisms is the activation and enhancement of cytotoxic T lymphocytes (CTLs) and dendritic cells (DCs). These immune cells are critical for initiating and sustaining an anti-tumor immune response. However, in many cancers, CTLs experience functional exhaustion due to the presence of immune checkpoint molecules such as PD-1 on T cells and PD-L1 on tumor cells, leading to immune suppression.

Examples of Immunomodulators:

• THALIDOMIDE – Initially developed as a sedative, later repurposed for multiple myeloma treatment.

• LENALIDOMIDE(Revlimid) – Used for multiple myeloma and myelodysplastic syndromes (MDS).

• POMALIDOMIDE (Pomalyst) – A more potent derivative of lenalidomide, used for relapsed multiple myeloma.



Courtesy: https://www.nature.com

What percentage of people with cancer can immunotherapy help?

It depends on the type of cancer in general, immmunotherapy helps

- Between 15 and 30 out of every 100 people who have common solid tumor. This includes lung, bladder, kidney cancer
- Between 45 to 60 out of every 100 people with certain skin cancers as well as people with solid tumor that have a type of mutation called MMRd/MSI-high

Side effects of immunotherapy:

The most common side effects are from the immune system overreacting to normal tissues. Side effects include

- Skin problems, such as a rash or itching

- Chills, fatigue(feeling very tired) and other flue like symptoms
- Gastrointestinal problems such as diarrhoea
- Pain from joint inflammation

Most side effects can be managed safely if treated early sometimes side effects cause harm if they are not treated and they involve organs such as the lung

Conclusion

The rise in cancer cases and the limitations of traditional chemotherapy have led to the development of more advanced and targeted treatment strategies. Biological therapies have gained significant attention due to their ability to interact with specific molecular pathways involved in tumor growth and progression. This review highlights various biological treatments and their effectiveness in addressing different types of cancer, with a particular focus on monoclonal antibodies and adoptive cell transfer as key components of personalized medicine.

One of the major challenges in immunotherapy is the accurate identification of biomarkers that can determine which patients are most likely to benefit from specific treatments. The lack of reliable biomarkers or incorrect identification can lead to suboptimal treatment responses and potential side effects. Therefore, ongoing research is essential to discover and validate biomarkers that can guide personalized treatment approaches. A deeper understanding of tumor biology and the identification of new cancer targets will improve the precision of biologic therapies, ultimately enhancing the success of immunotherapies.

Adoptive cell transfer techniques, including CAR-T cell therapy, have demonstrated the potential to strengthen the immune system's ability to recognize and attack cancer cells. Similarly, monoclonal antibodies continue to serve as a cornerstone of targeted cancer treatments. However, challenges such as resistance to therapy and adverse effects must be addressed to maximize their effectiveness. Additionally, innovative approaches such as angiogenesis inhibitors, DNA- and RNA-based cancer vaccines, and gene therapy present new possibilities for cancer treatment, though concerns regarding safety and efficacy remain.

The progress of biological therapies has been accelerated by advancements in molecular biology techniques, particularly next-generation sequencing (NGS). NGS has revolutionized our understanding of cancer genetics by enabling the identification of patient-specific mutations, leading to the development of highly individualized treatment options. Personalized therapies, which target specific genetic mutations within a patient's tumor, offer the potential for improved treatment precision while minimizing unwanted side effects.

In summary, while substantial advancements have been made in biological therapies for cancer, ongoing research is crucial to further refine these treatments and overcome challenges related to resistance and toxicity. The future of cancer care lies in personalized medicine, where treatments are tailored to the unique genetic and molecular characteristics of each patient's tumor. This approach has the potential to improve treatment outcomes and enhance the quality of life for individuals battling cancer.

Reference

1. Ghemrawi, R., et al. "Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy." *Biomedicines*, vol. 12, no. 9, 2024, p. 2158.
2. Fayyaz, A., et al. "Revolutionizing Cancer Treatment: The Rise of Personalized Immunotherapies." *Discovery Oncology*, vol. 15, no. 1, 2024, p. 756.
3. Sarkar, S., V. Srivastava, and M. Mohanty. *Postgraduate Pharmacology*. 2nd ed., Jaypee Brothers Medical Publishers, 2024.
4. "Immune System Modulators." *National Cancer Institute*, National Cancer Institute, www.cancer.gov/about-cancer/treatment/types/immunotherapy/immune-system-modulators. Accessed [Date]. *(Replace [Date] with the actual access date.)*
5. "Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy." *Biomedicines*, vol. 12, no. 9, 2024, p. 2158. *(Duplicate of entry 1.)*
6. Mohite, P., et al. "Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy." *ACS Omega*, vol. 9, no. 7, 2024, pp. 7277-95.
7. Sheykhhasan, M., and A. Ahmadieh-Yazdi. "Revolutionizing Cancer Treatment: The Power of Dendritic Cell-Based Vaccines in Immunotherapy." *Medical Oncology*, vol. 42, no. 3, 2025, pp. 52-63.
8. Graeber, Charles. *The Breakthrough: Immunotherapy and the Race to Cure Cancer*. Twelve, 2018.
9. Bauman, J., et al. "Safety, Tolerability, and Immunogenicity of mRNA-4157 in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors (KEYNOTE-603): An Update." *Journal for Immunotherapy of Cancer*, vol. 8, no. 2, 2020, p. e000530.

10. Lee, Linda. "Covid Vaccines Have Paved the Way for Cancer Vaccines." *Wired*, 14 Mar. 2025.
11. Smith, I. "Neighbours' Ian Smith Says He's 'Defying the Odds' After Terminal Cancer Diagnosis and Being Told He'd Die This Month." *The Sun*, 20 Mar. 2025.
12. "AstraZeneca Pays Up to $1bn for Biotech Firm 'That Could Transform Cell Therapy'." *The Guardian*, 17 Mar. 2025.
13. "Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy." *Biomedicines*, vol. 12, no. 9, 2024, p. 2158. *(Duplicate of entry 1.)*
14. "Bug Drugs: Bacteria-Based Cancer Therapies Are Finally Overcoming Barriers." *Health Economic Times*, 20 Mar. 2025.
15. "Revolutionizing Cancer Treatment: The Rise of Personalized Immunotherapy." *Endocrine*, vol. 74, no. 3, 2024, pp. 456-68.
16. "Present and Future of Cancer Nano-Immunotherapy: Opportunities and Challenges." *Molecular Cancer*, vol. 24, no. 1, 2025, p. 14.

CHAPTER 7

PRODUCTION OF VEGAN LEATHER USING KOMBUCHA DRINK

R. Sophia[1], R. Manju [2]

[1] Undergraduate, Hindusthan College of Arts and Science, Coimbatore – 641028 (India)

[2] Department of Microbiology, Hindusthan College of Arts and Science, Coimbatore – 641028 (India)

Corresponding authors : rsophiasophia61@gmail.com, manju.r@hicas.ac.in

ABSTRACT

Most leather produced across the globe is made from the skins of a variety of animals like cattle, sheep, tiger, goats, snakes, fish, leopard and many others. These animals are hunted and killed specifically for their skins. Another biomaterial manufactured without fleshing any animal is environmentally friendly and animal free leather, often known as "vegan leather" or "artificial leather" as an alternative to animal leather. One promising solution is vegan leather derived from bacterial cellulose produced during kombucha fermentation. Kombucha is a fermented tea drink that generates a symbiotic culture of bacteria and yeast (SCOBY), forming a thick cellulose mat on the surface. This bacterial cellulose, when harvested and processed, offers unique properties that make it a viable substitute for conventional leather. The study further highlights the material's potential applications in industries such as fashion, accessories, and upholstery, offering a sustainable and ethical alternative to conventional leather. While the kombucha-derived leather shows promise, challenges related to enhancing its water resistance, scalability, and long-term durability remain. Future research could focus on refining the production process and exploring commercial viability, paving the way for a more sustainable future in materials science.

Key Words: Leather, Vegan, SCOBY, Bacterial Cellulose

INTRODUCTION:

Leather has been prized for centuries for its durability, flexibility, and aesthetic appeal, making it a preferred material for fashion, accessories, furniture, and automotive industries. However, the production of traditional animal leather poses significant ethical and environmental concerns. The leather industry is a major contributor to deforestation, water pollution, and greenhouse gas emissions, largely due to the raising of livestock and the chemical-intensive tanning process. Additionally, the slaughter of animals for leather production raises ethical questions that have fueled the search for cruelty-free alternatives.

Bacterial cellulose (BC) is an environmentally benign natural polymer made from microbial organisms that has been hailed as a material of the future. Due to its distinct physicochemical and mechanical characteristics BC has been used in medicine for a long time. Wound dressings that are antibacterial. In the presence of possible nitrogen and carbon sources such as yeast extract, peptone, glycine, glucose, sucrose, mannitol, fructose, and other dietary derivatives, microorganisms metabolize, resulting in increased growth, development, and formation of gel-like cellulose membranes. The beverage is made by fermenting tea leaf infusions or decoctions with the help of a symbiotic association of bacteria and yeasts known as SCOBY (symbiotic association of bacteria and yeasts) stated that they had created a cellulose form of kombucha for use in the production of footwear. They used wax to improve the hydrophobic qualities of the created cellulosic fabric without altering its tensile properties or comfortability. They've created footwear employing bacterial cellulose as an alternative to leather as a result of their product. According to their findings, bacterial cellulose may be created in custom shapes and used as a zero-waste manufacturing material. Glucose is converted to cellulose through a series of intermediary molecules, including glucose-6-phosphate, glucose-l-phosphate, and uridine-5-diphosphate glucose . Scientists are currently obtaining valuable products by combining natural/waste resources with better biological synthesis technologies in order to build a "zero waste" society andeconomy.

Kombucha SCOBY leather is made from the cellulose layers produced by bacteria during the kombucha fermentation process. As the fermentation progresses, the bacteria secrete cellulose fibers that form a thick mat on the surface of the liquid. This mat, often referred to as the “SCOBY pellicle,” grows denser over time and can be harvested, dried, and treated to create a flexible, leather-like material.

The beauty of this process lies in its simplicity and sustainability. Unlike conventional leather, which involves raising livestock and using harsh chemicals for tanning, or synthetic leather, which relies on plastic-based materials, kombucha leather is entirely plant-based and biodegradable. The production process has a minimal carbon footprint and can even be done at home or on a small scale, making it accessible to DIY enthusiasts and eco-conscious designers

PRODUCTION PROCESS :

Step 1: Brewing Kombucha and Growing Bacterial Cellulose

1. Prepare sweet tea by dissolving sugar in hot water and steeping tea leaves.
Measurement:

Water - 1.5l

Sugar – 100g

Green tea bags - 4

2. Allow the tea to cool to room temperature and pour it into a clean glass jar.

3. Add the kombucha starter culture and cover the jar with a breathable cloth.

4. Ferment the mixture at room temperature for one month. During fermentation, a thick cellulose mat forms on the surface.

Step 2: Harvesting and Processing

1. Remove the cellulose mat (SCOBY) and rinse it thoroughly with water to remove excess acids.
   Lay the cellulose flat on a drying surface and allow it to air-dry for several days. A dehydrator or oven set at low temperature can speed up the process.
2. To improve flexibility, soak the dried material in a glycerin solution, then air-dry again.
3. Natural dyes can be applied at this stage for color customization (optional)

Step 3: Final Treatment

1. Wait until one of your kombucha biofilms becomes thick. The biofilm sheet will shrink significantly during the drying process. Thinner biofilms might not have a leather-like consistency, they may be more similar to tissue paper or printer paper.
2. Once one of your biofilms reaches a thickness, harvest biofilms. Remove the cloth from the container and with disinfect hands, carefully take the biofilm sheet from the liquid.
3. Rinse and wash the biofilm sheet with lukewarm water and a little bit of dish soap.
4. Place your biofilm sheet on a wooden board and measure the final thickness of the wet biofilm.
5. Let the biofilm on the wooden board dry. It might take several days to dry at room temperature.
6. The next step is to condition your kombucha leather. Apply coconut oil to both sides of your leather and it in with your hands. The oil prevents the biofilm from drying out and becoming brittle.

RESULT AND DISCUSSION:

First day (Inoculation)

After one month (Harvesting)

QUALITATIVE TESTS :



1.Water Solubility Test

2. Biodegradability(soil embedding test)



3. UV Exposure **After UV Exposure**

CONCLUSION:

As sustainability becomes a central focus in design and manufacturing, kombucha SCOBY leather holds exciting potential. Researchers are working to improve its durability, exploring treatments to make it more water-resistant and long-lasting. Additionally, advancements in biofabrication could pave the way for large-scale production, making kombucha leather a viable alternative to animal and synthetic leathers in mainstream markets.

In conclusion, kombucha SCOBY leather represents more than just an innovative material — it symbolizes a shift toward more conscious, sustainable practices in fashion and design. With continued research and development, this eco-friendly leather could play a significant role in reducing our reliance on traditional leather and synthetic materials, paving the way for a greener, more ethical future.

REFERENCES:

1. Aduri, P., et al. "Study of Biodegradable Packaging Material Produced from SCOBY." *Research Journal of Life Sciences, Bioinformatics, Pharmaceutical and Chemical Sciences*, vol. 5, 2019, pp. 389-404.
2. Chakravorty, S., et al. "Kombucha Tea Fermentation: Microbial and Biochemical Dynamics." *International Journal of Food Microbiology*, vol. 220, 2016, pp. 63-72.

3. Chen, C., and B. Y. Liu. "Changes in Major Components of Tea Fungus Metabolites During Prolonged Fermentation." *Journal of Applied Microbiology*, vol. 89, no. 5, 2000, pp. 834-39.
4. Constantas, J. A., and J. D. Hatle. "Kombucha Leather Durability: Sugar Concentration's Effect on Bacterial Cellulose." *(No journal or publication information provided).* 2020.
5. Domskiene, J., F. Sederaviciute, and J. Simonaityte. "Kombucha Bacterial Cellulose for Sustainable Fashion." *International Journal of Clothing Science and Technology*, 2019.
6. Freeman, C. E., et al. "Production of Microbial Leather from Culled Sweet Potato Sugars via Kombucha Culture." *International Textile and Apparel Association Annual Conference Proceedings*, vol. 73, no. 1, 2016.
7. Gam, H. J., et al. "Quest for the Eco-Apparel Market: A Study of Mothers' Willingness to Purchase Organic Cotton Clothing for Their Children." *International Journal of Consumer Studies*, vol. 34, no. 6, 2010, pp. 648-56.
8. Harris, S. "Sensible Dress: The Sight, Sound, Smell and Touch of Late Ertebølle Mesolithic Cloth Types." *Cambridge Archaeological Journal*, vol. 24, no. 1, 2014, pp. 37-56.
9. Hussain, Z., et al. "Production of Bacterial Cellulose from Industrial Wastes: A Review." *Cellulose*, vol. 26, no. 5, 2019, pp. 2895-2911.
10. Jackson, T. "Lifestyle Change and Market Transformation." *A Briefing Paper Prepared for DEFRA's Market Transformation Programme*, 2005.
11. Jansson, J. "Consumer Eco-Innovation Adoption: Assessing Attitudinal Factors and Perceived Product Characteristics." *Business Strategy and the Environment*, vol. 20, no. 3, 2011, pp. 192-210.
12. Kim, H., et al. "Adoption of Eco-Friendly Faux Leather: Examining Consumer Attitude with the Value–Belief–Norm Framework." *Clothing and Textiles Research Journal*, vol. 34, no. 4, 2016, pp. 239-56.
13. Lee, S. H. N., H. Kim, and K. Yang. "Impacts of Sustainable Value and Business Stewardship on Lifestyle Practices in Clothing Consumption." *Fashion and Textiles*, vol. 2, no. 1, 2015, pp. 1-18.
14. Mateo, J. J., and S. Maicas. "Valorization of Winery and Oil Mill Wastes by Microbial Technologies." *Food Research International*, vol. 73, 2015, pp. 13-25.
15. Moisander, J. "Motivational Complexity of Green Consumerism." *International Journal of Consumer Studies*, vol. 31, no. 4, 2007, pp. 404-09.
16. Peterson, H. H., G. M. Hustvedt, and Y. J. Chen. "Consumer Preferences for Sustainable Wool Products in the United States." *Clothing and Textiles Research Journal*, vol. 30, no. 1, 2012, pp. 35-50.

17. Portela, R., et al. "Bacterial Cellulose: A Versatile Biopolymer for Wound Dressing Applications." *Microbial Biotechnology*, vol. 12, no. 4, 2019, pp. 586-610.
18. Rathinamoorthy, R., and T. Kiruba. "Bacterial Cellulose—A Sustainable Alternative Material for Footwear and Leather Products." *Leather and Footwear Sustainability*, Springer, 2020, pp. 91-121.

CHAPTER 8

RECENT STUDY OF IMPLANTS & APPLICATIONS OF IMPLANTS FOR DRUG TARGETING IN NOVEL DRUG DELIVERY SYSTEM

Prof. (Dr.) Niraj Gupta
Professor, College of Pharmacy Agra, Dr. *A.P.J. Abdul Kalam* Technical *University, Lucknow*
***E.mail* - nirajg261@gmail.com**

ABSTRACT

Today, implant placement isn't limited to fixed principles. Long- term and stable fixation of implants is one of the most important points for a successful orthopedic surgery in the field of endoprosthesis. Extending contraceptive implant duration of use increases accessibility by maximizing the lifetime of devices. Oral contraceptives are widely used hormonal contraceptives compared to other dosage forms. Dental implants are a common treatment for the loss of teeth. Most of the implant surface modifications showed good osseointegration results. Regarding bio molecular coatings, which have been recently developed and studied, good results were observed in animal experiments. Short implants are considered a predictable treatment for posterior jaws. However, short implants with length less than 8 mm (4–7 mm) should be used with caution because they present greater risks to failures compared to standard implants. With the growing use of dental implants, the incidence of implants failures grows. Late treatment complications, after reaching full osseointegration and functionality, include mechanical failures, such as fracture of the implant and its components. The insertion of dental implants containing titanium can be associated with various complications (e.g. hypersensitivity to titanium). The overall aim of imaging breast implants is to provide essential information about tissue and prosthesis integrity, detect implant abnormalities and detect breast diseases unrelated to implants, such as breast cancer. However, data from animal research, human case reports and case series, and prospective studies showed similar success rates for implants placed into infected sites compared to implants placed in non-infected or pristine sites.

Keywords:

INTRODUCTION:

An implant is a medical device manufactured to replace a missing biological structure, support a damaged biological structure, or enhance an existing biological structure. For example, an implant may be a rod, used to strengthen weak bones. Medical implants are human-made devices, in

contrast to a transplant, which is a transplanted biomedical tissue. The surface of implants that contact the body might be made of a biomedical material such as titanium, silicone, or apatite depending on what is the most functional.

In dentistry, dental implants consist of titanium posts surgically placed in the jawbone to replace missing teeth. They provide a durable, natural-looking solution for tooth loss, restore functionality, and help maintain jawbone density. Like contraceptive implants, dental implants require a surgical procedure and ongoing care for optimal results. Both types of implants exemplify advancements in medical technology, enhancing quality of life through effective solutions.

A pictorial representation of dental implant

In the context of contraceptive implants, these are small, flexible rods inserted under the skin that release hormones to prevent pregnancy. They offer long-lasting protection, typically effective for three to five years, and are over 99% effective at preventing pregnancy.

The insertion is minimally invasive and reversible, allowing for quick return to fertility after removal. However, they may cause side effects such as irregular bleeding and hormonal changes.

A pictorial representation of contraceptive implant

ADVANTAGES OF IMPLANTS:

Dental implants: -

Advantages of dental implants are given as under: -

- **Natural appearance**: Dental implants are designed to look, feel, and function like natural teeth. They can be difficult to distinguish from natural teeth with the naked eye.
- **Long-lasting**: Dental implants can last a lifetime if properly maintained.
- **Preserves jawbone**: Dental implants help prevent bone loss and maintain the structure of your face.
- **Doesn't affect other teeth**: Dental implants don't require altering or shaping neighboring teeth.
- **Easy to care for:** You can brush, floss, and use mouthwash to clean dental implants just like you would with natural teeth.
- **Boosts confidence**: Dental implants can help you feel better about yourself by allowing you to smile, eat, and speak without worrying about loose dentures or gaps.
- **Improves speech:** Dental implants can make speech clearer.
- **Comfortable**: Dental implant treatment is more comfortable than other dental treatments.

Contraceptive implants: -

Contraceptive implants offer several advantages, including:

- **Long-Lasting Protection**: Implants provide effective contraception for several years (typically 3 to 5 years), reducing the need for frequent attention.
- **High Efficacy**: They are over 99% effective in preventing pregnancy, making them one of the most reliable forms of contraception.

- **Convenience**: Once implanted, they require no daily action, which can help with compliance compared to pills that need to be taken daily.
- **Reversibility**: Fertility generally returns quickly after the implant is removed, allowing for easier family planning.
- **Reduced Menstrual Symptoms**: Many users experience lighter periods, fewer cramps, or even cessation of periods over time.
- **No Estrogen**: Most implants contain only progestin, making them suitable for those who cannot use estrogen-based methods.
- **Discreetness**: Implants are inserted under the skin and are not visible, providing privacy and convenience.
- **Minimal Maintenance**: There's no need to remember to take a pill every day or manage refills regularly.

DISADVANTAGES OF IMPLANTS:

Dental implants:-

Dental implants, while beneficial, also come with some disadvantages:

- **Surgical Procedure**: The placement of dental implants requires surgery, which involves anesthesia, potential discomfort, and a recovery period.
- **Cost**: Dental implants can be expensive, and insurance may not cover the full cost, making them less accessible for some patients.
- **Time-Consuming**: The process can take several months, including healing time after the implant placement and subsequent fitting of the crown.
- **Bone Loss Requirement**: Sufficient bone density is necessary for successful implantation. Patients with significant bone loss may require additional procedures like bone grafting.
- **Potential Complications**: As with any surgical procedure, there are risks of infection, nerve damage, or implant failure.
- **Maintenance**: Implants require proper oral hygiene and regular dental check-ups to prevent complications like peri-implantitis.
- **Not Always Suitable**: Certain health conditions (like uncontrolled diabetes or smoking) may affect eligibility for implants or increase the risk of complications.
- **Aesthetic Concerns**: In some cases, the implant may not match the surrounding teeth perfectly, affecting appearance.
- **Adjustment Period**: Some patients may take time to adjust to the feel of implants, which can feel different from natural teeth.

CONTRACEPTIVE IMPLANTS: -

While contraceptive implants have many benefits, they also come with some disadvantages:

- **Irregular Bleeding**: Many users experience changes in menstrual bleeding patterns, including irregular periods, heavier bleeding, or no periods at all.
- **Initial Side Effects**: Common side effects during the first few months can include headaches, weight gain, mood changes, and acne.
- **Surgical Procedure**: Insertion requires a minor surgical procedure, which can lead to discomfort, bruising, or infection at the insertion site.
- **Cost**: The upfront cost can be high, although it may be more economical over time compared to other methods.
- **Limited Protection**: Implants do not protect against sexually transmitted infections (STIs); additional protection, like condoms, is necessary for STI prevention.
- **Not Immediately Reversible**: While fertility returns quickly after removal, there may be a short delay in the return of regular menstrual cycles or fertility for some women.
- **Possible Complications**: There's a risk of the implant moving or becoming dislodged, requiring surgical removal or replacement.
- **Hormonal Effects**: As a hormonal method, it may not be suitable for individuals with certain health conditions or hormone-sensitive issues.
- **Need for Medical Consultation**: Regular follow-ups with a healthcare provider are necessary to monitor the implant's effectiveness and manage any side effects.

HISTORY OF IMPLANTS:

Discoveries	Inventor	Year	Application	Images
Early dental implants	Various ancient researchers	3000 BC	Ancient cultures used materials like ivory and stone for tooth replacements, showing early dental practices	

Titanium dental implants	Dr.Per-Ingvar Brånemark	1952	Dr.Per-Ingvar Brånemark discovers titanium's biocompatibility when studying bone healing in rabbits	
First successful dental implants	Dr.Per-Ingvar Brånemark	1965	Brånemark places the first titanium dental implant in a human patient, leading to a successful outcome.	
Osseointegration concept	Dr. Per-Ingvar Brånemark	1970	osseointegration" is introduced, describing how bone bonds with the implant surface, crucial for stability.	
First FDA approval for dental implants	Dr. Stephen J. Furney	1982	The FDA approves titanium dental implants, marking a significant step in modern dentistry.	
Advancement in dental implants	Dr. Thomas B. P.van Steenberghe	1990s	Introduction of various implant shapes (e.g., tapered, cylindrical) and surface treatments to enhance osseointegration	

Development of mini-implants	Dr. T. W. M. van der Weijden	1997	introduced, offering a less invasive option for patients with limited bone structure	
3D printing in imlantology	Dr. Yong Zhang	2000s	3D printing technology begins to be utilized for creating patient-specific implants and surgical guides.	
Introduction of cone beam CT imaging	Dr. Paul T. Insua	2010	Cone Beam CT provides high-resolution imaging for precise planning and placement of dental implants	
Bio active materials	Dr. Michael L. K. Wong	2010s	Research into bioactive coatings that enhance bone growth and reduce infection risks surrounding implants	
Growth factors for enhanced	Dr. R. H. O. C . H. V. Leeming	2014	Studies explore the use of growth factors (e.g., BMPs) to improve	

Osseointegration			healing and integration of implants	
Smart implants	Dr. H. Lee. *Et al*	2020	Development of implants equipped with sensors to monitor parameters like temperature, stress, or infection.	
Gene therapy for bone regeneration	Dr. Jennifer Daunda and others	2021	Research into gene editing techniques (e.g., CRISPR) to promote bone healing around implants	
Personalized implants	Dr. A. J. Stokes	2022	Advances in bioprinting and materials science lead to the creation of custom implants tailored to individual patients	
Robotics assisted surgery implants	Dr. T. C. W. H. Chiu	2023	Introduction of robotic-assisted surgical techniques to enhance precision and reduce recovery times.	

AI-Driven Predictive Models	Dr. Deepak Aggarwal	2024	AI algorithms are developed to predict implant success rates and optimize treatment plans based on individual patient data	

TYPES OF IMPLANTS:

On the basis of mechanism of action, implants can be categorized in following types: -

Type of Implant	Mechanism of action	Description	Images
Subperiosteal implants	External bone support	Positioned on the top of the jawbone but beneath the gum tissue, used when bone height is insufficient.	

Transosteal implants	Through the bone	A type of subperiosteal implant that passes through the mandible, providing support for dentures.	
Mini implants	Immediate stabilization	Smaller in diameter, often used for retention of dentures in patient with limited bone structure.	
Zygomatic implants	Long term anchorage	Placed in the zygomatic bone (cheekbone) for patients with severe maxillary bone loss.	
Biodegradable implants	Gradual absorption and replacement	Made from materials that gradually dissolve in the body, often used for drug delivery or temperory support.	

Endosseous implants	Osseointegration	Placed directly into the jawbone, promoting direct bonding with the bone for stability.	
Smart implants	Sensor-based monitoring	Equipped with sensors to monitor conditions like temperature and pressure, providing data for health tracking.	
Magnetically retained implants	Magnetic attraction	Utilize magnets for retention for prosthetic devices, allowing easy removal and cleaning.	

RECENT ADVANCEMENT IN IMPLANTS:

Latest materials being used for dental implants in 2024.

In 2024, dental implants are increasingly made from advanced materials like zirconia, in addition to the traditional titanium. Zirconia implants are favoured for their tooth-like colour, offering better aesthetics. Both materials are biocompatible, ensuring a lower risk of inflammation and promoting faster healing.

3D printing technology.

3D printing technology has revolutionised dental implant procedures by allowing for highly accurate and customized implants. This technology enables the creation of implants tailored to the specific anatomical structure of each patient's jaw, leading to better fitting implants, reduced surgery times, and improved overall outcomes.

Role of AI play in dental implant technology.

AI plays a significant role in improving the planning and execution of dental implant procedures. It aids in the analysis of dental imaging, helps in predicting the best implant positions, and can forecast potential complications. This leads to more precise implant placements and better long-term success rates.

Digital imaging and diagnostics improve dental implant procedures.

Digital imaging and diagnostics, like Cone Beam Computed Tomography (CBCT), provide detailed 3D images of the jaw, which are crucial for precise implant placement. These tools allow for accurate assessment of bone quality and structure, enabling dentists to plan and execute implant procedures with greater accuracy and safety.

Teeth in a Day: Same-Day Implants.

The demand for efficient solutions has given rise to the trend of same-day implants. Leveraging advanced planning techniques and immediate loading protocols, patients can now walk out with a new set of teeth in a single day, revolutionizing the traditional implant timeline.

Biocompatible Materials: The Future of Implantology.

In 2024, biocompatible materials take center stage in dental implant procedures. Innovations in implant materials not only enhance osseointegration but also contribute to the overall longevity and success of implants. Sustainability and patient well-being are at the forefront of material advancements.

Digital Impressions.

No more traditional molds. Digital impressions are gaining prominence in dental implant procedures, offering a more comfortable and efficient alternative. This trend not only improves the patient experience but also contributes to the precision of implant placement.

Mini Implants

A hot trend in 2024 is the emergence of mini implants. These smaller-sized implants are designed for specific cases, offering a minimally invasive solution with quicker recovery times. The versatility of mini implants opens doors for a broader range of patients seeking implant-supported restorations.

Customized Prosthetics

The era of one-size-fits-all is long gone. 2024 sees a surge in customized prosthetics for dental implants. From crowns to abutments, personalized solutions are on the rise, ensuring that each patient receives a tailored implant restoration that complements their unique oral anatomy.

Sustainable Practices

In response to environmental consciousness, sustainable practices are becoming a notable trend in implantology. From eco-friendly packaging to recyclable implant materials, the industry is making strides towards minimizing its ecological footprint.

Nanotechnology

Nanostructured surfaces on implants help the jawbone grow and attach faster, resulting in stronger and more stable implants.

Patient-centered care

A shift towards patient-centered care models prioritizes the patient's experience and ensures that treatments are effective, accessible, and comfortable.

Immediate Load Implants

In the past, patients often had to wait several months for their implants to fully integrate with the jawbone before receiving their permanent crowns. However, in 2024, immediate load implants have gained popularity. Dentists can now place the implant and the crown in a single visit, allowing patients to walk out with a fully functional tooth on the same day. This approach saves time, reduces discomfort, and provides instant results for those needing quick tooth replacement.

Minimally Invasive Techniques

Innovations in surgical techniques have made dental implant procedures less invasive than ever before. In 2024, dentists are utilizing advanced imaging and robotics to plan and execute implant surgeries with unprecedented precision. These minimally invasive techniques reduce trauma to the surrounding tissues, leading to less pain, minimal swelling, and a quicker recovery. Patients who may have been hesitant about undergoing implant surgery can now consider it with greater confidence.

Regenerative Medicine Approaches

The integration of regenerative medicine with dental implants marks another significant innovation in 2024. Dentists are exploring the use of stem cells and growth factors to enhance bone regeneration around the implant site. These approaches not only accelerate healing but also improve the long-term stability of the implant. Patients with compromised bone structure, who might have been ineligible for implants in the past, can now explore this option with new hope.

CONCLUSION: -

The history and evolution of implants highlight the ongoing commitment to improving patient care through technological advancements. As research continues, future developments in implant technology promise to address current limitations, enhance customization, and optimize patient outcomes, making implants an integral part of modern medicine. In conclusion, implants represent a significant advancement in medical technology, offering innovative solutions for both dental and contraceptive needs. Dental implants have evolved from ancient practices to sophisticated titanium devices that not only restore function and aesthetics but also promote jawbone health and enhance the overall quality of life for patients. Their development reflects decades of research and innovation, leading to improved designs and materials that ensure durability and compatibility with the human body. Contraceptive implants, on the other hand, provide a reliable and convenient method of birth control, offering long-lasting protection and ease of use. While both types of implants come with advantages such as effectiveness and minimal maintenance, they also present challenges, including surgical risks and potential side effects.

REFERENCES

1. Miglani, Abhinn, et al. "Short Implants: A Review." *Journal of Research in Medical and Dental Science*, vol. 10, no. 12, 2022, pp. 123-27.
2. Mukherjee, Suman. "Current Status of Implant Placement: A Review Article." *Journal of The West Bengal University of Health Sciences*, vol. 1, no. 3, 2021, pp. 1-13.

3. Liu, Yu, et al. "Role of Implants Surface Modification in Osseointegration: A Systematic Review." *Journal of Biomedical Materials Research Part A*, vol. 108A, 2020, pp. 470-84. doi:10.1002/jbm.a.36829.
4. Thaxton, Lauren, and Antonella Lavelanet. "Systematic Review of Efficacy with Extending Contraceptive Implant Duration." *International Journal of Gynecology & Obstetrics*, vol. 144, 2019, pp. 2-8. doi:10.1002/ijgo.12696.
5. Wathoni, Nasrul, et al. "EVOLUTION OF CONTRACEPTIVE IMPLANTS: A REVIEW." *International Journal of Applied Pharmaceutics*, vol. 10, no. 6, 2018, pp. 16-22. doi:10.22159/ijap.2018v10i6.28391.
6. Pieralli, S., et al. "Clinical Outcomes of Zirconia Dental Implants: A Systematic Review." *Journal of Dental Research*, vol. 96, no. 1, 2017, pp. 38-46. doi:10.1177/0022034516664043.
7. Hong, Do Gia Khang, and Ji-hyeon Oh. "Recent Advances in Dental Implants." *Maxillofacial Plastic and Reconstructive Surgery*, 2017, pp. 1-10. doi:10.1186/s40902-017-0132-2.
8. Lemosa, Cleidiel Aparecido Araujo, et al. "Short Dental Implants Versus Standard Dental Implants Placed in the Posterior Jaws: A Systematic Review and Meta-Analysis." *Journal of Dentistry*, vol. 47, 2017, pp. 8-17. doi:10.1016/j.jdent.2016.01.005.
9. Shemtov-Yona, Keren, and Daniel Rittel. "An Overview of the Mechanical Integrity of Dental Implants." *BioMed Research International*, 2015, pp. 1-11. doi:10.1155/2015/547384.
10. Javed, Fawad, and Georgios E. Romanos. "Role of Implant Diameter on Long-Term Survival of Dental Implants Placed in Posterior Maxilla: A Systematic Review." *Clinical Oral Investigations*, vol. 19, 2015, pp. 1-10. doi:10.1007/s00784-014-1333-z.
11. Tadikonda, Deepti Chaitanya, and Sasikala Pagadala. "Immediate Implant Placement - A Review." *Scholars Journal of Dental Sciences*, vol. 2, 2015, pp. 296-301. doi:10.36347/sjds.2015.v02i04.008.
12. Schwitalla, Andreas, and Wolf-Dieter Müller. "PEEK Dental Implants: A Review of the Literature." *Journal of Oral Implantology*, vol. 39, no. 6, 2013, pp. 743-49. doi:10.1563/AAID-JOI-D-11-00002.
13. Annibali, S., et al. "Short Dental Implants: A Systematic Review." *Clinical Oral Implants Research*, 2012, pp. 1-8. doi:10.1177/0022034511425675.

14. Todescan, Sylvia, et al. "Guidance for the Maintenance Care of Dental Implants: Clinical Review." *Journal of the Canadian Dental Association*, vol. 78, 2012, pp. 1-8.
15. Alla, Rama Krishna, et al. "Surface Roughness of Implants: A Review." *Trends in Biomaterials and Artificial Organs*, vol. 25, no. 3, 2011, pp. 112-18.
16. Juanpere, Sergi, et al. "Imaging of Breast Implants—A Pictorial Review." *Insights into Imaging*, vol. 2, 2011, pp. 653-70. doi:10.1007/s13244-011-0122-3.
17. Sohrabi, Keyvan, et al. "How Successful Are Small-Diameter Implants? A Literature Review." *Clinical Oral Implants Research*, 2011, pp. 1-11. doi:10.1111/j.1600-0501.2011.02410.x.
18. Jawed, Fawad, and Georg Romanos. "The Role of Primary Stability for Successful Immediate Loading of Dental Implants: A Literature Review." *Journal of Dentistry*, vol. 38, 2010, pp. 612-20. doi:10.1016/j.jdent.2010.05.013.
19. Waasdorp, Jonathan A., et al. "Immediate Placement of Implants Into Infected Sites: A Systematic Review of the Literature." *Journal of Periodontology*, vol. 81, no. 6, 2010, pp. 801-08. doi:10.1902/jop.2010.090706.
20. Pye, A. D., et al. "A Review of Dental Implants and Infection." *Journal of Hospital Infection*, vol. 72, 2009, pp. 104-10. doi:10.1016/j.jhin.2009.02.010.
21. Andreiotelli, Marina, et al. "Are Ceramic Implants a Viable Alternative to Titanium Implants? A Systematic Literature Review." *Clinical Oral Implants Research*, 2009, pp. 32-47. doi:10.1111/j.1600-0501.2009.01785.x.
22. Subramani, Karthikeyan, et al. "Biofilm on Dental Implants: A Review on Literature." *The International Journal of Oral & Maxillofacial Implants*, vol. 24, no. 4, 2009, pp. 616-26.
23. Hultin, Margareta, et al. "Supportive Therapy and the Longevity of Dental Implants: A Systematic Review of the Literature." *Clinical Oral Implants Research*, 2007, pp. 50-62. doi:10.1111/j.1600-0501.2007.01447.x.

CHAPTER 9

PROTEOME RESEARCH: CHALLENGES, INNOVATIONS, AND FUTURE PERSPECTIVES

V.G. Vidhya1, S. Vijaya Bharathi 2
Department of Biotechnology, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur- 603 203, Chennai, Tamil Nadu, India

ABSTRACT
Proteomics, the large-scale study of proteins, is a dynamic field crucial for understanding biological systems. Unlike the relatively static genome, the proteome reflects cellular responses to diverse stimuli through variations in protein structure, function, interactions, and post-translational modifications. Advancements in mass spectrometry and bioinformatics have made proteomics indispensable in molecular biology, biomedicine, and biotechnology, revolutionizing biomarker discovery, drug development, and personalized medicine. This overview highlights the significance of proteomics in deciphering disease mechanisms, its applications in various fields like agriculture and environmental science, and the inherent complexities arising from alternative splicing, PTMs, and protein-protein interactions. Furthermore, it discusses key proteomic techniques, including protein separation methods and mass spectrometry, alongside the challenges of data complexity, reproducibility, and cost, while also outlining future perspectives in multi-omics integration.

Introduction to Proteomics

Proteomics is the large-scale study of proteins, focusing on their structure, function, interactions, and post-translational modifications within biological systems. The term "Proteome" was first introduced by Marc Wilkins in 1995, combining “protein” and “genome” to describe the entire set of proteins expressed by a genome, cell, tissue, or organism at a given time. Unlike the genome, which remains relatively constant, the proteome is highly dynamic, responding to various factors such as environmental conditions, disease states, and developmental stages). With advancements in high-throughput technologies such as mass spectrometry (MS) and computational biology, proteomics has become an indispensable field in molecular biology, biomedicine, and biotechnology. Mass spectrometry-based proteomics enables precise identification and quantification of proteins, while bioinformatics tools facilitate large-scale data analysis, functional annotation, and pathway mapping. These advancements have revolutionized biomarker discovery, personalized medicine, and drug development

Proteomics is instrumental in understanding disease mechanisms, particularly in cancer, neurodegenerative disorders, and infectious diseases, by identifying differentially expressed proteins and altered signaling pathways. The integration of proteomics with other omics disciplines, such as genomics, transcriptomics, and metabolomics, has further enhanced our ability to decode complex biological systems and develop targeted therapeutic strategies.

Proteomics is broadly classified into:

- Structural Proteomics: Determines the 3D structures of proteins.
- Functional Proteomics: Explores protein interactions and biochemical pathways.
- Expression Proteomics: Analyzes protein expression patterns in different conditions.

Importance of Proteomics

Proteomics plays a crucial role in various fields, including:

Biomedical Research: Proteomics has revolutionized biomedical research by facilitating the identification of protein biomarkers for various diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions. By analyzing differentially expressed proteins in diseased versus healthy tissues, researchers can identify novel diagnostic and prognostic biomarkers. For instance, proteomic studies have revealed specific proteins such as alpha-fetoprotein (AFP) for liver cancer and tau proteins for Alzheimer's disease, aiding in early disease detection and monitoring. Additionally, proteomic profiling helps elucidate disease mechanisms by mapping altered signaling pathways and protein-protein interactions.

Drug Development: Proteomics plays a pivotal role in drug discovery and development by identifying drug targets and understanding their mechanisms of action . Mass spectrometry-based proteomics allows for the screening of protein interactions with drug candidates, accelerating the identification of potential therapeutic targets. In precision medicine, proteomics is used to stratify patients based on their protein expression profiles, allowing for personalized drug interventions. For example, proteomic analysis has helped in identifying HER2-positive breast cancer subtypes, leading to targeted therapies such as trastuzumab. Furthermore, proteomics is instrumental in understanding drug resistance mechanisms, improving drug efficacy, and minimizing adverse effects

Agriculture: In agriculture, proteomics is applied to enhance crop resilience by studying stress-response proteins under various environmental conditions such as drought, salinity, and pathogen attacks. By identifying key proteins involved in stress tolerance, researchers can develop genetically modified crops with improved resistance and productivity. For instance, proteomic studies in rice (*Oryza sativa*) have identified heat shock proteins (HSPs) that play a crucial role in heat and drought resistance, guiding the development of climate-resilient crop varieties.

Additionally, plant proteomics helps in optimizing fertilizer use by understanding nutrient uptake mechanisms, thereby promoting sustainable agricultural practices.

Environmental Science: Proteomics contributes significantly to environmental science by investigating microbial proteomes in ecosystems, which aids in bioremediation, pollution monitoring, and ecological studies. Metaproteomics—the large-scale study of proteins from environmental microbiomes—provides insights into microbial community functions in soil, water, and industrial waste treatment. For example, proteomic analyses of bacterial species such as *Pseudomonas putida* have revealed proteins involved in the degradation of toxic pollutants, enabling the development of effective bioremediation strategies. Additionally, proteomics is used to assess the impact of climate change on marine ecosystems by monitoring stress-response proteins in aquatic organisms.

Proteome and Its Complexity

The proteome is significantly more complex than the genome due to various factors, including alternative splicing, post-translational modifications (PTMs), and dynamic protein-protein interactions. Unlike the genome, which remains largely stable across different cell types and conditions, the proteome is highly dynamic, influenced by developmental stages, environmental stressors, and disease states. The complexity of the proteome arises from the vast diversity of protein structures and functions, regulated by multiple mechanisms at the transcriptional, translational, and post-translational levels. Understanding this complexity is crucial for deciphering cellular mechanisms and disease pathogenesis, as well as for developing therapeutic strategies.

Alternative Splicing and Proteome Diversity

Alternative splicing is a key mechanism contributing to proteome diversity, enabling a single gene to produce multiple protein isoforms with distinct structures and functions. This process occurs during mRNA processing, where specific exons are selectively included or excluded, generating different protein variants from the same genetic sequence. Alternative splicing plays a critical role in tissue specificity, cell differentiation, and adaptive responses to environmental changes. In humans, more than 95% of multi-exonic genes undergo alternative splicing, significantly expanding the functional repertoire of proteins beyond the genome's coding capacity. Dysregulation of alternative splicing has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. For example, aberrant splicing of the BCL-X gene can result in the expression of pro-apoptotic or anti-apoptotic isoforms, influencing cell survival and tumor progression.

Post-Translational Modifications (PTMs) and Functional Complexity

Post-translational modifications (PTMs) add another layer of complexity to the proteome by chemically modifying proteins after translation, altering their stability, localization, activity, and interactions. PTMs include phosphorylation, glycosylation, ubiquitination, acetylation, methylation, and others, each playing crucial roles in regulating cellular functions. For instance, phosphorylation, mediated by kinases, is essential for signal transduction and cell cycle control, while ubiquitination regulates protein degradation via the proteasome. More than 200 different types of PTMs have been identified, each contributing to proteome diversity and functional complexity. Dysregulated PTMs are often associated with diseases; for example, hyperphosphorylation of tau protein is a hallmark of Alzheimer's disease, leading to neurofibrillary tangle formation . Additionally, glycosylation defects have been linked to cancer progression and immune system dysfunction.

Protein-Protein Interactions and Functional Networks

Proteins rarely function in isolation; rather, they interact dynamically with other proteins to form intricate networks regulating cellular processes. Protein-protein interactions (PPIs) are central to signal transduction, enzymatic activity modulation, and structural assembly. The human interactome, comprising all PPIs, consists of thousands of interactions, many of which are context-dependent and influenced by environmental conditions. Advances in high-throughput techniques, such as yeast two-hybrid screening, affinity purification-mass spectrometry (AP-MS), and proximity labeling, have significantly expanded our understanding of PPIs. Disruptions in PPI networks have been implicated in numerous diseases, including cancer and neurodegenerative disorders, where aberrant interactions can lead to pathological signaling. For instance, the dysregulation of tumor suppressor p53 interactions with other proteins is a common feature in many cancers.

Techniques in Proteomics

Proteomics relies on a variety of analytical techniques that enable the large-scale identification, quantification, and characterization of proteins. These techniques encompass protein separation methods, mass spectrometry (MS)-based proteomics, and bioinformatics tools that facilitate data analysis and interpretation. Advancements in these methods have significantly enhanced our understanding of protein expression, modifications, and interactions in various biological systems. The integration of these techniques is essential for biomedical research, biomarker discovery, and drug development.

Protein Separation Techniques

Before protein identification and analysis, proteins are typically separated based on their physical and chemical properties. The two main approaches for protein separation are gel-based and chromatography-based techniques.

Two-Dimensional Gel Electrophoresis (2D-GE)

Two-dimensional gel electrophoresis (2D-GE) is a widely used technique for protein separation, combining isoelectric focusing (IEF) in the first dimension and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the second dimension (O'Farrell, 1975). IEF separates proteins based on their isoelectric points (pI), while SDS-PAGE further resolves them by molecular weight. This technique is particularly useful for comparing protein expression under different conditions, such as disease versus healthy states (Görg *et al*., 2004). However, 2D-GE has limitations, including difficulty in analyzing hydrophobic proteins and low-abundance proteins.

Liquid Chromatography (LC)

Liquid chromatography (LC) techniques are commonly used for protein and peptide separation before mass spectrometry analysis. High-performance liquid chromatography (HPLC) and its variant, reverse-phase liquid chromatography (RP-LC), separate peptides based on hydrophobicity. Another widely used method is ion-exchange chromatography (IEX), which separates proteins based on charge, and size-exclusion chromatography (SEC), which separates them based on molecular weight.

Mass Spectrometry-Based Proteomics

Mass spectrometry (MS) is the cornerstone of modern proteomics, enabling the identification and quantification of proteins and their modifications with high accuracy and sensitivity. The workflow typically involves protein digestion into peptides, separation using liquid chromatography (LC), and analysis using MS. The key steps in MS-based proteomics include ionization, mass analysis, and fragmentation for peptide sequencing.

Ionization Techniques

Two major ionization methods are used in proteomics:

Matrix-Assisted Laser Desorption/Ionization (MALDI): This technique ionizes proteins from a solid matrix, allowing for the analysis of intact proteins and peptides with minimal fragmentation. It is particularly useful in clinical proteomics for biomarker discovery.

Electrospray Ionization (ESI): ESI generates charged droplets that gradually evaporate, producing ions suitable for MS analysis. ESI is widely used for coupling with liquid chromatography (LC-MS), providing high-resolution peptide identification and quantification

Mass Analyzers: Different mass analyzers determine the mass-to-charge (m/z) ratio of ions, providing insights into protein identity and structure. The commonly used mass analyzers include:

- Time-of-Flight (TOF): Measures ion velocity to determine m/z values
- Quadrupole: Uses oscillating electric fields to filter ions of specific m/z ratios

- Orbitrap: Provides high-resolution and accurate mass measurements for complex proteomes.

Fourier Transform Ion Cyclotron Resonance (FT-ICR): Offers ultra-high-resolution analysis, ideal for studying post-translational modifications.

Tandem Mass Spectrometry (MS/MS) and Protein Identification

Tandem mass spectrometry (MS/MS) involves fragmentation of peptides to generate sequence-specific fragment ions, enabling protein identification through database searches. Algorithms such as SEQUEST and Mascot compare MS/MS spectra against protein databases, allowing accurate protein identification.

Quantitative Proteomics

Quantitative proteomics provides insights into protein abundance changes under different conditions. Methods include:

Label-Free Quantification (LFQ): Compares peptide intensities across samples without chemical labeling

Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC): Incorporates isotopically labeled amino acids into proteins for precise quantification

Isobaric Tag for Relative and Absolute Quantitation (iTRAQ): Uses chemical tags to label peptides from different samples for multiplexed quantification

Bioinformatics Tools in Proteomics

Bioinformatics plays a critical role in proteomics by processing and interpreting large-scale protein data. Computational tools facilitate protein identification, functional annotation, and pathway analysis.

Protein Identification Databases

Proteomics relies on comprehensive protein databases for identification and annotation. The most commonly used databases include:

- UniProt: A curated repository of protein sequences and functional annotations
- NCBI Protein Database: Provides protein sequence information from GenBank
- PRIDE (Proteomics Identifications Database): A public repository for proteomics data
- Functional Annotation and Pathway Analysis
- Gene Ontology (GO): Categorizes proteins based on biological processes, molecular functions, and cellular components.
- Kyoto Encyclopedia of Genes and Genomes (KEGG): Provides pathway maps for understanding metabolic and signaling networks.
- STRING (Search Tool for the Retrieval of Interacting Genes/Proteins): Analyzes protein-protein interaction networks.

Structural Proteomics and Molecular Docking

- Structural proteomics aims to determine the three-dimensional structures of proteins using computational modeling and experimental data.

- AlphaFold: A deep learning-based tool for protein structure prediction
- Molecular Docking: Tools like AutoDock predict how small molecules interact with proteins, aiding drug discovery.

Applications of Proteomics

Proteomics has revolutionized multiple scientific and industrial fields by enabling a comprehensive understanding of protein expression, interactions, and modifications. Its applications extend across disease biomarker discovery, drug development, personalized medicine, agriculture, and environmental science. The ability to study proteins on a large scale has led to significant advancements in biomedical research, aiding in early disease detection, targeted therapies, and improved patient outcomes.

Disease Biomarker Discovery

Biomarkers are measurable indicators of physiological and pathological processes, providing critical insights into disease diagnosis, progression, and treatment responses. Proteomics plays a key role in identifying novel biomarkers by analyzing differentially expressed proteins in biological samples such as blood, urine, and tissues (Anderson & Anderson, 2002). Mass spectrometry-based proteomic approaches, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), have been extensively used to discover protein biomarkers for various diseases.

Cancer Biomarkers

Proteomics has facilitated the identification of protein biomarkers for cancer detection and prognosis.

Examples include:

- Prostate Cancer: Prostate-specific antigen (PSA) is widely used for early prostate cancer screening
- Breast Cancer: Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with aggressive breast cancer and targeted therapies like trastuzumab
- Ovarian Cancer: Cancer antigen 125 (CA-125) is a biomarker used for ovarian cancer diagnosis

Neurodegenerative Disease Biomarkers

- Proteomics has identified key biomarkers for neurodegenerative diseases, improving early diagnosis and disease monitoring.
- Alzheimer's Disease: Tau proteins and β-amyloid peptides are hallmarks of Alzheimer's disease, detected in cerebrospinal fluid and plasma

- Parkinson's Disease: α-Synuclein aggregates serve as biomarkers for Parkinson's disease and other synucleinopathies.

Drug Development

Proteomics plays a crucial role in drug discovery and development by identifying drug targets, understanding disease mechanisms, and assessing drug efficacy and toxicity. Mass spectrometry and protein interaction studies allow researchers to explore the impact of drugs on cellular pathways and protein networks.

Target Identification and Validation

Proteomics enables the identification of disease-associated proteins that serve as potential drug targets. Techniques such as quantitative proteomics and protein-protein interaction studies help validate target proteins and assess their functional roles in disease pathways. Examples include:

- Imatinib (Gleevec): Targeted inhibition of BCR-ABL fusion protein in chronic myeloid leukemia
- Trastuzumab (Herceptin): HER2-targeted monoclonal antibody therapy for breast cancer

Toxicology and Drug Safety Studies

Proteomics is widely used in toxicology studies to assess drug-induced alterations in protein expression and metabolic pathways. Identifying proteomic changes in response to drug exposure helps predict adverse effects and improve drug safety

Examples include:

- Hepatotoxicity Studies: Proteomic analysis of liver tissues helps detect early biomarkers of drug-induced liver injury
- Nephrotoxicity Studies: Urinary proteomics aids in detecting kidney toxicity caused by pharmaceutical compounds

Personalized Medicine

Personalized or precision medicine tailors treatments based on an individual's genetic, proteomic, and metabolic profiles. Proteomics provides crucial insights into protein expression patterns, enabling customized therapeutic strategies that enhance drug efficacy and reduce side effects

Proteomics and Genomics Integration

Integrating proteomic and genomic data allows for a more comprehensive understanding of disease mechanisms. While genomics provides information on genetic predispositions, proteomics reveals real-time functional changes in the proteome

Examples include:

- Oncotype DX: A proteogenomic test used to predict breast cancer recurrence risk and guide chemotherapy decisions
- Pharmacoproteomics: Personalized drug selection based on individual proteomic signatures, improving treatment outcomes for diseases like cancer and autoimmune disorders

Applications in Disease Treatment

- Cancer Therapy: Proteomics-guided precision oncology helps select targeted therapies based on tumor-specific protein expression.
- Cardiovascular Disease: Proteomics identifies novel cardiac biomarkers for personalized risk assessment and treatment.

Agricultural and Environmental Applications

Beyond medicine, proteomics has significant applications in agriculture and environmental science.

Agricultural Proteomics

- Proteomics helps in improving crop productivity and resilience by analyzing plant responses to stress conditions such as drought, salinity, and pathogens.
- Stress-Responsive Proteins: Proteomics identifies proteins involved in stress tolerance, aiding in the development of climate-resilient crops
- Genetically Modified Crops: Comparative proteomic studies assess the safety and nutritional value of genetically modified organisms (GMOs)

Environmental Proteomics

- Proteomics is used to study microbial communities and their role in environmental sustainability.
- Bioremediation: Identifying proteins involved in pollutant degradation helps develop bioremediation strategies
- Microbial Ecology: Metaproteomics provides insights into microbial diversity and function in ecosystems

Data Complexity and Dynamic Range of the Proteome

One of the major challenges in proteomics is the vast complexity of the proteome. Unlike the genome, which is relatively stable, the proteome is highly dynamic and varies across tissues, cell types, developmental stages, and environmental conditions

Proteins exhibit a wide dynamic range of concentrations, spanning several orders of magnitude, which makes detecting low-abundance proteins particularly challenging

For example, in human plasma, high-abundance proteins like albumin can mask the detection of low-abundance biomarkers, making biomarker discovery difficult

To overcome this challenge, researchers have employed techniques such as:

- Protein Fractionation and Depletion Strategies: Methods like immunodepletion remove high-abundance proteins to enhance the detection of low-abundance proteins (Pieper *et al*., 2003).
- Advanced Mass Spectrometry Technologies: Innovations like data-independent acquisition (DIA) and targeted proteomics improve protein quantification across diverse samples.

Reproducibility and Standardization Issues

Reproducibility remains a significant challenge in proteomics due to variations in sample preparation, data acquisition, and analysis workflows. Differences in protein extraction methods, enzymatic digestion efficiency, and instrument calibration can lead to inconsistent results between laboratories.

Efforts to improve reproducibility include:

- Standardized Sample Preparation Protocols: The Human Proteome Organization (HUPO) has established guidelines for proteomic sample processing and data reporting
- Quality Control and Benchmarking: Inter-laboratory studies and quality control measures help validate experimental reproducibility.
- Use of Machine Learning in Data Analysis: AI-driven algorithms enhance reproducibility by minimizing human biases in data interpretation.

High Costs and Technological Barriers

Proteomics research requires expensive instrumentation, such as high-resolution mass spectrometers, liquid chromatography systems, and computational resources for data analysis. The cost of reagents, specialized software, and bioinformatics expertise adds to the financial burden, limiting access to advanced proteomics technologies in resource-limited settings.

Potential solutions to cost-related challenges include:

Development of Cost-Effective Technologies: Miniaturization of mass spectrometry and advances in label-free quantification reduce experimental costs.

- Cloud-Based Data Analysis Platforms: Online proteomics platforms provide computational support for researchers without requiring high-end local infrastructure.
- Collaborative Research Initiatives: Open-access proteomics databases like PRIDE and ProteomeXchange facilitate data sharing and reduce duplication of experiments

Future Perspectives in Proteomics

Integration with Multi-Omics Approaches

The future of proteomics lies in its integration with genomics, transcriptomics, metabolomics, and lipidomics. Multi-omics approaches provide a more comprehensive understanding of biological systems by linking genetic variations with protein expression and metabolic changes. For example, proteogenomics combines proteomic and genomic data to discover novel protein isoforms and alternative splicing events.

Advancements in Single-Cell Proteomics

Traditional proteomics studies analyze bulk tissue samples, averaging out cellular heterogeneity. Recent advances in single-cell proteomics enable the study of protein expression at the individual cell level, providing insights into cell-to-cell variability in diseases such as cancer. Techniques like nanoproteomics and microfluidics-based single-cell mass spectrometry are revolutionizing precision medicine by identifying rare cell populations and their functional states.

Artificial Intelligence and Machine Learning in Proteomics

AI-driven data analysis is set to transform proteomics by improving protein identification, quantification, and interaction network predictions. Machine learning algorithms enhance the accuracy of peptide identification from mass spectrometry data and facilitate large-scale functional annotations. AI models are also being used to predict protein structures and interactions, as demonstrated by AlphaFold's success in protein structure prediction.

Clinical Translation and Biomarker Validation

Despite the identification of numerous potential biomarkers, only a few have been successfully translated into clinical practice. Future proteomics research will focus on rigorous validation of biomarkers through large-scale clinical studies and regulatory approval processes. The use of targeted proteomics methods like multiple reaction monitoring (MRM) will enhance biomarker verification and clinical.

Expansion of Proteomics into Non-Model Organisms

Proteomics has traditionally focused on human and model organisms such as mice and yeast. However, future studies will expand into non-model organisms, including extremophiles, rare microbial species, and underexplored plant species. This expansion will provide new insights into biodiversity, evolutionary biology, and environmental adaptations.

Conclusion

Despite significant advancements, proteomics continues to face challenges related to data complexity, reproducibility, high costs, and standardization. However, ongoing technological innovations, such as multi-omics integration, single-cell proteomics, AI-driven data analysis, and improved biomarker validation, offer promising solutions. The future of proteomics lies in its ability to translate fundamental research into clinical and industrial applications, ultimately contributing to precision medicine, drug development, and environmental sustainability. Continued investment in proteomic technologies and collaborative efforts will be key to overcoming current limitations and unlocking the full potential of proteomics in biomedical and life sciences research.

References

1. Aebersold, Ruedi, and Matthias Mann. "Mass-Spectrometric Exploration of Proteome Structure and Function." *Nature*, vol. 537, no. 7620, 2016, pp. 347-55.
2. Anderson, Norman L., and N. G. Anderson. "The Human Plasma Proteome: History, Character, and Diagnostic Prospects." *Molecular & Cellular Proteomics*, vol. 1, no. 11, 2002, pp. 845-67.
3. Anderson, Norman L., and C. L. Hunter. "Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins." *Molecular & Cellular Proteomics*, vol. 5, no. 4, 2006, pp. 573-88.
4. Armengaud, Jean, et al. "Non-Model Organisms, A Species Endangered by Proteogenomics." *Journal of Proteomics*, vol. 105, 2013, pp. 5-18.
5. Bittremieux, Wout, et al. "Quality Control in Mass Spectrometry-Based Proteomics." *Mass Spectrometry Reviews*, vol. 37, no. 5, 2017, pp. 697-711.
6. Deutsch, Eric W., et al. "The ProteomeXchange Consortium in 2017: Supporting the Cultural Change in Proteomics Public Data Deposition." *Nucleic Acids Research*, vol. 45, no. D1, 2017, pp. D1100-D1106.
7. Domon, Bruno, and Ruedi Aebersold. "Options and Considerations When Selecting a Quantitative Proteomics Strategy." *Nature Biotechnology*, vol. 28, no. 7, 2010, pp. 710-21.
8. Edfors, Fredrik, et al. "Gene-Specific Correlation of RNA and Protein Levels in Human Cells and Tissues." *Molecular Systems Biology*, vol. 12, no. 10, 2016, p. 883.

9. Gillet, Laurent C., et al. "Targeted Data Extraction of the MS/MS Spectra Generated by Data-Independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis." *Molecular & Cellular Proteomics*, vol. 11, no. 6, 2012, p. O111.016717.
10. Hasin, Yosef, et al. "Multi-Omics Approaches to Disease." *Genome Biology*, vol. 18, 2017, p. 83.
11. Jumper, John, et al. "Highly Accurate Protein Structure Prediction with AlphaFold." *Nature*, vol. 596, no. 7873, 2021, pp. 583-89.
12. Kelly, Ryan T. "Single-Cell Proteomics: Progress and Prospects." *Molecular & Cellular Proteomics*, vol. 19, no. 11, 2020, pp. 1739-48.
13. Marx, Vivien. "A Dream of Single-Cell Proteomics." *Nature Methods*, vol. 16, no. 9, 2019, pp. 809-12.
14. Nesvizhskii, Alexey I. "Proteogenomics: Concepts, Applications, and Computational Strategies." *Nature Methods*, vol. 11, no. 11, 2014, pp. 1114-25.
15. Pieper, Ralf, et al. "The Human Serum Proteome: Display of Nearly 3700 Chromatographically Separated Protein Spots on Two-Dimensional Electrophoresis Gels and Identification of 325 Distinct Proteins." *Proteomics*, vol. 3, no. 7, 2003, pp. 1345-64.
16. Sinitcyn, Pavel, et al. "MaxQuant Goes Linux." *Nature Methods*, vol. 15, no. 6, 2018, pp. 401-02.
17. Smith, Lloyd M., et al. "Proteoform: A Single Term Describing Protein Complexity." *Nature Methods*, vol. 10, no. 3, 2013, pp. 186-87.
18. Surinova, Svetlana, et al. "On the Development of Plasma Protein Biomarkers." *Journal of Proteome Research*, vol. 10, no. 1, 2011, pp. 5-16.
19. Tiwary, Sarthak, et al. "High-Quality MS/MS Spectrum Prediction for Data-Dependent and Data-Independent Acquisition Data Analysis." *Nature Methods*, vol. 16, no. 6, 2019, pp. 519-25.
20. Tyanova, Stefka, et al. "The MaxQuant Computational Platform for Mass Spectrometry-Based Shotgun Proteomics." *Nature Protocols*, vol. 11, no. 12, 2016, pp. 2301-19.
21. Vizcaíno, Juan A., et al. "2014 Update of the PRIDE Database and Related Tools." *Nucleic Acids Research*, vol. 42, no. D1, 2014, pp. D1009-D1013.

22. Wilhelm, Matthias, et al. "Mass-Spectrometry-Based Draft of the Human Proteome." *Nature*, vol. 509, no. 7502, 2014, pp. 582-87.
23. Zhou, Yixian, et al. "Artificial Intelligence in Proteomics." *Proteomics*, vol. 19, no. 19, 2019, p. 1800413.

CHAPTER 10

CRISPR-CAS9 IN GENE THERAPY: ADVANCEMENTS, CHALLENGES, AND FUTURE DIRECTIONS

*S. Salomie Jennifer**

Institute of Scholars, Bangalore

Email ID: salomiejennifer@gmail.com

ABSTRACT

CRISPR-Cas9 has emerged as a transformative tool in the field of gene therapy, offering precise and efficient editing of genetic material. This chapter explores the current successes and future prospects of CRISPR-Cas9 in treating a wide range of genetic disorders, including monogenic and polygenic diseases, cancer, and infectious diseases. By harnessing the natural bacterial immune mechanism of CRISPR and engineering it for targeted genome editing, researchers have developed powerful therapeutic approaches that promise long-term solutions for previously untreatable conditions. The chapter delves into the molecular mechanisms of CRISPR-Cas9, highlighting advancements in somatic and germline editing, innovative delivery strategies, and successful preclinical and clinical applications. Additionally, it examines the ethical considerations, regulatory challenges, and societal implications associated with human genome editing. Despite its promise, the application of CRISPR-Cas9 faces hurdles such as off-target effects, variable efficiency of homology-directed repair, and complexities in in vivo delivery. The chapter concludes by considering future innovations aimed at increasing specificity, minimizing risks, and broadening the clinical scope of CRISPR-Cas9-based gene therapies. These advancements may ultimately shape the future of personalized medicine, offering hope for precision-targeted, curative interventions for genetic disorders.

Keywords: CRISPR-Cas9, Gene Therapy, Genome Editing, Precision Medicine, Somatic Editing, Germline Editing, Monogenic Disorders, Cancer Therapy, Ethical Considerations, Future Prospects

Introduction

The discovery of CRISPR-Cas9 as a genome-editing tool has fundamentally transformed the landscape of genetic research and therapy. Initially identified as an adaptive immune mechanism in prokaryotes, CRISPR-Cas9 has been repurposed to enable precise, programmable editing of eukaryotic genomes. Its ability to introduce targeted double-strand breaks (DSBs) and facilitate sequence modifications has unlocked unprecedented potential for correcting genetic mutations that underlie various hereditary and acquired diseases.

CRISPR-Cas9 functions through a simple yet powerful mechanism. The system relies on a guide RNA (gRNA) that directs the Cas9 endonuclease to a specific DNA sequence complementary to the gRNA's spacer region. Once bound, the Cas9 enzyme introduces a DSB at the target site, activating cellular DNA repair pathways—either non-homologous end joining (NHEJ) or homology-directed repair (HDR). NHEJ can lead to random insertions or deletions (indels), while HDR enables precise sequence corrections using a donor DNA template.

The rapid transition of CRISPR-Cas9 from basic research to clinical applications has led to its exploration in treating a broad spectrum of diseases. In monogenic disorders such as sickle cell anemia, β-thalassemia, and Duchenne muscular dystrophy, CRISPR-Cas9 has demonstrated the ability to correct pathogenic mutations ex vivo in hematopoietic stem cells, which can then be reintroduced into patients. Clinical trials targeting hematological conditions have shown promising results, with some patients achieving significant therapeutic benefits. In oncology, CRISPR-Cas9 is being applied to enhance the efficacy of immunotherapies. By engineering T cells to express chimeric antigen receptors (CARs) or knock out inhibitory receptors, researchers are developing more potent and precise cancer treatments. Infectious diseases like HIV have also become targets, with CRISPR strategies aiming to excise integrated viral genomes from host cells, offering a potential cure.

Despite its potential, CRISPR-Cas9 raises ethical and societal concerns, particularly regarding germline editing. The possibility of heritable modifications that could affect future generations has sparked debates about the limits of human genetic intervention. Regulatory bodies face the challenge of balancing innovation with ethical responsibility, necessitating stringent oversight and international collaboration. Future innovations aim to improve the precision and efficiency of CRISPR-Cas9. Strategies like base editing, prime editing, and epigenome editing minimize off-target effects and expand the versatility of genome modification. Additionally, advances in delivery mechanisms, such as nanoparticle-based and viral vector systems, seek to enhance the specificity and safety of CRISPR-based therapies.

As research progresses, CRISPR-Cas9 holds the promise to revolutionize personalized medicine, offering curative solutions for previously intractable genetic disorders. Continued interdisciplinary collaboration will be essential to fully realize the therapeutic potential of this groundbreaking technology.

Mechanism of CRISPR-Cas9 in Gene Editing

Components of CRISPR-Cas9 System

The CRISPR-Cas9 system consists of three primary components: the Cas9 endonuclease, a programmable RNA molecule (gRNA), and a protospacer adjacent motif (PAM) sequence. The

Cas9 protein acts as molecular scissors, creating double-strand breaks (DSBs) in the target DNA. The gRNA, composed of a scaffold sequence and a spacer region, guides Cas9 to the target sequence by base-pairing with complementary DNA. The PAM sequence, typically NGG for *Streptococcus pyogenes* Cas9, is a crucial recognition site for Cas9 activity, distinguishing foreign DNA from the host genome.

Researchers have developed various Cas9 variants to enhance specificity and minimize off-target effects. Enhanced specificity variants include eSpCas9, high-fidelity SpCas9-HF1, and xCas9, which exhibit reduced off-target cleavage while maintaining high on-target activity. Additionally, orthologous Cas9 proteins from other bacterial species, such as *Staphylococcus aureus* Cas9 (SaCas9), provide alternative PAM requirements and distinct delivery advantages due to their smaller size.

Mechanism of Action of CRISPR-Cas9

CRISPR-Cas9 operates through a highly coordinated series of steps, each crucial for the precise editing of genetic material. These steps include target recognition, DNA cleavage, and DNA repair. Here's a detailed look at each phase:

1. Target Recognition

The specificity of CRISPR-Cas9 is primarily guided by the engineered guide RNA (gRNA), which consists of two components: the CRISPR RNA (crRNA) that is complementary to the target DNA sequence and a trans-activating CRISPR RNA (tracrRNA) that helps stabilize the complex. In engineered systems, these two components are often fused into a single-guide RNA (sgRNA).

A critical requirement for the gRNA to bind its target is the presence of a protospacer adjacent motif (PAM) sequence, typically 'NGG' for Streptococcus pyogenes Cas9 (SpCas9). The Cas9 protein scans the genome for PAM sequences and initiates DNA unwinding. When the gRNA finds a complementary DNA sequence adjacent to a PAM site, it hybridizes through Watson-Crick base pairing, establishing the specificity of the targeting mechanism.

2. DNA Cleavage

Upon successful binding, the Cas9 protein undergoes a conformational change that activates its nuclease domains — the RuvC and HNH domains. The HNH domain cleaves the DNA strand complementary to the gRNA (the target strand), while the RuvC domain cleaves the non-target strand. The result is a double-stranded break (DSB) approximately three nucleotides upstream of the PAM site. Notably, these DSBs are blunt-ended, which distinguishes CRISPR-Cas9 from other nucleases that often produce staggered cuts.

3. DNA Repair

The cellular machinery responds to DSBs by engaging DNA repair pathways. There are two primary mechanisms for repair:

a) Non-Homologous End Joining (NHEJ): NHEJ is the predominant pathway for DSB repair in most organisms due to its rapid and efficient nature. However, it is considered error-prone because the ligation process may introduce insertions or deletions (indels) at the break site. These indels can disrupt reading frames, resulting in gene knockouts. In biomedical research, this characteristic is leveraged to create loss-of-function models or disrupt pathogenic alleles.

b) Homology-Directed Repair (HDR): HDR is a more precise but less efficient pathway, active predominantly during the S and G2 phases of the cell cycle. It requires a homologous DNA template that aligns with sequences flanking the break site. The repair machinery uses this template to restore the original sequence or introduce specific genetic modifications. Researchers exploit HDR for precise genome editing tasks, such as correcting point mutations, inserting transgenes, or engineering subtle genetic alterations.

Despite its precision, HDR efficiency is a limiting factor for clinical applications. Factors like the availability of a suitable donor template, the cell cycle phase, and the presence of competing NHEJ pathways influence HDR efficiency. Current research aims to enhance HDR rates through chemical inhibitors of NHEJ, synchronized cell cycle modulation, and novel CRISPR variants that bias repair toward HDR.

Delivery Methods

Effective and safe delivery of CRISPR-Cas9 components to target cells is essential for successful therapeutic applications. Current strategies include:

a) **Viral Vectors:** Adeno-associated viruses (AAV) and lentiviruses are commonly employed due to their high transduction efficiency. However, viral vectors pose risks, including immunogenicity, insertional mutagenesis, and size constraints that limit the packaging of large Cas9 variants.
b) **Non-viral Methods:** Lipid nanoparticles, electroporation, and gold nanoparticles are used to enhance tissue-specific delivery while reducing immunogenicity. Nanocarriers are continuously optimized for improved targeting, stability, and delivery efficiency.
c) **Physical Methods:** Techniques like microinjection, hydrodynamic injection, and electroporation are utilized for ex vivo and in vivo applications. While these methods offer high precision, they face challenges related to scalability and tissue accessibility.

Additionally, advancements in RNA-based delivery approaches, such as the use of self-replicating RNA and synthetic mRNA, have shown promise in achieving transient yet effective CRISPR-Cas9 expression while reducing the risks associated with permanent genomic integration.

Current Successes of CRISPR-Cas9 in Gene Therapy

Monogenic Disorders

CRISPR-Cas9 has shown remarkable efficacy in treating disorders caused by single-gene mutations:

a) **Sickle Cell Disease (SCD) and Beta-Thalassemia:** Clinical trials, such as those led by CRISPR Therapeutics and Vertex Pharmaceuticals, have demonstrated the potential to reactivate fetal hemoglobin through BCL11A enhancer editing, leading to a functional cure. These advancements offer curative possibilities for patients who previously relied on life-long transfusions and risky bone marrow transplants. Ongoing studies aim to optimize in vivo delivery methods to reduce treatment complexity and expand accessibility.
b) **Duchenne Muscular Dystrophy (DMD):** Researchers have employed exon skipping and HDR to correct mutations in the DMD gene, restoring dystrophin production in muscle cells. Advancements in precision and efficiency have shown potential to treat a broader spectrum of DMD mutations. Although clinical application remains complex, preclinical models have demonstrated significant functional recovery in affected tissues.
c) **Cystic Fibrosis (CF):** In vitro studies have successfully corrected CFTR mutations in patient-derived airway epithelial cells, paving the way for future clinical trials. Current research focuses on developing efficient in vivo delivery techniques, potentially transforming treatment approaches for CF patients.

Cancer Therapy

CRISPR has significantly expanded the scope of precision oncology:

a) **CAR-T Cell Therapy:** CRISPR has been utilized to enhance CAR-T cell efficacy by knocking out immune checkpoints like PD-1, boosting their anti-tumor potential. Multi-targeting strategies combining CRISPR with other immunotherapies are being explored to enhance specificity, persistence, and reduce relapse rates in cancers like leukemia and lymphoma.
b) **Oncogene Editing:** Disruption or deletion of oncogenes such as KRAS, MYC, and TP53 has shown promise in preclinical cancer models. Researchers are exploring synthetic lethality approaches, targeting vulnerabilities in cancer cells to develop effective therapies for resistant cancers. Innovative delivery methods, such as nanoparticle-mediated CRISPR delivery, aim to maximize specificity and minimize off-target effects.

Infectious Disease Research

CRISPR-Cas9 offers novel approaches to tackling infectious diseases:

a) **HIV Cure Research:** CRISPR is being tested to excise integrated HIV-1 proviral DNA from host cells, potentially leading to a sterilizing cure. Strategies combining CRISPR with antiretroviral therapy (ART) aim to eradicate latent viral reservoirs, a significant barrier to curing HIV.
b) **Hepatitis B Virus (HBV):** CRISPR-based strategies target and disrupt HBV covalently closed circular DNA (cccDNA), a critical barrier to eradication. Research is focused on optimizing delivery to hepatocytes while minimizing unintended immune responses. If successful, this approach could provide a definitive cure for chronic HBV infections, reducing the risk of liver cancer and cirrhosis.

Future Innovations in CRISPR-Cas9 Technology

Future advancements in CRISPR-Cas9 technology aim to overcome current limitations and expand its therapeutic applications. As the field of genome editing evolves, researchers and developers are exploring innovative strategies to enhance precision, safety, delivery, and applicability.

a) **Base Editing and Prime Editing:** These next-generation editing techniques offer precise, programmable nucleotide changes without inducing double-strand breaks (DSBs), minimizing the risk of off-target effects. Base editing allows the conversion of specific nucleotides (e.g., C-to-T or A-to-G), while prime editing uses a guided reverse transcriptase to rewrite targeted DNA sequences. These approaches could expand treatment options for a broader range of genetic disorders, including those unsuitable for conventional CRISPR-Cas9 editing.
b) **Epigenome Editing:** Unlike traditional gene editing, which alters the DNA sequence, epigenome editing targets histone modifications and DNA methylation patterns to regulate gene expression. This approach has potential applications for complex, multifactorial conditions like neurodegenerative diseases, cardiovascular disorders, and certain cancers, where modifying gene expression may be more beneficial than permanent genetic alterations.
c) **In Vivo Delivery Systems:** A significant challenge in clinical applications is delivering CRISPR-Cas9 components efficiently and safely to target cells. Emerging strategies include:

d) **Virus-like Particles (VLPs):** Engineered to mimic viruses without the risk of genomic integration, VLPs can deliver CRISPR components with high efficiency.

e) **Synthetic Exosomes:** These nanoscale vesicles facilitate targeted delivery, minimizing immune responses and enhancing tissue-specific uptake.

f) **Cell-Penetrating Peptides (CPPs):** CPPs offer a non-viral, low-toxicity approach to transporting CRISPR molecules across cellular membranes, expanding the scope of in vivo editing.

g) **Expanding Targeting Scope:** The discovery and engineering of novel Cas proteins, such as Cas12, Cas13, and Cas14, with diverse PAM compatibilities and reduced immunogenicity, broaden the range of targetable genomic loci. Researchers are also developing CRISPR variants that can function in more complex or inaccessible genomic regions, potentially overcoming the limitations associated with conventional SpCas9.

h) **Multiplexed Editing and Gene Regulation:** Advanced CRISPR systems now enable simultaneous targeting of multiple genes, allowing for the correction of polygenic disorders or complex traits influenced by multiple genetic factors. Additionally, CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi) systems can upregulate or downregulate specific genes, providing therapeutic flexibility for diseases requiring fine-tuned gene expression control.

i) **Ethical and Regulatory Frameworks:** As CRISPR-based therapies move toward widespread clinical use, establishing ethical standards and regulatory guidelines becomes imperative. Issues like germline editing, long-term effects, consent for genetic modifications, and equitable access require comprehensive frameworks to ensure responsible and inclusive implementation. Engaging stakeholders, including patients, scientists, policymakers, and ethicists, will be crucial for navigating these complexities.

j) **Artificial Intelligence (AI) Integration:** AI and machine learning are being utilized to design more accurate gRNAs, predict off-target effects, and optimize delivery systems. Computational modeling can streamline the identification of optimal targets and improve the efficiency of CRISPR-based interventions, accelerating the transition from research to clinical application.

k) **Personalized and Precision Medicine:** CRISPR technology is moving towards highly personalized approaches, where individual genetic profiles can guide customized treatments. This personalized approach holds promise for tailored therapies in oncology, rare genetic disorders, and autoimmune conditions.

Advanced Techniques

CRISPR-Cas9 technology has rapidly transformed the field of genetic engineering, providing an efficient, precise, and cost-effective tool for editing DNA. However, despite its groundbreaking capabilities, the initial versions of CRISPR-Cas9 faced significant limitations, particularly related to off-target effects — unintended edit to non-target regions of the genome. These unintended modifications can lead to undesirable mutations or potential harm, posing a challenge to the safe therapeutic application of this technology.

To address these challenges, advanced techniques like base editing, prime editing, and epigenome editing have been developed.

a) Base editing enables the precise conversion of a single DNA base pair without causing double-strand breaks. This method is particularly effective in correcting point mutations, which are responsible for a large portion of genetic disorders. By minimizing the occurrence of unintended cuts, base editing reduces the risk of off-target effects, making it a promising approach for therapeutic interventions.

b) Prime editing builds upon base editing and traditional CRISPR-Cas9 by introducing more complex and versatile changes, such as insertions, deletions, and all 12 possible base-to-base conversions. Often described as a "search-and-replace" tool for DNA, prime editing is designed to be more accurate and versatile, expanding the scope of treatable genetic conditions.

c) Epigenome editing targets the regulation of gene expression without altering the underlying DNA sequence. By modifying epigenetic marks like DNA methylation or histone modifications, researchers can fine-tune gene expression, providing potential treatments for diseases caused by dysregulated genes rather than genetic mutations.

Advances in delivery mechanisms further enhance the safety and efficiency of CRISPR-based therapies. Nanoparticle-based delivery systems offer a non-viral approach, reducing the risk of immune responses and minimizing toxicity. Viral vectors, such as adeno-associated viruses (AAVs), have been optimized to deliver CRISPR components more precisely, improving the targeting of specific tissues while minimizing unintended impacts.

As research progresses, CRISPR-Cas9 holds the potential to revolutionize personalized medicine, offering curative solutions for previously intractable genetic disorders like cystic fibrosis, sickle cell disease, and muscular dystrophy. Additionally, it has shown promise in the field of oncology, where it can be used to target and modify cancer-associated genes.

However, realizing the full therapeutic potential of CRISPR-Cas9 will require ongoing interdisciplinary collaboration among geneticists, bioengineers, clinicians, and ethicists. Addressing ethical concerns related to germline editing, equitable access to therapies, and long-term safety will be crucial as these technologies move closer to clinical applications. Continued research and dialogue will help establish appropriate guidelines and standards, ensuring that this powerful technology is used responsibly and effectively.

Ethical considerations

Ethical and regulatory considerations play a pivotal role in shaping the future of CRISPR-based therapies. As this transformative technology advances, the implications of its use extend far beyond the laboratory, raising critical questions about its application in society. The debate around germline editing—where genetic changes are inheritable and passed on to future generations—remains a central ethical concern. While the potential to eliminate genetic disorders before birth is promising, the possibility of unintended consequences or genetic discrimination cannot be

overlooked. Informed consent also presents challenges, particularly in cases involving embryos or individuals unable to provide consent themselves. Ensuring that patients and their families fully understand the risks, benefits, and limitations of CRISPR-based therapies is crucial for ethical decision-making.

Equitable access to these treatments further complicates the ethical landscape. If left unregulated, CRISPR could exacerbate existing healthcare disparities, creating a divide between those who can afford genetic enhancements and those who cannot. Policymakers and global health organizations must work to establish guidelines that ensure fairness, inclusivity, and accessibility to avoid a scenario where genetic therapies become the privilege of the wealthy. Long-term monitoring and assessment are essential to understand the enduring impact of genetic modifications. The possibility of off-target effects or unintended genetic consequences necessitates strict oversight and transparency in research and clinical applications. Robust regulatory frameworks must be established to balance innovation with patient safety, while also considering the societal implications of altering the human genome.

Future advancements are expected to refine CRISPR-Cas9's precision, expand its applicability, and address the ethical complexities it raises. Efforts to improve the specificity and accuracy of gene editing could minimize risks, reducing the likelihood of off-target mutations. As research progresses, the development of safer, more effective, and accessible CRISPR-based therapies could revolutionize the treatment of genetic disorders, potentially shifting the paradigm of medicine from symptom management to true genetic cures. Ultimately, fostering a collaborative dialogue among scientists, ethicists, policymakers, and the public is essential to navigate the complex ethical landscape of CRISPR technology. By considering diverse perspectives and anticipating the long-term implications, society can harness the power of gene editing responsibly and equitably.

Conclusion

CRISPR-Cas9 has redefined the scope of gene therapy, offering hope for genetic disorders once considered incurable. Despite its potential, challenges in precision, delivery, ethics, and regulation must be navigated to realize its full potential. Future advancements may create more effective, accessible, and ethically sound CRISPR-based therapies. CRISPR-Cas9 has redefined the scope of gene therapy, offering hope for genetic disorders once considered incurable. By enabling precise and programmable alterations in the genome, CRISPR-Cas9 has opened avenues for treating a wide range of genetic conditions, including monogenic disorders, cancers, and infectious diseases. Its ability to target and modify specific genes with relative ease and efficiency has marked a significant departure from traditional gene therapy approaches reliant on viral vectors and random integration techniques.

However, significant challenges remain before CRISPR-Cas9 can fully realize its therapeutic potential. Precision remains a critical concern, as off-target effects can lead to unintended genetic

alterations with potentially harmful consequences. The development of high-fidelity Cas9 variants and novel base and prime editing techniques aims to address these limitations, improving the accuracy of genome editing. Effective and safe delivery of CRISPR components to target cells poses another significant hurdle. Current delivery methods, including viral vectors, lipid nanoparticles, and electroporation, each have inherent limitations related to immunogenicity, efficiency, and tissue specificity. Future innovations in non-viral delivery systems—such as virus-like particles, cell-penetrating peptides, and synthetic exosomes—promise to enhance the precision and safety of in vivo applications.

References

1. Anzalone, David V., et al. "Search-and-Replace Genome Editing Without Double-Strand Breaks." *Nature*, 2019.
2. Doudna, Jennifer A., and Emmanuelle Charpentier. "The New Frontier of Genome Engineering with CRISPR-Cas9." *Science*, 2014.
3. Frangoul, Haydar, et al. "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia." *New England Journal of Medicine*, vol. 384, no. 3, 2021, pp. 252-60.
4. Gao, Qiang, et al. "Disruption of Oncogenes via CRISPR-Cas9 in Cancer Therapy." *Nature Cancer*, vol. 1, no. 2, 2020, pp. 213-24.
5. Gaudelli, Nicole M., et al. "Programmable Base Editing of A•T to G•C in Genomic DNA." *Nature*, 2017.
6. Ishino, Yoshizumi, et al. "History and Development of CRISPR-Cas." *Nature Reviews Microbiology*, 2018.
7. Jinek, Martin, et al. "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity." *Science*, 2012.
8. Lanphier, Edward, et al. "Don't Edit the Human Germ Line." *Nature*, 2015.
9. Li, Chen, et al. "Targeting HIV-1 Provirus Using CRISPR-Cas9." *Nature Communications*, 2022.
10. Li, Ming, et al. "Gene Editing for DMD Therapy: Current Progress and Future Prospects." *Molecular Therapy*, vol. 30, no. 7, 2022, pp. 1572-84.
11. Liu, Y., et al. "CRISPR-Cas9 for Hepatitis B Virus Therapy." *Journal of Hepatology*, vol. 73, no. 2, 2020, pp. 445-55.

12. Stadtmauer, Edward A., et al. "CRISPR-Engineered T Cells in Cancer Immunotherapy." *Science*, 2020.
13. Wang, Haixia, et al. "CRISPR-Cas9 Delivery to the Lung Genome by Nanoparticles for Cystic Fibrosis Treatment." *Science Advances*, 2020.

CHAPTER 11

A GREAT IMPACT OF HYDROPONICS IN AGRICULTURE USING MICROBES

Dr.T.Vinotha[1] , Dr.G.Arun Kumar[2], Ms.S.Abirami[3]
Assistant Professor, Department of microbiology
Hindusthan College of arts &science, Coimbatore, Tamilnadu, India – 641028.
Corresponding author, Email : vinotha.t@hicas.ac.in ORCID ID: 0000-0003-3958-6646

ABSTRACT
Hydroponics, a soilless cultivation method, has transformed food production through the ability to produce high yields in controlled conditions. The inclusion of beneficial microbes in hydroponic systems has also improved plant growth, nutrient acquisition, and disease resistance. Microbial inoculants like plant growth-promoting rhizobacteria (PGPR) and mycorrhizal fungi are key to nutrient solubilization, nitrogen fixation, and pathogen inhibition. These microorganisms enhance root growth, plant resilience, and maximum nutrient utilization efficiency, rendering hydroponics more productive and environmentally friendly agriculture. Microbial uses also decrease reliance on chemical pesticides and fertilizers, resulting in cost- effective and environmentally friendly farming practices. In this paper, the synergistic interactions between microbial biotechnology and hydroponics are discussed and their role on food security, environmental protection, and sustainable farming.

Key Words: PGPR, Bacteria, Fungi, Mycorizhae, Environment

Introduction

Since forever the Revolution of farming in 10,000 BC, mankind has been creating material through planting seeds in the soil. It worked for the people for the last few millenium, but that does not imply that the process is not limited by constraints farmers have always fought against. Hydroponics is a fairly new development that compels us to at least reevaluate everything we think we know about what agriculture should look like. It presents the paradigm shift that plants don't need soil in order to live - they just need a substrate that can support the nutrients and water they need in order to grow. When it is replaced, hydroponics carries with it many benefits and could be the way knowledge sustains itself for the next couple of centuries. From this new market, hydroponics can be viewed as a more traditional form of agriculture. Maintaining this in view is designed to create a small affordable hydroponic technique which is appropriate for urban farming. The rural regions of India witnessed a population drift during recent years owing to animal risk and low returns from the conventional cultivating system. Therefore the hydroponics business is a sheer solution for cultivating plants in limited space. Hydroponics is the method of plant

cultivation without soil using water solvent that is made of mineral nutrients. This method provides greater yield and economic returns over traditional farming methods, due to increased harvest cycles and continuous supply of nutrients. Urbanization created dense urban areas and land shortages. Hydroponic practices are controlled as a mass space and resource-saving model of agriculture and are a significant source of industrially produced products". The hydroponic system is weather, wild life, and any of the remaining biotic or abiotic factors independent. In regard to these advantages, hydroponic systems also use less and efficient water utilization.



Hydroponics Farming

The basic concept of a hydroponic farm is substituting soil with water. Solutions are placed in the water for readily available nutrients for a good harvest. The solutions in water that may be added include phosphorus, nitrogen, calcium, potassium, and many more, depending on the plants one is growing.

Advantages of Hydroponics

There are many advantages to a hydroponic vegetable garden. They can be utilized to correct problems without taking up too much space or water, are reported to grow vegetables with very high nutrient levels, and grow vegetables faster than traditional methods. It seems all but certain that this form of agriculture will be a primary source of fruits and vegetables in the future. There are not a lot of basic elements that make up a successful hydroponic farming system.

Fresh water

Plants prefer water that is very purified and filtered, and kept at pH 6-6.5. There are various solutions on the market that can be purchased over the counter to keep the desired pH balance, which will depend on the crop being cultivated.

Oxygen

Just like the soil, the plant's roots are also looking for oxygen. To avoid drowning the plants, the water needs to have enough air bubbles when first added. This can be regulated with an air stone or air pump.

Root support

Even though they're not fighting their way through soil in a hydroponic agriculture system, plant roots need something to hold onto for some form of structure and support. The most popular substrates employed for this purpose are vermiculite, perlite, peat moss, coconut fiber, and rockwool.

Nutrients

Necessary minerals all plants love are magnesium, potassium, calcium, phosphorus, and nitrogen. In traditional agricultural systems, these would be introduced via compost, mulch, or mineral fertilizers. But in hydroponic systems, these are added directly into the water to provide an adequately balanced solution. Keep in mind that your "plant food" mixture might affect the pH of your water, so keep this in mind when planning your hydroponic farm.

Light

Naturally, plants need light to survive and flourish. Various plants need various Daily Light Integrals - the amount and quality of light needed. Indoor growing will likely necessitate a purchase of specialized lighting supplies.

Use of Hydroponic Systems

Hydroponic agricultural systems possess several advantages compared to field crops raised on soil. Some of these advantages you may realize from a hydroponic farm include:

Grow indoors

Hydroponics is usually grown indoors, and that has some advantages of its own, the first one being the ability to control a number of factors of the environment with very-refined precision. Once these optimised conditions for growth are set up and in motion, the plants have nothing to fear but to grow fast, sturdy, and healthy.

Nutrient solution and control

In such systems, plants are fed with solutions of nutrients dissolved in water, which gives the hydroponic farmer full control of the nutrient delivery and administration frequency. This not only

makes the system more resource-efficient, but also decreases plant energy spent looking for nutrients since it is taken in directly. The result is faster-growing, healthier plants

Healthier plants

Hydroponics eliminates the risk of soil-based diseases. They also do not compete with weeds since they will not be able to reproduce if they were never seeded into the system in the first place.

Increased growth

They grow 30-50% faster on hydroponic farms than on soil. This soilless cultivation of plants is due to the reduced environmental stress (they're usually grown indoors), and optimized delivery of water and nutrients to the plant. With plenty of water and nutrients, the plant won't be so concerned about survival, so it can focus its energy on growing fast instead.

If planted in soil, roots need to travel a distance to find water, so the plants need to be planted at a certain distance from each other. This does not happen with hydroponic farming, thus these soilless systems take much less space compared to their traditional counterparts.

Greater yields

Because plants are grown closer together than in soil-based production systems, hydroponic farms are more productive per square foot than almost any other form of farming. And because they are grown indoors, any and all kinds of crops can be produced throughout the year. Weather constraints are virtually a thing of the past, so hydroponic farms are literally lean, mean, production machines.

Water reservoir conservation

80% of water that is used in the USA for consumption is dedicated to irrigation of field crops. It is so high due to the fact that most of the water is wasted - it's not taken in by the root and ends up flowing into groundwater (if soil is good and permeable). Hydroponic systems use 10 times less water as it is provided in a controlled and very efficient method.

Types of hydroponic system

The growing practice for each crop type can be different, i.e., the hydroponic system. If you are choosing among the various hydroponic systems, then you should be aware of the fundamentals of that system in order to make a choice. Following is a brief overview of some of the hydroponic systems:

Wick system



The nutrient solution is forced from the reservoir up the growing tray and into plant roots by the capillary action of the wick. The wick system is a passive system. It uses no pumps, and there are no moving parts. This hydroponic system is by far the easiest type of Hydroponic system. The name itself reveals that the wick system operates through drawing nutrient solutions from the reservoir to the plants using the capillary action similar to a wick in the medium. And some good choices for the medium are perlite, coconut fiber, or vermiculite. The drawback is that because the wick is not able to produce a strong water flow, and nutrient solution, it is only ideal for small plants, and non-fruiting ones, like lettuce and herbs. Also, the system maintains the growing medium in a moist condition. Excess moisture makes the oxygen absorbing activities of the plant roots more challenging. The wick system is not the ideal way for hydroponic plants.

Deep Water Culture (DWC) System



How it works:

Plants are placed in a net pot and are held by a floating platform above a reservoir of water and nutrients. Plant roots are suspended and stretched into the oxygenated nutrient solution. It is an active recovery system, so there are moving parts. Of all the functional systems of hydroponic growing, this one is the simplest. All you need is a net pot, a reservoir/container, a lid, and a pump. Plants will be grown in a net pot with some growing medium. They are placed and held in position by the lid on top of the reservoir/container. Roots emerge out the net pot and draw in the nutrient solution contained in the reservoir below. An air pump aerates the water and provides roots with oxygen to breathe. That is, this system works by immersing plant's roots directly into the reservoir's highly oxygenated nutrient solution. The disadvantage of this system is that it does not accommodate large and long-growing plants. Very few plants other than lettuce thrive in this system.



Ebb and Flow System (Flood and Drain)

How it works:

The system sprays the nutrient solution over the grow tray to cover plant roots before draining off. Typically automated by a pump that is connected to a timer.

How this system

It works very much like it says. Nutrient solutions are sprayed onto the plant root system and then drain periodically. And the cycle repeats. Plants are grown in a tray/container with a growing medium. A timer is set to turn on the pump, which pushes water with nutrient solutions in a reservoir at the bottom of the tube and onto the bulk of the system.

Once the tray/container becomes full (flooded) and drenches plant roots at fixed times and water level, gravity returns the solution downward into the reservoir. By employing this system, any growing medium can be used, e.g., gravel, granular Rockwool, grow rocks, perlite, etc., as per the choice of Hydroponic gardeners.

Even then, there is always a risk of power failure, or pump and timer breakdown, causing root dryness, and water cycles are disrupted.



Nutrient Film Technique (N.F.T)



How it works:

The pump delivers the nutrient solution onto the grow tray continuously, pouring over plants. Then it goes back to the reservoir through the slightly inclined channel. No use of timer needed. This recovery and active system is a most popular hydroponic one that has been used by numerous growers in commercial horticulture. N.F.T again uses submersible pump and reusable nutrition solutions. It runs continuously passing through the solutions, hence there is no timer usage. The nutrient is pumped to the growing tray (or in a tube) and supplied to the root systems of the plants. Once the flow is at the end of the channel, it returns to the reservoir through the slight decline tube.

Nutrient Film Technique, within this system gully channels are used for growing plants, the nutrient solution keeps flowing through these gully channels. The nutrient solution is supplied to NFT channels through a pump fitted to the reservoir.

One of the advantages of the NFT is that installing the system is easy and material cost is relatively low.

There are two different types of NFT system:

Horizontal NFT System

Vertical NFT System

Aeroponic System:

Aeroponic System greatly reduces water usage in plant cultivation. In the Aeroponic System, plant roots get their nutrients and water through the aerosol mist sprayed onto them. Plant roots take oxygen from air while hanging. Aeroponic System is comparatively hard to manage but far cheaper when it comes to utilizing nutrients and water.



How it works:

Plant roots are hung in the air and are continuously misted with the nutrient solution. The interval for misting is relatively short, carried out by a timer-controlled pump. Aeroponic system is perhaps the most technologically advanced of the six mentioned. Similar to the N.F.C system, plant roots freely dangle in the air, without any growing medium. But in Aeroponics, the nutrient solution is sprayed and pumped onto the root systems continuously rather than flowing through a thin layer of nutrients by a channel. The nutrient pump is controlled by a timer, but the cycle is much shorter than in other hydroponic forms. Usually, it is a few minutes between misting intervals. Again, because the roots are open to the air, the roots will dry quickly in the event of a misting cycle break. And this system is not as inexpensive, and simple to install as other forms. Drip System:



How it works:

Drip system injects the nutrient solution through the tube and drips on plant roots through a system of drip lines. The process is usually made automatically by a timer. Drip systems may be active recovery or non-recovery system type. They are one of the most widely used hydroponic systems worldwide, particularly among commercial growers. The principles on which the system operates are rather straightforward but effective, and so is their popularity. A timer is programmed to program the submerged pump. While the timer is on, the nutrient solution is pumped and dripped into plants' bottom via a diminutive drip line. And thanks to this plant line emitter, gardeners will be able to modify the size of solution for each plant as they desire. In a drip recovery system, the nutrient solution is returned back to the tank via the drip pan. At the same time, the non-recovery system does not recover the leach-out, which is not effective, and this is utilized only frequently in the initial days of hydroponics.

However, although the recovery one may be more effective, and economical by recycling the excess solution, non-recovery one requires less maintenance because of the same reason that solution is not recycled, and therefore pH of the reservoir is not changed. By this, gardeners are able to combine pH adjusted nutrient solution within the reservoir, and leave it alone, until they wish to refill more. In between, with recovery, hydroponic gardeners have to monitor pH often. Because this is a drip system, slow drainage medium is also used such as Rockwool, coconut coir, or peat moss The negative aspect of the drippers/emitters system is the clogging, which is created by the particles from nutrients that built up in the emitter.

Dutch Bucket Grow System

As the name is representing, this system utilizes buckets to cultivate plants. These buckets may differ in size, based on the need of the grower. The bucket contains an expanding media such as vermiculite to nourish the growing plant. Plants with much bigger roots are cultivated with the assistance of the Dutch Bucket system such as tomato and cucumber. Dutch Bucket, or Bato Bucket system is certainly one of the most versatile hydroponic systems employed to cultivate a wide range of plants by hobbyists as well as greenhouse farmers. The most widely cultivated plant is tomatoes, which are well adapted to this system since it is designed to hold big, vine-type plants.



How it works:

A number of buckets are put on the bench or the ground. One plant is supposed to be in each bucket. A large reservoir contains the nutrient solution, which is pumped through the irrigation line, then drop on the plants through the emitters. The excess solution can come back to the reservoir through the drain line, or drain from the system

How much does it cost to set up a Hydroponic farm in one Acre?

Adaptation of new technology makes you more self-assured about yourself. In adapting those technologies in the farm enterprise, people generally stepped back. The reason is there is lacking accurate information about it. If you are planning to establish your dream hydroponic farm, we are here to guide you on your road to success. We will talk about those things here that take up a large part of your investment in the hydroponic farm.

Land where the hydroponic farm will establish:

Selecting where to establish your hydroponic farm is important. The land must have adequate access to electricity, water, and a local market.

Outer Structure:

The outer structure of the hydroponic farm provides a protected place to the crops. There are two types of outer structure, one is polyhouse type, and the other is the greenhouse type. Both the structure has special

Growing System:

The system of growing depends on the plant you will grow in your hydroponic farm. If you will grow crops like lettuce, kale, the NFT system would be suitable and if you will grow vegetable crops like tomato and cucumber, the Dutch bucket system would be suitable.

Temperature and Irrigation Controlling System:

Temperature control system will be having a perfect temperature for plant growth. Irrigation system will water or pumps the fertilizer solution to growing system and continuously checks the humidity. The estimated cost of setting up a hydroponic farm in India in one-acre will be around Rs. 1.45 Cr to Rs. 1.80 Cr. It is an estimated cost and can vary depending on your personal choice of equipment. A hydroponic farm of one acre can produce 90,000 to 95,000 lettuce plants which will ensure good profitability. For more specific details about Return on Investment (RoI), you can contact our customer care.

How Barton Breeze help in setup up of Hydroponic Farming System?

We at Barton Breeze are utilizing our experience, knowledge, and expertise to provide you the services that you are waiting for.

We have our professionals who offer you the best farm services.

Barton Breeze will help you find the ideal location for your farm:

As we have expanded our hydroponic business internationally, we have established a strong network of growers, marketers, and professionals who will help you find the ideal location for your hydroponic farm.

Setting up your hydroponic farm:

At Barton Breeze, we have experts who will give you hassle-free service. Your hydroponic setup price will be affordable since we believe in value for money and will make sure to build your hydroponic farm the way you want it.

Our fixed price policy will guarantee that you will not have to pay any extra price once the project is done.

We offer the installation of naturally ventilated polyhouse, climatized polyhouse, net house, and polycarbonate house.

Installation of Hydroponic Equipment:

Barton Breeze is a supplier of every big component of a hydroponic system as well as hydroponic kits. We install equipment to integrate a fully automatic hydroponic farm, the types of automated equipment we deal in are

Fertigation and dosing controllers,

Temperature and Water Sensor alarms

Temperature controller,

Humidity controller,
Reserving timer,
Priming timer,
Clock timer
Beneficial Microbes

Beneficial microbes make the world of difference when planting plants. Beneficial microbes assist plants in nutrient and water absorption, help prevent diseases, are more accessible to plants for nutrients and more. Beneficial fungi, bacteria, and Trichoderma play a vital role in crop productivity and root development and are vital to any kind of plant. The majority of such microbes are tailor-made for use with over-fed plants or high-intensity growing conditions.

Bacteria

Bacteria are the most widespread organisms on Earth, and impossible to avoid completely from your garden. Many hydroponic growers like to make their water as "sterile" as they can, so that they avoid infection with bacteria. The ideal way for house growers to avoid infection is to ADD the useful microbes first, so that they can get settled and stop pathogenic bacteria from growing instead.

Bacteria will feed on everything, primarily dead or decaying tissues of your plant roots. As colonies become larger, they begin to aggressively kill the roots of your plants, and thereby feeding their colonies more. A small quantity of bacteria, even pathogenic in nature, causes little damage to your garden. The problem lies only when colonies are not in check and allowed to expand without control.

How to Use Friendly Bacteria

Bacteria are great survivors.

They breed rapidly, and can withstand a lot of temperature, moisture, and food fluctuation. So it's really very easy to inoculate your garden with friendly species of bacteria and see them thrive. And one thing to remember is that it is not useful to add only one type of bacteria. Even beneficial bacteria may grow into large colonies large enough to cause trouble. Optimum health systems will contain an equilibrated colony of mixed positive microbes battling each other out and keeping numbers equal, so huge destructive colonies never form. A great good microbe such as Azotobacter and Azospirillum, Pseudomonas, Bacillus Subtilis supplement is Tarantula advanced Nutrients. It provides 19 types of bacteria to your system, helping to establish a strong colony of beneficial microbes. Tarantula is easy to use, and highly effective for preventing the growth of pathogen bacteria in your garden.

To use these products, you simply add the solution to your water on a regular basis.

By doing so, you are providing direct support troops to the good side, thus strengthening their army, and keeping the good side in power. So newly evolving pathogenic species that might find

their way into the rhizosphere will be swiftly eradicated by the well-established communities of beneficial microbes you have been cultivating from the very beginning. Bacteria are so essential that plants actually invite them deliberately by employing sugars. When they are provided with sugars, bacteria multiply and grow at an exponential level. So, plants synthesize sugars in the process of photosynthesis, subsequently releasing them through roots in the form of a sugary solution known as 'root exudates'. It invites bacteria to their roots.

Fungi

Fungi are fairly less abundant on this planet and estimated to be 5.1 million different kinds. This is still a huge figure, and most of them can grow on your plant's root. There are 3 categories of classification of fungal species as per your hydroponic garden;

Pathogenic or Parasitic

These types of fungi actively search out, and destroy your plants, starting with the roots. Some other pathogens infect the leaves, such as powdery mildew. Some grow within the substrate or soil such as the blue and green moulds, and some prefer to colonize within the wet habitat of the submerged rhizosphere.

Wherever they might be found, pathogenic fungi are always unwanted and should be destroyed at all expense.

Neutral

There are certain fungi that are simply neutral. They are subsisting on something your plant does not provide for them, and thus will never harm your plants, nor will they provide them with any benefit.

Beneficial or Symbiotic

Helpful fungi also thrive when your plants are healthy. This category is mostly made up of the mycorrhizae that form in the interior of plant roots to supply nutrients, in exchange for protection and a water reservoir. Both the plant and the fungi benefit from this relationship.

Mycorrhizae

Mycorrhiza actually has root (rhizae) in the name. The fungi prefer to be within the roots of plants. They're everywhere in nature, and according to the noted mycologist Paul Stamets, they form a sort of "internet for the forest". They're everywhere in and around the roots of plants throughout the forest, exchanging nutrients and water. This works to keep the forest healthy as a whole, rather than plant-by-plant.

The relationship of mycorrhizae with plants is very complicated, and something which most scientists have very closely studied over the past couple of decades. The effects of these types of fungi towards overall plant health are always very positive.

The fungi help your plants extract nutrients from the water better, and prevent the spread of disease species into the roots. Fungi have been fighting off bacteria for hundreds of years, and have devised wonderfully innovative antibacterial secretions that have gone so far as to attract the interest of pharmaceutical companies looking for answers to the rapidly growing fad of super bugs. Penicillin, the world's first antibiotic was even isolated from a fungus. This is why mycorrhizae are so useful in increasing your plants' general resistance to infection by pathogens.

How to Use Mycorrhizae

Fungi reproduce via spores, which are small fragments of fungal DNA contained within an airtight protective covering. To apply, simply sprinkle the powder on the rock wool, substrate, or exposed roots of your plants. It is advisable to perform this at an early stage of growth, and can be applied as early as the cloning process or once your seeds have germinated.

Other Fungi

Trichoderma harzianum the fungus organism may be added to anything from soil, to hydroponics and is a preventative for infection by both bacterial and fungal infection. One of the key players in strengthening the side for the plants is good microbes.

When it comes to your plants health, it is best to accept the fact early on that there is no way to keep bacteria and fungi, both good and bad, out of your garden. The best thing to do is to expect this, and take measures to boost the resistance your plants have to the pathogenic species, and boost the beneficial side.

List of beneficial microorganism for plant in hydroponic system

Genus	*Species*	Host plant
Pseudomonas	*Aeruginosa, aureofaciens, chlororaphis, corrugate, fluorescens, fulva, marginalis, oligandrum, plecoglossicida, putida, syringae*	Bean, carnation, chickpea, cucumber, lettuce, peppers, potato, radish, tomato
Bacillus	*Amyloliquefaciens, cereus, subtilis, thuringiensis*	Carrot, chrysanthemum, cucumber, lettuce, pepper, tomato
Enterobacter *Streptomyce*	*Aerogenes*	Cucumber, tomato
Gliocladium *Trichoderma*	*Catenulatum* *Trichoderma Asperellum, atroviride, harzianum, virens*	Bean, cotton, cucumber, maize, rice

Conclusion and Future Perspectives

Hydroponics is becoming mainstream fast and the optimal way of cultivating everything from flowers and food to medicine. The objective of this chapter is to discover if growing using a water and nutrient solution instead of soil will produce a healthier plant. With no molecules of unwanted material hindering a plant's roots, the nutrients are absorbed more quickly allowing the plant to grow quicker and healthier. Due to the use of a constant feeding of water and nutrients, the hydroponic plants have grown much taller and produced more leaves quicker than the plants in normal soil. The use of fertilizer at a consistent rate throughout the day helped the plants to grow at a controlled and steady rate. Hydroponics is expanding all over the world and these systems offer many new possibilities and choices for producers and consumers to enjoy high-quality productions, including vegetables with high levels of bioactive compounds. In this chapter, the big picture has been provided regarding how hydroponics can assist in enhancing such critical types of nonessential nutrients, and based on the discussion above, one could state that hydroponics can be an essential way of having highly nutritional vegetables. But hydroponics and microbial soil systems must be properly controlled and also have to be used in the correct manner with greatest respect with plant needs, soil, water, environment, farmers, and consumer safety.

Hydroponic systems also became extremely popular, both in agriculture and home gardening, because they offer many advantages over soil cultures. Hydroponic systems possess the potential

to thrive as a primary source of food production for neighborhood communities. Urban areas can experience freight containers or their equivalents emerging, holding vertical hydroponic systems and farms to cultivate hyper-local food supply chains. This will promote local food security, and provide access to high-nutrient foods to those who might otherwise not have access. Microbes help the plants to uptake nutrients and water, help in the fight against diseases; make nutrients available for plant use and so on. Information regarding the process by which beneficial organism such as bacteria fungi & actinomycetes, they also act as a biofertilizer to promote plant growth by nitrogen fixing, phosphorus fixing and some trace elements such as Z, Mo, Mn, Co,& K and also prevent damage caused by phytopathogens. In the future, hydroponics can be utilized widely in developing countries to produce crops in extreme conditions or limited areas.

References

1. Kumar, Sanjay. Director, CSIR-IHBT. Council of Scientific and Industrial Research-Institute of Himalayan Bio Resource Technology. *(Note: This is a professional title, not a typical citation. If you are citing a specific work by Dr. Kumar, please provide more details.)*
2. Barbosa, G. L., et al. "Comparison of Land, Water, and Energy Requirements of Lettuce Grown Using Hydroponic vs. Conventional Agricultural Methods." *International Journal of Environmental Research and Public Health*, vol. 12, no. 6, 2015, pp. 6879-91.
3. Resh, Howard M. *Hydroponic Food Production: A Definitive Guidebook for the Advanced Home Gardener and the Commercial Hydroponic Grower*. [1] CRC Press, 2012.
4. Lennard, W. A., and B. V. Leonard. "Comparación de Tres Subsistemas Hidropónicos Diferentes (Lecho de Grava, Técnica de Película Flotante y Nutriente) en un Sistema de Prueba Aquaponic." *Aquaculture International*, vol. 14, 2006, pp. 539-50.
5. Jones, J. Benton. *Hydroponics: A Practical Guide for the Soilless Grower*. CRC Press, 2005.
6. Bridgewood, Lucy. *Hydroponics: Soilless Gardening Explained*. Crowood Press (UK), 2002.
7. Sgherri, Cristina, et al. "Levels of Antioxidants and Nutraceuticals in Basil Grown in Hydroponics and Soil." *Food Chemistry*, vol. 123, no. 2, 2010, pp. 416-22.
8. Buchanan, D. N., and S. T. Omaye. "Comparative Study of Ascorbic Acid and Tocopherol Concentrations in Hydroponic- and Soil-Grown Lettuces." *(No journal or publisher info provided)* 2013.
9. Aires, Alfredo. "Hydroponic Production Systems: Impact on Nutritional Status and Bioactive Compounds of Fresh Vegetables." *IntechOpen*, 2017.
10. Lee, S., and J. Lee. "Beneficial Bacteria and Fungi in Hydroponic Systems: Types and Characteristics of Hydroponic Food Production Methods." *Scientia Horticulturae*, vol. 195, 2015, pp. 206-15.

CHAPTER 12

THE DAWN OF REGENERATIVE MEDICINE: CHARTING THE FRONTIERS OF STEM CELL RESEARCH

M. Isai[1], P. Subavathy[2]

[1]Assistant Professor, Department of Zoology, Seethalakshmi Ramaswami College (Autonomous), Affiliated to Bharathidasan University, Tiruchirappalli, Tamilnadu

[2]Assistant Professor, PG and Research Department of Zoology, St. Mary's College (Autonomous), Thoothukudi, Tamilnadu

Corresponding author E mail Id: mathivananisai@gmail.com, +919655354144

ABSTRACT

This review article considers whether the stem cell therapies can transform modern medicine. This seems that just about any disease may be addressed with them. Examples include neurodegenerative diseases, cardiovascular diseases, and diabetes. Methods supporting stem cell research include induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and stem cell-derived extracellular vesicles (EVs), each with specific benefits for regeneration. Moreover, it reiterates that 3D culturing and organoids signify more use towards replicating human physiology and improving drug responses while also personalizing treatment strategies. Deep learning technologies are also integrated for speeding the discovery process in the differentiation of stem cells as well as therapeutic applications. Though advancements have been made, the paper mentions challenges faced by stem cell research, including ethics and regulation issues, safety, and a need for scalable manufacturing. These barriers remain important to be overcome before reaching great therapeutic promises on stem cell-derived therapies and their safe and effective delivery in the clinic. The comprehensive analysis will also include aspects about the present and future of stem cell research too. It would be in favor of responsible practice and informed public dialogue to build confidence in this promising field.

Given this great expectation, it is in the throes of great promise to change medicine, providing promise of potential cures and treatments for a multitude of incapacitating diseases. The number of conditions that might be treated with stem cells is growing rapidly: from neurodegenerative conditions such as Alzheimer's and Parkinson's to conditions of the heart, blood sugar disorders such as diabetes, and potentially even infectious diseases like COVID-19. The rapidly changing scenario, this new avenue, is in continual need of new and in-depth exploration of the processes and methods warranted, coupled with ethical and translational pathways to be traversed, for

assuring the complete safety and efficacy of the R&D cycle for the effective clinical translation of stem cell-derived therapies.

Scientific innovations and advancements method: a machine for propelling progress

Stem-cell research stands certainly on its complex and ever-evolving methodologies each, with individual advantages for rapid advancement to offer.

Induced Pluripotent Stem Cells: The Future

The phenomenon in which already matured and differentiated cells are capable of being reprogrammed into pluripotent stem cells (iPSCs) has shaken the foundations of regenerative medicine. Hence it proved a much better alternative to the ethical dilemmas involved in the use of ESCs derived from blastocysts, in capturing one more way to cell therapy in regenerative medicine. There is hope that iPSCs will herald a new era and promise much more for personalized medicine by enabling studying disease mechanisms at an individual level and creating patient-specific therapies. For instance, these iPSCs derived from cancer patients can be used to create an in vitro model of the tumors from which the patient has come, thus providing a platform for studying cancer development and predicting individual reactions to chemotherapy. Such an approach could actually spell an overhaul of the way cancer treatment is viewed and given to tailor specific therapies based on unique genetic makeup in each individual.

Mesenchymal Stem Cells (MSCs): Regenerative Versatility

Mesenchymal stem cells (MSCs) are multipotent stem cells that exhibit remarkable immunomodulatory and regenerative properties . They have the ability to differentiate into a variety of cell types, including bone, cartilage, and fat cells. They secrete bioactive factors that enhance tissue repair while reducing inflammation MSCs are currently being studied in many conditions, including cartilage damage, corneal disorders, and autoimmune Their intrinsic immune modulating properties are particularly attractive for treating autoimmune diseases, in which the immune system erroneously attacks the patient's tissues.

Cell-Free Therapy: Stem Cell-Derived Extracellular Vesicles (EVs)

in increasingly known developments that have now been tagged with the miraculous rights of stem cell-derived EVs such as exosomes that mediate cell-to-cell communication and tissue regeneration in translational research Cell-free regenerative medicine offers EVs, avoiding problems associated with the direct application of cells such as immune rejection and tumor formation. A cutting-edge approach that informs the use of these cell-derived vesicles promises potential avenues for therapeutic molecule delivery toward target tissues, hence promoting repair and regeneration without using live cells.

3D Culturing and Organoids: Mimicking Human Physiology

A development which newly states advances in biomaterials and 3D culture techniques is organoids. Organoids are miniaturized and simplified versions of Organoids serve as good models to study development, study disease, and test drug responses. For example, rectal cancer organoids can predict responses to chemoradiation in patients, paving the way for personalized treatment strategies. This very technology can indeed be a powerful tool in studying human biology and disease in a controlled and reproducible manner.

Deep Learning Applications: Accelerating Discoveries

Indeed, deep learning is becoming one of the important and effective ways for developing stem cell data and predicting differentiation outcomes. The potential of convolutional neural networks (CNNs) can be extended further toward the prediction of neural stem cell differentiation and quantification of sarcomere structure organization in cardiomyocytes . Through these AI-driven mechanisms, research accelerates and stem cell-based therapies become much more efficient with the ability to automate some of the more complex data analyses and spot subtle patterns that may remain hidden to humans.

Clinical Applications in Regenerative Medicine: Healthcare Transformation

Stem cell research is rapidly translating into clinical applications and therapeutic interventions for what were previously considered untreatable diseases.

Cardiovascular diseases: Repairing the damaged heart tissues.

Stem cell-based therapies clearly target cardiovascular diseases such as heart failure and myocardial infarction. Nanomedicines and engineered tissues have displayed promise in cardiac regenerative capabilities (Christman & Lee, 2006). Researchers are working on using MSCs and cardiac progenitor cells toward damage-repairing and restoring of cardiac function in the heart.

Neurodegenerative Disorders: Neural Repairtage

Much nautical therapeutic prospects remain with neural stem cells as therapeutic tools for the treatment of diverse neurological disorders including Alzheimer and Parkinson diseases. Deep learning models can predict as well as optimize neural stem cell differentiation for these applications. Scientists come together to integrate their efforts bargaining for the development of strategies, whereby neural stem cells will be transplanted within the brain so that repair and re-establishment of normal neural function happen.

Diabetes: Restoration of Insulin Production

Stem Cell Therapy, in principle, can provide the means with a potentially expandable and scalable resource of pancreatic beta cells for the treatment of type 1 diabetes. The aim of these therapies is restoration of endogenous insulin production, thus nullifying the need for exogenous insulin administration. They are working on generating functional beta cells for iPSCs and their transplantation into diabetic patients.

Pulmonological Injuries: Healing of the Damaged Lungs

Stem cell technologies are being incorporated in chest medicine for purposes like drug discovery, cell-based therapy for diseases such as COPD and cystic fibrosis, and development of functional lung tissues that can be transplanted Some researchers are engaged in developing means of repairing damaged lung tissues and how to restore lung function using stem repair cells.

Osteoarthritis: Cartilage Regeneration

Stem cells have recently been researched as a valuable method in regeneration of the articular cartilage and treatment of osteoarthritis . Also, research on animal mesenchymal stem cells is giving directions for the future of cartilage regenerative medicine. Researchers are studying using MSCs for stimulating cartilage repair and relieving pain and inflammation in osteoarthritis patients.

Conditions of the Cornea in Restoring Vision

Because of the regenerative potential and immunomodulatory features, mesenchymal stem cells (MSCs) are currently studied as an alternative therapeutic approach for the treatment of corneal injuries, infections, and degenerative diseases. Studying MSCs application for the repair of cornea damage and restoring eyesight will help normalize patients with corneal diseases.

The Challenges and Future Directions: The Road Ahead

Although there has been considerable progress, stem cell research is fraught with many hurdles that should be addressed in realizing its full therapeutic potential.

Ethics: Responsible Research

Ethics in stem cell research come into play, especially with embryonic stem cells and the possibility of building human tissues and organs. It is important to establish a clear regulatory framework and ethical standards to ensure responsible research practices.

Regulatory Bottlenecks: Accelerating Translation

Regulatory labyrinths make it difficult to translate findings of stem cell studies into clinical applications harmonizing the regulatory standards among different countries will help in facilitating international collaborative research.

Safety Considerations: Keeping the Patient Safe

Potential dangers are an inherent part of stem cell therapy, such as tumorigenicity, immune rejection, and off-target effects Therefore, it is necessary to conduct stringent preclinical and clinical trials to vet whether stem cell-based interventions can use those risks safely and effectively.

Manufacturing and Scalability: Making Therapies Realistic

The large-scale generation of stem cells and the products derived from stem cells still remain a challenge products and processes that are efficient on a cost-basis need to be developed for the therapies to become more widely accessible.

Fake News and Misinformation: Promoting Accurate Information

The dissemination of fake news and misinformation might shake public confidence and impede the advancement of legitimate research. It is only through accurate and transparent communication that the public will remain informed about the possibilities and limitations of stem cell therapies .

Referecnes

1. Angermueller, Christoph, et al. "Deep Learning for Computational Biology." *Molecular Systems Biology*, vol. 12, no. 7, 2016, p. 878.
2. Caplan, Arnold I. "Mesenchymal Stem Cells: Cell-Based Therapeutics at the Dawn of a New Frontier." *Tissue Engineering Part A*, vol. 23, no. S1, 2017, pp. S1-218-S1-228.
3. Caulfield, Timothy, and Ubaka Ogbogu. "Stem Cell Hype and Misinformation: Time for a Public Education Campaign." *BMC Medicine*, vol. 11, 2013, p. 271.
4. Clevers, Hans. "What Are Organoids and Why Are They Important?" *EMBO Reports*, vol. 17, no. 6, 2016, pp. 688-92.
5. El Andaloussi, Samir, et al. "Extracellular Vesicles: Biology and Emerging Therapeutic Opportunities." *Nature Reviews Drug Discovery*, vol. 12, no. 5, 2013, pp. 347-57.

6. Hyun, Insoo, et al. "Anticipating Stem Cell Ethics: Origins, Assumptions, and Trajectories." *Nature Reviews Genetics*, vol. 9, no. 6, 2008, pp. 452-58.
7. Joyce, N. C., et al. "Mesenchymal Stem Cells for Corneal Repair." *Progress in Retinal and Eye Research*, vol. 31, no. 6, 2012, pp. 723-40.
8. Laflamme, Michael A., and Charles E. Murry. "Regenerating the Heart." *Nature Biotechnology*, vol. 29, no. 3, 2011, pp. 226-33.
9. Lindvall, Olle, and Zaal Kokaia. "Stem Cell Therapy for Human Neurodegenerative Disorders—How to Make It Work." *Nature Medicine*, vol. 21, no. 4, 2015, pp. 392-96.
10. Loh, Y. H., et al. "Generation of Induced Pluripotent Stem Cells." *Nature Protocols*, vol. 5, no. 4, 2010, pp. 703-07.
11. Murphy, J. M., et al. "Stem Cell Therapy in a Caprine Model of Osteoarthritis." *Arthritis & Rheumatism*, vol. 48, no. 12, 2003, pp. 3464-74.
12. Pagliuca, Felicia W., et al. "Generation of Functional Human Pancreatic β Cells in Vitro." *Cell*, vol. 159, no. 2, 2014, pp. 428-39.
13. Sipp, Douglas, et al. "How Public Perceptions Influence Stem Cell Research and Governance." *Nature Biotechnology*, vol. 26, no. 1, 2008, pp. 13-17.
14. Takahashi, Kazutoshi, and Shinya Yamanaka. "Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors." *Cell*, vol. 126, no. 4, 2006, pp. 663-76.
15. Trounson, Alan, et al. "Clinical Trials of Stem Cell Therapies." *BMC Medicine*, vol. 7, 2009, p. 52.
16. Weiss, David J., et al. "Stem Cells and Lung Regeneration: A Consensus Statement." *Proceedings of the American Thoracic Society*, vol. 8, no. 3, 2011, pp. 293-304.
17. Yamanaka, Shinya. "Induced Pluripotent Stem Cell (iPSC) Research: Past, Present, and Future." *Cell Stem Cell*, vol. 10, no. 6, 2012, pp. 678-84.
18. Zakrzewski, Wojciech, et al. "Stem Cells: Potential Applications in Regenerative Medicine and Disease Treatment." *Stem Cells International*, vol. 2019, 2019, p. 9628307.

CHAPTER 13

BIOACTIVITY PROFILING OF ETHANOL EXTRACT FROM *SANTALUM ALBUM* FOR ANTICANCER APPLICATIONS

Dr Arun Kumar G [1], Dr T Vinotha [2], Ms Abirami [3]

Assistant Professor, Department of Microbiology

Hindusthan College of Arts & Science, Coimbatore

ABSTRACT

This research was designed to determine the phytochemical components and characteristics of the hexane fractionof *Santalum album* Linn. Gas chromatography mass spectrometry (GC-MS) analysis revealed the presence of total number of 4 compounds from the hexane fraction of *Santalum album* Linn. Leaves. This study showed that *Santalum album* Linn. Leaves are a potential source of natural bioactive compounds for biological and pharmacological applications and revealed the presence of bioactive compounds that differ from each territory. The hexane fraction was analyzed using GC–MS, which showed the presence of many biologically important volatile constituents. The compounds were identified by comparing their retention time with that of literature and by interpretation of mass spectra. The quantitative estimation of each peak was made by estimating area of the peak bycomputer attached to GC-MS instrument.

Keywords: *Santalum album* linn., fraction and Gas chromatography mass spectrometry (GC-MS).

INTRODUCTION

Medicinal plants have played an essential role in the development of human culture in religious and various otheroccasions. Plant products are important gift of nature to human being and these are the best sources of medicinalcompounds since ancient times. Uses of naturally occurring drug molecules are better than synthesized ones with respect to cost and purity as well. One of the earliest developments in this field is the isolation of aspirin from plants. Among the earliest pure compound obtained was salicin, isolated from the bark of the white willow *Salix alba*. Paclitaxel (taxol) is a natural product derived from the Yew tree and used in chemotherapy. India has been the major source and traditional leaderof sandalwood and sandalwood oil production which is used in perfumery and pharmaceutical industries[1]. Sandalwood (*S. album* Linn.) is known as

'Royal tree' belongs to the family Santalaceae. A small evergreen glabrous tree with slender drooping branches the sapwood white and odorless. The heartwood is yellowish brown and strongly scented[2]. *S. album* and *Pterocarpus santalinus* have been mentioned along with their medicinal properties and therapeutic uses[3]. Sandal safed is a small, evergreen tree with slender and drooping branches reaching up to 40 feet in height and 3 feet in girth. Leaves are thinand opposite. Flowers are dark brown, violet, or reddish in colour. Fruits are black having single seed, appear in bunches. The underground part of the stem is whitish and odourless while the middle part of it is somewhat yellowish and strongly scented[4].

SCIENTIFIC CLASSIFICATION

Phylum	:	Spermatophyta
Sub Phylum	:	Angiospermae
Class	:	Magnoliopsida
Order	:	Santalales
Family	:	*Santalaceae*
Genus	:	Santalum
Species	:	Album
Botanical name	:	*Santalum album* Linn

Sandalwood is mainly used as coolant, and also showed sedative effect. Sandalwood is also useful as disinfectant in genitourinary and bronchial tracts, diuretic, expectorant and stimulant. The sweet powerful odor makes sandalwood oil useful in perfume industry. The same is also used as tonic for heart, stomach liver, anti-poison, fever, blood purifier and for memory improvement. Several uses mentioned in Ayurveda system about sandalwood are in the treatment of various other ailments like diarrhea with bleeding, intrinsic hemorrhage, bleeding piles and vomiting, poisoning, hiccoughs, initial phase of pox, urticaria, eye infections and inflammation of umbilicus[5,6].

Fig. 1: ***Santalum album*** **Linn leaves**

EXPERIMENTAL WORK

Material and method

For the present study we have chosen the *Santalum album* leaves. The plant materials were collected from from a local nursery in Coimbatore and have been grown. The authentication of plants has been done by Dr. R. Gopalan (Rtd. Scientist) BSI Coimbatore. The leaves were separated from dried pods by crumbling and then screening. The dried leaves were blended using a blender and stored in a clean glassware container until needed for analysis.

Preparation of extract

Leaves powders (2kg) were extracted with ethanol. Powder of *Santalum album* is taking in round bottom flask and deep in 3 liter ethanol for 15 days then use distillation method to prepare extract of *Santalum album* in ethanol. The distillation process is continuing for some days. The solvent was recovered under vacuum to afford thick liquid. It was again fractionated by different solvents in increasing order of polarity viz. hexane, benzene, ethyl acetate and chloroform. The ethanol extract was again analyzed by TLC technique using different solvent systems.

RESULTS AND DISCUSSION

The oily fractions of *Santalum album* leaves which were obtained from the separation of ethanol extract were separated by GC-MS technique. The fraction revealed the presence of 30 compounds in the form of chromatograms as followings

Figure 1: GC Chromatogram of Hexane Fraction (RC-01) of Ethanol Extract

The quantitative estimation of each peak was made by estimating area of the peak by computer, attached by GC-MSinstrument. The results of GC-MS analysis are reported below in Table 1.

Table 1: Showing Compounds, Retention Times and Area % from GC-MS Analysis

Peak no.	**Retention time**	**Peak area**	**Peak %**	**Name of compounds**	**Molecular Formula**	**MW**
1	9.31	5721735.05	0.93	Propylecosanoate	$C_{20}H_{40}O_2$	354.6
2	19.89	124931714.53	20.31	Ethylhexadecanoate	$C_{18}H_{36}O_2$	284.6
3	28.94	21764327.63	1.35	Icosane	$C_{20}H_{40}$	282
4	32.86	12510083.76	0.44	Dotriacontanoic acid	$C_{32}H_{64}O_2$	480.8

IDENTIFICATION OF COMPONENTS

The retention index is calculated for all volatile constituents using a homologous series of *n*-alkanes and other classes of compounds. The components of oil were identified by matching their mass spectra with those stored in the computer librarysuch as Wiley, NewYork mass spectral (MS) library and their retention indices (RI) either with authentic compounds or with published data in the literature[7-10]. Some of the identified compounds obtained from above analyzed fractions of *Santalum album* leaves are named and deduced as- Propylecosanoate, Ethylhexadecanoate, Icosane

and Dotriacontanoic acid.

RC-01, R.Time 9.31







m/z 199





m/z 284.6

Molecular Formula = $C_{18}H_{36}O_2$

Ethylhexadecanoate
(Hexadecanoic acid, ethyl ester)

$-C_3H_6O_2$



m/z

157

Mclafferty rearrangement

RC-01, R.Time 28.94


RT: 28.38 - 29.54 SM: 7G
RT: 28.94
NL:
1.55E7
TIC MS
ICIS
RC-01-
28.63
28.81
29.07
29.22
29.32
29.48
Relative Abundance
Time (min)


RC-01- #7038 RT: 28.94 AV: 1 AV: 5 SB: 12 7031-7036 7040-7045 NL: 7.49E5
T: + c EI Full ms [50.000-1000.000]
281.1
419.4
522.7
597.8
700.4
831.3
906.2
981.8
Relative Abundance
m/z



RC-01, R.Time 32.86



CONCLUSION

We prepared extract of *Santalum album* leaves using various solvents and analysed by GC-MS. By GC-MS spectrum we obtained several compounds having different peaks. By analyzing and fragmentation patterns of the peaks we confirmed 4 compounds. These compounds are expected to show medicinal activities. As the world is moving towards herbal medicine due to

its safety and efficacy, this work is a conventional approach to discover new drugs for different diseases. Further, pharmacological and toxicity studies should be conducted on the same to explore the exact mechanism of action as well as sub-acute and chronic toxicities if any.

REFERENCES

1. Fox, J.E. "Sandalwood: The Royal Tree." *Biologist (London)*, vol. 47, 2000, pp. 31-34.
2. Benencia, F., and M.C. Courreges. "Antiviral Activity of Sandalwood Oil Against Herpes Simplex Viruses 1 & 2." *Phytomedicine*, vol. 6, no. 2, 1999, pp. 119-23.
3. Ghani, N. *Khazainul Advia*. Aijaz Publishing House, 2007, pp. 932-33.
4. Kamal, S. "Untitled." *World Journal of Pharmacy and Pharmaceutical Sciences*, vol. 3, no. 8, 2014, pp. 21-35. *(Note: Please provide the article title for this entry.)*
5. Brunke, E.J. "Cyclosantal and Epicyclosantalal - A New Sesquiterpene Aldehyde from East Indian Sandalwood Oil." *Flavour & Fragrance Journal*, vol. 10, 1995, pp. 211-19.
6. Desai, V.B. "Pharmacological Screening of HESP and Sandalwood Oil." *Indian Perfumer*, vol. 35, no. 2, 1991, pp. 69-70.
7. Hendre, A.S., et al. "Phytochemical Composition of Methanolic Extract of Pomegranate Flower Petals by GC-MS Analysis." *International Journal of Pharmaceutical Sciences Review and Research*, vol. 35, no. 1, 2015, pp. 201-02.
8. Revenkar, G.D., and D.P. Sen. "Combination of Capillary GC, GC/MS and 13C-NMR for the Characterization of the Rhizome Oil of *Piper betle* L. (Piperaceae) from Vietnam." *Journal of Oil Technologists' Association of India*, vol. 10, no. 4, 1978, pp. 156-60.
9. Santhakumari, P., et al. "Modulation of Oxidative Stress Parameters by Treatment with *Piper betle* Leaf in Streptozotocin Induced Diabetic Rats." *Indian Journal of Pharmacy*, vol. 35, 2003, pp. 373-78.
10. Sharma, M.L., et al. "Combination of Capillary GC, GC/MS and 13C-NMR for the Characterization of the Rhizome Oil of *Piper betle* L. (Piperaceae) from Vietnam." *Proceedings of the 11th International Congress of Essential Oils, Fragrances and Flavours*, 1989.

CHAPTER 14

ADVANCING GLOBAL HEALTH AND SUSTAINABILITY THROUGH BIOLOGICAL SCIENCE, BIOTECHNOLOGY, AND NANOBIOTECHNOLOGY

Charan Kumar H C [1] and Shilpa.R[2]
[1]Department of Chemistry, P.E.S. College of Engineering Mandya-571401
[2]Department of Chemistry, Manasagangotri, University of Mysore, Mysuru-570006

ABSTRACT

Nanotechnology, a revolutionary field, enables the manipulation of materials at the nanoscale (1–100 nm), offering enhanced properties for applications across multiple disciplines. The convergence of nanotechnology with biological sciences has given rise to biotechnology and nanobiotechnology, driving significant advancements in healthcare, agriculture, industry, and environmental sustainability. Biotechnology utilizes biological systems, genetic engineering, and biochemical processes to develop essential medical, agricultural, and industrial products, including vaccines, genetically modified crops, biofuels, and enzyme-based bioprocesses. Meanwhile, nanobiotechnology integrates nanomaterials with biological systems, leading to breakthroughs in targeted drug delivery, biosensors, precision diagnostics, and nano-enabled environmental remediation. The unique size-dependent properties of nanomaterials, such as high surface-to-volume ratios and quantum effects, enhance their reactivity and interaction with biological systems, making them invaluable in medical therapies, sustainable agriculture, and pollution control. Additionally, advances in nanotoxicology and green nanotechnology aim to mitigate potential risks associated with nanomaterial exposure, ensuring safe and sustainable applications. Collectively, these fields bridge the gap between molecular biology, nanoscience, and engineering, fostering innovations that address global challenges, including disease prevention, food security, industrial sustainability, and environmental conservation. Their interdisciplinary integration is poised to revolutionize modern science, paving the way for a more efficient, sustainable, and technologically advanced future.

Keywords:

Nanotechnology, Biotechnology, Nanobiotechnology, Nanoscale, Gene Editing, Drug Delivery

Introduction:

Nanotechnology is a ground breaking field that enables the development of materials with enhanced properties, applicable across diverse sectors. It involves the precise study, manipulation, and control of materials at the Nano scale, typically ranging from 1 to 100 nanometres. As a science of the infinitesimally small, nanotechnology encompasses various

interdisciplinary domains, including Nano-biotechnology, Nano-chemistry, Nano-physics, Nano-medicine, Nano-engineering, and Nano-science. Nano-science specifically focuses on the study of atomic and molecular structures at this minuscule scale, where one nanometre equates to 10^{-9} meters. To put this into perspective, the width of a human fingernail spans approximately ten million nanometres.The convergence of nanotechnology with biology has given rise to a multitude of applications that significantly benefit science, industry, and economic development. Biological materials, including microorganisms and enzymes, play a crucial role in various bioprocess applications. However, inherent limitations such as poor mechanical and chemical stability necessitate advanced technological interventions. Biotechnology, as a discipline, leverages biological entities such as organisms, their components, and genetically modified variants to engineer valuable products and processes. Through genetic engineering, the modification of an organism's genetic material enables the enhancement of desirable traits, facilitating the production of essential biomolecules, including enzymes, antibiotics, and vaccines. The applications of biotechnology extend across multiple sectors, including healthcare, agriculture, the food industry, environmental remediation, and biofuel production. An emerging interdisciplinary field, bionanotechnology, integrates biological molecules with nanomaterials to enhance their functional efficiency, leading to the development of bio-hybrid, self-assembled, and advanced materials. In contrast, nanobiotechnology applies nanotechnological tools and nanodevices to decipher biological processes and molecular structures. Although the terms are often used interchangeably, bionanotechnology primarily focuses on utilizing biological systems to enhance nanomaterial applications, while nanobiotechnology employs nanotechnology to understand and manipulate biological systems. Together, these fields bridge the gap between nanotechnology and biotechnology, driving innovation in medicine, environmental science, and industrial applications, ultimately revolutionizing modern scientific advancements.

Principles of biological sciences and Nanobiotechnology

The principles of biological sciences establish a comprehensive framework for understanding life and its intricate processes. Cell theory serves as a cornerstone, asserting that all living organisms are composed of cells the fundamental units of life and that new cells originate from pre-existing ones through cellular division. Gene theory further elucidates the molecular basis of inheritance, demonstrating how genetic information encoded in DNA governs cellular functions and is transmitted across generations. The mechanisms of evolution and natural selection drive biodiversity, equipping species with adaptive traits that enhance survival in dynamic environments. Organisms uphold homeostasis, finely regulating internal conditions to maintain equilibrium and ensure optimal physiological performance. A profound interconnection exists between structure and function in biological systems, exemplified by the aerodynamic design of birds for flight or the specialized shape of enzymes for catalytic activity. Life is sustained by energy flow and metabolism, where organisms harness and convert energy through biochemical pathways such as photosynthesis and cellular respiration. At the ecological

level, interactions between organisms and their surroundings shape biodiversity, fostering complex ecosystems governed by ecological balance and interdependencies. The principles of growth and development direct the transformation of living beings across their life cycles, guided by genetic blueprints that dictate morphological and physiological changes. Reproduction and inheritance drive species propagation, ensuring genetic variation through the transmission of hereditary traits. Furthermore, the ability to respond to stimuli and adapt to environmental changes enables organisms to modulate behavior and physiology in response to external factors. Collectively, these principles form the bedrock of biological sciences, facilitating the exploration of life from the molecular to the ecological scale. Nanobiotechnology, an advanced interdisciplinary domain, bridges nanotechnology and biological sciences to engineer nanoscale materials and devices with transformative applications in medicine, agriculture, and environmental science. Central to this field is the unique size-dependent properties of nanomaterials, characterized by an exceptional surface-to-volume ratio, which enhances their reactivity, bioavailability, and interaction with biological systems. The integration of biocompatibility and bio functionality ensures the seamless interaction of nanomaterials with cells and tissues, often achieved through surface functionalization with biomolecules for targeted therapeutic and diagnostic applications. Drawing inspiration from nature, nanobiotechnology harnesses self-assembly and biomimicry, where nanoscale structures emulate biological architectures for superior functionality and efficiency. The field also capitalizes on quantum and optical properties, paving the way for ground breaking innovations in bioimaging, sensing, and diagnostics, such as the deployment of quantum dots for fluorescence-based detection. Targeted drug delivery and controlled release systems revolutionize precision medicine by utilizing nanocarriers to transport therapeutic agents directly to diseased tissues, mitigating side effects and enhancing treatment efficacy. Despite these advancements, the field necessitates rigorous scrutiny through nanotoxicology and risk assessment to mitigate potential cytotoxic and environmental hazards associated with nanomaterial exposure. Furthermore, biosensors and nanoscale diagnostic platforms facilitate ultra-sensitive disease detection and real-time imaging, augmenting early diagnostic capabilities and medical interventions. Emphasizing sustainability and green nanotechnology, researchers are developing eco-friendly synthesis methodologies to minimize ecological impact while simultaneously addressing pollution control, water purification, and environmental remediation. As a rapidly evolving discipline, nanobiotechnology is poised to revolutionize biomedicine, biotechnology, and environmental science, offering pioneering solutions to some of the most formidable challenges in healthcare, industry, and sustainability.

Difference between Biological Science, Biotechnology, and Nanobiotechnology

Aspect	Biological Science	Biotechnology	Nanobiotechnology
Definition	The study of living organisms, their structure, function, evolution, and interactions.	The application of biological systems, organisms, and processes for technological advancements.	The integration of nanotechnology and biotechnology to manipulate biological systems at the nanoscale.
Focus Area	Understanding life processes at molecular, cellular, organismal, and ecological levels.	Developing technologies using biological components for industrial, medical, and agricultural applications.	Designing nanoscale materials and devices for biomedical, diagnostic, and environmental applications.
Key Principles	Cell theory, genetics, evolution, metabolism, ecology, and homeostasis.	Genetic engineering, fermentation technology, biopharmaceuticals, and bioinformatics.	Nanoparticle synthesis, targeted drug delivery, biosensors, quantum effects, and biocompatibility.
Applications	Medicine, ecology, microbiology, genetics, zoology, botany, and physiology.	Production of vaccines, biofuels, genetically modified organisms (GMOs), and tissue engineering.	Drug delivery systems, nanomedicine, biosensors, cancer therapy, and environmental remediation.
Tools & Techniques	Microscopy, DNA sequencing, spectroscopy, and bioinformatics.	CRISPR gene editing, fermentation, bioprocessing, tissue culture, and recombinant DNA technology.	Nanoparticle synthesis, quantum dots, nanocarriers, plasmonic imaging, and nano-biosensors.

Scale of Study	Macroscopic to microscopic levels (molecules to ecosystems).	Molecular and cellular levels, often involving genetic and biochemical modifications.	Nanoscale (1–100 nm), focusing on interactions of biomolecules with nanomaterials.
Relation to Other Fields	Broad field that includes biotechnology, ecology, genetics, and microbiology.	Interdisciplinary field overlapping with molecular biology, engineering, and medical sciences.	Subset of both nanotechnology and biotechnology, applying nano-concepts to biological processes.

Summary

- **Biological Science** is the broadest field, focusing on understanding all aspects of life.
- **Biotechnology** applies biological knowledge to develop new technologies and products.
- **Nanobiotechnology** combines nanotechnology and biotechnology to manipulate biological systems at the nanoscale for advanced applications like drug delivery, biosensors, and nanomedicine.

Applications of Biological Science, Biotechnology, and Nanobiotechnology

The multifaceted applications of biological science, biotechnology, and nanobiotechnology extend across diverse disciplines, profoundly transforming healthcare, agriculture, industry, and environmental sustainability. Biological science serves as the cornerstone for unraveling the complexities of life, driving revolutionary advancements in medicine, genetic research, and ecological conservation. It plays a pivotal role in disease pathology, enabling the development of next-generation antibiotics, precision vaccines, and regenerative medicine techniques that enhance human health. In agriculture, biological science facilitates genomic innovations and microbiome engineering, leading to improved crop resilience, enhanced soil fertility, and sustainable food production systems. Furthermore, it contributes to ecosystem restoration and climate resilience by supporting biodiversity conservation, carbon sequestration strategies, and bioremediation of environmental pollutants. Biotechnology, leveraging molecular biology and genetic engineering, has transformed medicine through cutting-edge innovations such as CRISPR-based gene editing, personalized therapeutics, and synthetic biology, revolutionizing disease treatment and prevention. The advent of Genetically Modified Organisms (GMOs) has led to bioengineered crops with superior yield potential, pest resistance, and nutrient fortification, addressing global food security challenges. In the industrial sector, biotechnology is catalyzing sustainable biomanufacturing, leading to the production of biodegradable polymers, bio-based fuels, and enzymatic catalysts that replace conventional fossil-based

materials, significantly reducing environmental footprints. Moreover, it plays a crucial role in bioremediation technologies, where engineered microbes and enzyme-based systems degrade toxic pollutants, purify wastewater, and mitigate oil spill contamination, ensuring ecological restoration. Nanobiotechnology, an interdisciplinary fusion of nanotechnology and biological sciences, has redefined the landscape of modern medicine, diagnostics, and environmental engineering. In nanomedicine, targeted drug delivery systems utilizing smart nanocarriers enable site-specific therapeutic interventions, minimizing adverse effects and maximizing efficacy. The integration of gold and silver nanoparticles in photothermal therapy provides a high-precision approach to cancer treatment, selectively eradicating malignant cells with minimal damage to healthy tissues. Nano-biosensors revolutionize early disease detection and real-time health monitoring, enhancing diagnostic accuracy for conditions such as oncological, neurodegenerative, and metabolic disorders. In agriculture, nano-enhanced fertilizers and precision-targeted pesticides optimize nutrient uptake and pest control while minimizing ecological disruption. Nano-enabled smart packaging extends food shelf life, ensuring global food security. From an environmental perspective, nanotechnology-driven water purification systems facilitate advanced filtration and heavy metal sequestration, mitigating water contamination crises. Additionally, nanobiotechnology fosters the development of bio-nano solar cells, hydrogen fuel cells, and next-generation green energy solutions, propelling the shift towards sustainable energy landscapes. Collectively, the synergy of these transformative fields is reshaping scientific frontiers, pioneering breakthrough innovations that tackle global health disparities, food insecurity, industrial sustainability, and environmental degradation. As these domains continue to evolve, their interdisciplinary integration is poised to unlock unprecedented solutions to some of humanity's most pressing challenges, heralding a new era of scientific and technological excellence.

Impact of Biological Science, Biotechnology, and Nanobiotechnology on Society

Biological sciences provide the foundation for understanding life, driving advances in medicine, agriculture, and environmental conservation. Breakthroughs in **genetics, microbiology, and immunology** have led to **personalized medicine, vaccines, and gene therapies.** In agriculture, **CRISPR and genetic engineering** improve crop yield and resilience. Additionally, biological science supports **biodiversity conservation, climate change mitigation, and ecosystem restoration** through **bioremediation and synthetic biology.** Biotechnology applies biological principles to **healthcare, food security, and industry,** enabling innovations like **mRNA vaccines, gene therapy, and regenerative medicine. GM crops** enhance **nutritional value, pest resistance, and climate adaptability,** ensuring food security. In industry, biotechnology **reduces fossil fuel dependency** through **biofuels, bioplastics, and enzyme-based processes,** promoting a **circular bioeconomy** and sustainable industrial solutions. Nanobiotechnology merges nanotechnology with biology, leading to **advanced drug delivery, biosensors, and environmental applications. Nanocarriers improve targeted therapy** with fewer side effects, while **gold and silver nanoparticles aid cancer treatment. Nano-biosensors enhance disease**

detection, and **nano-fertilizers and pesticides optimize agricultural productivity.** Additionally, nanotechnology **revolutionizes water purification, pollution control, and renewable energy,** supporting global sustainability efforts. These fields collectively address global challenges such as disease outbreaks, food shortages, and environmental degradation. Biological sciences provide fundamental knowledge, biotechnology applies this knowledge for practical solutions, and nanobiotechnology refines these applications at the molecular level. Together, they enhance human health, ensure food security, and promote a cleaner environment, paving the way for a sustainable and technologically advanced future.

Conclusion

Biological science, biotechnology, and nanobiotechnology collectively drive innovations in healthcare, agriculture, industry, and sustainability. Biological science provides fundamental knowledge, biotechnology applies it for advancements like GMOs and biopharmaceuticals, while nanobiotechnology enhances precision in medicine, diagnostics, and environmental solutions. Their integration addresses global challenges, ensuring a healthier, sustainable, and technologically advanced future.

Reference:

1. Abidalhussein, Hassanain Jwad, et al. "Principles and Applications of Nano-Biotechnology." *International Journal of Research in Applied*, vol. 10, no. 5, 2022, pp. 1-10.
2. Singh, A. P., et al. "Targeted Therapy in Chronic Diseases Using Nanomaterial-Based Drug Delivery Vehicles." *Signal Transduction and Targeted Therapy*, vol. 4, 2019, pp. 1-21. doi:10.1038/s41392-019-0068-3.
3. Mishra, A., et al. "Silica Based Bio-Hybrid Materials and Their Relevance to Bionanotechnology." *Austin Journal of Plant Biology*, vol. 6, no. 1, 2020, p. id1024.
4. Boyer, H. *Biotechnology: Principles and Processes*. National Council of Educational Research and Training, 2016.
5. Niemeyer, C. M., and C. A. Mirkin. *Nanobiotechnology: Concepts, Applications and Perspectives*. Wiley, 2004.
6. Shahcheraghi, Nikta, et al. "Nano-Biotechnology, an Applicable Approach for Sustainable Future." *3 Biotech*, vol. 12, 2022, p. 65.
7. Adeel, M., and H. M. N. "Graphene and Graphene Oxide: Functionalization and Nano-Bio-Catalytic System for Enzyme Immobilization and Biotechnological Perspective." [1] *International Journal of Biological Macromolecules*, vol. 120, part B, 2018, pp. 1430-40.

8. Barani, M., et al. "Nanotechnology in Ovarian Cancer: Diagnosis and Treatment." *Life Sciences*, vol. 266, 2021, p. 118914.
9. Campbell, Neil A., and Jane B. Reece. *Biology*. 11th ed., Pearson Education, 2017.
10. Glick, Bernard R., and Cheryl L. Patten. *Molecular Biotechnology: Principles and Applications of Recombinant DNA*. ASM Press, 2017.
11. Bhushan, B. *Springer Handbook of Nanotechnology*. Springer, 2017

CHAPTER 15

LICHENS AS SOURCE OF BIOACTIVES - EXPLORING THEIR PHARMACEUTICAL ROLE IN PERSONALIZED DISEASE MANAGEMENT

Ms.S.Abirami[1], Dr.N.Hemashenpagam[2] , Dr.T.Vinotha[3] and Dr. Arunkumar G[4]
Assistant Professor, Department of Microbiology, Hindusthan College of Arts & Science, Coimbatore
Corresponding Author E-mail : abirami.s@hicas.ac.in

ABSTRACT
Lichens, symbiotic associations of fungi and photosynthetic partners, have emerged as a rich and under-investigated source of bioactive secondary metabolites with great pharmaceutical promise. The natural compounds from lichens display various biological activities, like antioxidant, anti-inflammatory, antimicrobial, anticancer, and antidiabetic activities. Over the last few years, breakthroughs in pharmacognosy, molecular biology, and systems pharmacology have stimulated interest in lichens as new potential candidates for inclusion in drug discovery pipelines. This chapter explores the diversity of lichens, their importance, and their therapeutic significance. As personalized medicine and pharmacogenomics gain prominence, the incorporation of lichen-derived bioactives into tailored treatment regimens has the potential to revolutionize the field. Genetic heterogeneity among individuals is a key determinant of drug metabolism, efficacy, and safety. Thus, the knowledge of lichen compounds' genetic profile interaction can open the door to patient-specific and targeted therapies.

Introduction

Lichens, the symbiotic relationship of fungi and algae are significant members of most ecosystems. Symbiosis is responsible for the formation of distinct secondary metabolites, called lichen compounds, which are produced within the thalli and are usually present in crystal structures on the external surface of the fungal hypha. Lichens and secondary metabolites have been gaining attention lately for their nutritional and pharmaceutical properties. Lichens can develop on a variety of surfaces from rocks to epiphytes on leaves or trees. Most lichens described are terrestrial, but some are marine and can tolerate water and salt stress. These metabolites may be fungal-derived, algal-derived, or novel compounds not synthesized by fungi or algae alone. Secondary metabolites have provided a broad variety of interesting compounds with biological activities ranging from antimicrobial to anticancer. In addition, the nutritional quality of lichens is recognized along with a function in environmental monitoring, and some commercialized products based on lichens are found.

Approximately 800 metabolites from lichens are known and new ones are discovered occasionally. The secondary metabolites of lichens are distinct from those of higher plants. The biological activity of lichen is primarily attributed to the occurrence of secondary metabolites

within them. Their therapeutic potential is yet to be fully explored and hence remains pharmaceutically unexploited. This is indeed because of the challenges faced in the identification of species and bulk collection. The slow growth of lichen in axenic culture is the biggest challenge for the easy availability of the desired metabolite. However, the culture conditions of the mycobiont can be optimized to produce interesting secondary compounds.

These days, lichens are utilized for numerous various medicinal applications worldwide. Numerous products based on lichen extracts are provided by numerous firms in the international market Numerous reviews have addressed the pharmaceutical potential and biological activities of lichen compounds In India, *Parmelia chinese* is used as a diuretic, as a liniment for headaches, and is used in powdered form to cure wounds, while the Tinea (ringworm) like disease is cured with *Parmelia sanctiangeli*. *Usnea longissima* is used as an antioxidant or a naturally occurring antitumor agent. The ethnic aspect of the uses of lichens by different communities has been researched in the past. In the past few decades, medicinal plant research has drawn significant interest all over the world. Plants possess a plethora of secondary metabolites like tannins, terpenoids, alkaloids, flavonoids, etc. which are found to be exhibiting antimicrobial activity in vitro. The application of plant extracts and phytochemicals with established antimicrobial activity is of immense importance, over the last few years various studies have been carried out globally to establish antimicrobial activities from medicinal activities. In the past, most of the world's medicine has been obtained from plants. Natural product chemistry started with Serturner's work, where he isolated morphine from Opium for the first time. This, in turn, was yielded by opium poppy (*Papaver somniferum*) through methods that have been in vogue for more than 5000 years. Most such similar innovations followed. Quinine from Cinchona tree took its origin from the royal courts of the South American Incas. Before the arrival of the first European explorers, the indigenous populations in the Americas had created sophisticated medical systems full of diagnosis and treatment of physical, as well as spiritual, diseases. Salicin in *Salix alba* which on oxidation was metabolized to salicylic acid is the active compound in aspirin which for centuries has been utilized as an efficient painkiller and an antipyretic. Medicines like aspirin, vincristine, vinblastine, cocaine, digitoxin, and morphine are also extracted from plants.

Industrial and medicinal significance of lichen

In India, many species of lichens are extensively used in traditional systems of medicine. The use of lichens in commercial, ethnobotany, and Ayurvedic and Unani systems of medicine in India is well documented. The most significant application of lichens is in traditional medicine for the treatment of animal and human diseases. Sodium usnate has been successfully used for the control of various plant diseases in the greenhouse . *Ramalina thrausta* is used in Finland for the treatment of wounds, athlete's foot, or other skin diseases and is taken to relieve sore throat and toothache . Two lichen species *Parmelia caperata* and *Umbilicaria sp*. are reported in a study of Chilean traditional medicine. There are numerous species of lichens, that have been

used in folk medicine to cure stomach diseases, diabetes, whooping cough, and pulmonary tuberculosis, and for the treatment of cancer and skin diseases.

Usnea species in Asia, Africa, and Europe are used for pain relief and fever control , and in New Zealand Maori traditionally for nappies and sanitary pads. Usnea densirostra, known as "barba de la piedra" served as a cure for various disorders in Argentina . Usnea has been used as antibiotics (Sharnoff,). *Usnea longissima* is reported to have been used as a dermatological aid for dressing wounds in the Pacific Northwest. Ethnobotanical uses of Usnea include its use as aromatic in health recipes in Darjeeling and Sikkim Himalayas. *Cetraria islandica* is an ancient cough remedy known as "tonicum amarum" accepted as a mucilage drug (Muller). Such metabolic products that are antibiotic in activity may even encompass the role of shielding the organisms from being attacked by other fungi. The intestinal worms are treated by *Flavoparmelia caperata* and dried powder of the thallus can be applied to burns. A blue dyeing matter from the fermentation of lichens, litmus, was used in the coloring of both textile and beverages. Preparations of some species of lichens, for example, *Evernia prunastri* are constituents of perfumes (Trease & Evans,). Lichens are used as a nutritional feed for many animals and humans during famine throughout the ages and getting colors, perfumes, alcohol, and in the medicine industry . Litmus paper strips impregnated with the dye, which was water extract from the *Roccella sp.*, have been in use as a pH indicator since ancient times and until today in laboratories. They are also used as deodorants, herbal coloring, dyes, and decorative materials for the production of clothes, and perfumes and also as a bioindicator for determining atmospheric pollution. Lichen dyes had considerable economic importance in the 18th century in some parts of the world as in the Canary Islands. It is also known that the Romans colored their togas with orchil, a purple pigment from *Roccella sp.,* and crottal, a brown pigment from *Parmelia ochrolechia* and *Evernia sp* . In many systems of traditional medicine around the world (Richardson, 1991) including the Indian system of medicine, lichen species are reported to be effective in curing disorders like dyspepsia, bleeding piles, bronchitis, scabies, stomach disorders, and many blood and heart disorders (Saklani and Upreti,; Negi and Kareem,).

Spectral analysis of lichens

The detection of active principle compounds in different samples of plants is done based on techniques such as TLC, LCMS, and GCMS analysis. Earlier Manojlovic (2010), established the HPLC method for the characterization of xanthones and anthraquinones from extracts of lichen *Laurera benguelensis*. Lichexanthone, secalonic acid D, norlichexanthon, paretin, emodin, telochistin, and citreorosein were thus identified by relative retention time and spectral information calculated yellow and new dark red pigments obtained from *Lethariella sernanderi*, *L. cashmeriana* and *L. sinensis* as antioxidant constituents. The yellow pigment was found to be canarione (1), and the rest were found to be 1,2-quinone derivatives, rubrocashmeriquinone (2) and 7-chloro rubrocashmeriquinone (3), and 7- chlorocanarione (4) based on their spectroscopic data analysis. described the bioactive principle compound, fatty acid derivative as methyl 6, 7-dithia stearate of *Wrightia tomentosa* by mass spectrum WTEF24 analysis. Bangajaualli and

Ramasuhramanian (2015), investigated and identified potential 16 bioactive components of ethanol bark and 24 components from the leaf of *Aglaia elaeagnoidea* based on GCMS analysis. Identified compounds exhibited antioxidant, antitumour, analgesic, anti-inflammatory, and antimicrobial activity. Two significant bioactive compounds i.e. squalene and phytol thereby discovered to exhibit chemopreventive activity against colon carcinogenesis and active against various stages of arthritis respectively.

Lichen bioactive compounds agents against various disease-caused pathogens

Lichen symbiosis possesses variety of secondary bioactive compounds and has many biological activities as reported earlier by Ingolfsdosttir *et al*., who used lichen species such as *Stereocaulon alpinum*, *P. aphthos* and *Thanolia subeliformis* for isolation of metabolites such as atranorin, tenviorin, methyl β-Oreseltinate, methyl orsellinate and ethyl-orsellinates and assessed for their biological activities. Their study suggests that among these compounds, β-orsellinate, methyl, and ethyl orsellinates showed good activity against the gram positive and gram-negative bacteria. Turk *et al*. investigated the antimicrobial efficiency of Cetraia aculeate and isolated protolichensteric acid and found that acetone, diethyl ether, and ethanol extract were effective against *E.coli, S. aureus, Aeromas hydrophilla,Proteius vulgaries, S. faecali, B. substilis, P. aeruginosa,* and *Listeria monocytogenes. Cereutraria aculeate* was not effective on the fungal pathogen and protolichesterinic acid was more effective against *E.coli, B.substillis, P. aeruginosa,* and *L. Moncytogenes*. Yilmaz *et al*. determined the antimicrobial potential of secondary metabolites of *C. foliacea* against bacteria and fungi and found that usnic acid, atranorin, and fumarprotocetratic acid found to be active against *S. aureus, B. cerues, B.subtilis, S. faecalis, Proteus vulgaris, Listeria monocytogenes, Aeromonas hydrophila, C.glabarata* and *C. albicans.* Candan *et al*. evaluated the antimicrobial study using the compounds obtained from *P. sulcata* and found that salazinic acid obtained in acetone, chloroform, diethyl ether, methanol, and petroleum ether extracts was effective against 28 food-borne pathogens and especially very effective against P. aeruginosa and S.typhimurium evaluated the antibacterial activities of lichen acids extracted from fruticose lichens. They used 63 lichens including *U. baileyi, R. dendriscoides, Stereocaulon massartianum* and *C. gracilis*, and the crude extracts obtained were tested against gram positive and gram negative bacteria using paper disk diffusion assay. Dharmadikari *et al*., successfully isolated fungal partners of the lichens, cultured and found despides, atranorin and depsidone, salazinic acid in natural lichen as well as in isolated mycobiont. Sisodia *et al*., investigated potential compounds and the antibacterial, and antioxidant potential of *R. roseleri* by using individual solvents with hexane, acetone, methanol, and water. They found that among these four solvents, hexane extract revealed potential antioxidant activity and comprise susptibility to S. aureus and Streptococcus, against isolated compounds such as atranorin, protolichenosteric acid, usnic acid, 2hydroxy-methoxy-6propyl benzoic acid, homoskikaic acid, sekikaic acid, benzoic ,2,4- dihydroxy-6propyl and 2,4-dihydroxy-3,6-dimethy benzoate. An extensive literature survey indicates that lichens are a good source of pharmaceutically important secondary metabolites and can be utilized to cure various pathogenic and

physiological disorders in humans. Hence, an attempt has been made to study the biological activity of some lichens for bioprospecting lichens for human welfare.

Methodology for determination of antimicrobial and antioxidant activity of lichen extracts

The lichen samples can be identified using directions outlined in British Lichen Society's communication. Each sample is examined for their morphology, anatomy, colour test, thin-layer chromatography, etc. The key to macro lichens (Awasthi, 1988) and key to micro lichens (Awasthi, 1991) are often referred to while identifying genus and species. Isolation of the lichen constituents are typically followed as per procedure. Kirby and Bauer disk diffusion technique (National Committee for Clinical Laboratory Standards, 1993) is commonly employed to find out the antimicrobial activity of lichen extracts against test bacteria and fungi. Determination of extracts' MIC can be performed by the aforesaid method. It is typically computed in the case of the test bacteria alone that display antimicrobial activity after the agar diffusion method. Minimum inhibitory concentrations (MICs) are determined by ascertaining inhibition zones developed. Bioautographic assay of lichen compounds is normally carried out by the technique described by Occasionally, the bioautographic assay is conducted after compound separation in thin-layer chromatography. MICs are established when a specified amount of extract of lichens is applied on silica gel thin layer chromatography (TLC) plates and the TLC plates are developed in three solvent systems commonly used in the TLC of lichen compounds. Solvent system A contained a mixture of toluene/dioxane/ glacial acetic acid (36:9:1 v/v), the solvent system B contained hexane/diethyl ether/formic acid (24:18:4 v/v), the solvent system C contain toluene/ glacial acetic (20:3 v/v) TLC. It is defined by comparing its Rf values with varying solvent systems to the ones provided in the literature and its melting point. Numerous methods and modifications have been proposed to evaluate antioxidant activity and to explain how antioxidants function, of these total antioxidant activity, reducing power, DPPH assay, metal chelating, ROS quenching assays are commonly used for the evaluation of antioxidant activities of extracts.

The lichen extracts can be specifically analyzed for antioxidant activity using five different assays: DPPH radical scavenging, reducing power, total phenolic compounds determination, and total flavonoid content determination. Various antioxidant activities of the test extracts are examined compared to reference antioxidants like ascorbic acid, butylated hydroxyanisole (BHA) butylated hydroxytoluene (BHT), and α- tocopherol. These procedures have been used for decades with minor alterations. The free radical scavenging activity of fractions is quantified in vitro using 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay. But generally, Ascorbic acid and BHT are taken as references. DPPH radical scavenging activity is calculated by the following formula:

DPPH radical scavenging activity (%) = $\frac{[(\text{Abs control} - \text{Abs sample})]}{}$

(Abscontrol)×100

where Abs control is the absorbance of DPPH radical + methanol; Abs sample is the absorbance of DPPH radical + sample extract /standard.

The (Oyaizu) method was employed for the determination of the reducing power of extracts.

Determination of the total antioxidant activity (FRAP assay) in the extract is performed using a modified method by (Benzie and Strain). The total phenolics content is determined using Folin and Ciocalteu's phenol reagent which reacts based on the chemical structure of phenolics (i.e. the more the number of functional –OH groups the more the total phenolics content). For the determination of total soluble phenolic compounds in the lichen extracts Folin- Ciocalteu reagents are utilized following the method of Slinkard and Slingleton. Total phenol content is described in the form of mg/g tannic acid equivalent by the following equation developed from the calibration curve: $y = mx+c$, and determination of R^2 ,where x was the absorbance and y was the tannic acid equivalent (mg/g). Quantification of the total flavonoids in the plant extracts was performed according to the method of The total flavonoid content was expressed as quercetin equivalent/mg by the following equation from the calibration curve: $y = mx+c$, and finding R^2 where x is the absorbance and was the quercetin equivalent/mg. The antioxidant capacity total by the phosphomolybdenum method as in the total antioxidant capacity of turmeric oil, and its various fractions are assessed by the method of (Prieto *et al*.). An assay of antioxidant capacity is also done by the colorimetric assay as Trolox equivalent antioxidant capacity (TEAC).

Synergistic activity of lichen with plant extracts

Along with the determination of plant extracts' antimicrobial and antioxidant activities, research has also been extended far across the globe on the synergistic activities of plants along with other plants or antibiotics. Synergism, that is, when the combined effect is much higher than the sum of the both effects. Numerous studies have been conducted on the useful role of bioactive plant extracts and isolated pure compounds in enhancing the in vitro activity of commonly employed antibiotics against a range of microorganisms, these studies have documented the application of plant extracts with antibiotics, with a notable decrease in the minimum inhibitory concentrations of the antibiotics. The combined extracts of black thyme (Thymbra spicata L), fennel (Foeniculum vulgare Mill), sage (Salvia pilifera), wild tea (Stachys pumilia) and wild mint (Micromeria fruticosa.L) were highly active against pathogenic bacteria and lactic acid bacteria. The synergistic activity of tea with different antibiotics against enteropathogens was documented. Tea extract possessed synergistic action with chloramphenicol as well as with other antibiotics such as gentamycin, methicillin and nalidixic acid towards test strains.

The synthesis of ethanolic extracts from the plants *Mentha longifolia*, *Melissa officinalis* and *Rosa damascena* exhibited synergistic antibacterial activity against MRSA (methicillin resistant

Staphylococcus aureus) strains (Bassam *et al*.,). Synthesis of *Vangueria spinosa* with doxycycline and ofloxacin against gram positive and gram negative bacteria was also experimented. Synergism between 13 antimicrobials and plant extracts i.e. "guaco" (Mikania glomerata), guava (*Psidium guajava*), clove (*Syzygium aromaticum*), garlic (*Allium sativum*), lemongrass (*Cymbopogon citratus*), ginger (*Zingiber officinale*), "carqueja" (*Baccharis trimera*) and mint (*Mentha piperata*) against Staphylococcus aureus strains were observed, studied herb-drug interaction between tea extract and penicillin G against *Staphylococcus aureus* and exhibited additive interactions. proved that propolis extract combinations with clarithromycin and Zingiber officinale with clarithromycin were able to control *Helicobacter pylori* related to gastroduodenal disease. Sibanda and Okoh (2008) established synergy potentials of acetone extracts of Garcinia kola seeds with amoxicillin, ciprofloxacin, tetracycline and chloramphenicol against microorganisms responsible for disease. Balanites aegyptiaca (L) Del. (Balanitaceae), Hyptis sauveolens Poit (Lamiaceae), Lawsonia inermis L. (Lathyraceae), Leucas aspera L. Lamiaceae, Nicotianae folia Roth.ex. Roem and Schult (Lobileaceae) and Phyllanthus madraspatana (Euphorbiaceae) treated separately and combined for the antimicrobial activity against five various diarrhaegenic bacteria and established that there is a potential to develop antimicrobial agent by combinations of plants and antibiotics.

Researches were conducted, to develop a novel cost effective antimicrobial drug for multi drug resistant organisms, from the synergistic action of tetracycline with methanolic extract of Tectona grandis . Salvadora persica has several medicinally useful properties such as abrasives, antiseptics, astringent, detergents, enzyme inhibitors and fluoride , Eight years after this study, examined Salvadora persica, the same medicinal plant of distinction for its antimicrobial action with two antibiotics viz., penicillin and tetracycline against Staphylococcus aureus alone and in combination (synergistic), exhibited their synergistic action much more potent. The maximum inhibition was observed (31.5 mm) when S. aureus was treated with tetracycline along with Salvadora stem extract, also investigated the combined application of ethanolic leaf extracts of Vangueria spinosa Roxb. (Rubiaceae) and antibiotics (doxycycline and ofloxacin) against Gram-positive bacterium (Staphylococcus aureus) and three Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa and found synergistic effects in all the cases except against *P. aeruginosa*. Varthemia iphionoides had MIC value of 0.03mg/ml against ATCC strains of *Staphylococcus aureus*, *Bacillis subtilis*, *S. epidermidis* and 4.0mg/ml against E. coli, V. iphionoides and Cefotaxime was tested synergistically and it was observed that FIC (Fractional inhibitory concentration against *B. subtilis* (ATCC 6633) and S. aureus was 0.75 to .0875mg/ml but FIC against *E. coli* and *S. epiderdimis* 2.5 to 16.4mg/ml. *Parmotrema pseudotinctorum* has been screened alone and in combination with honey for antimicrobial and antioxidant activity but the combination was not as good as scavenging potential of single lichen extracts. The bacteria i.e. *Escherichia coli*, *Staphylococcus aureus* and *Pseudomonas aeruginosa* were tested for sensitivity against the lichen extracts, honey and their combination using agar well diffusion method. Even in antibacterial assay *Parmotrema pseudotinctorum* and *Ramalina hossei*

extracts showed eminent antibacterial activity separately compared to their combination with honey. Therefore, combination of honey and lichen extracts was not found to have any synergistic effect.

Antimicrobial and antifungal activity of *Lawsonia inermis*, *Punica granatum* and *Hibiscus sabdariffa*, again their synergistic effect by blending plant extracts with antibiotic was conducted. The *Punica granatum* methanolic extract had maximum antibacterial activity particularly against *Staphylococcus aureus*, whereas, *Klebsiella pneumoniae* and *Escherichia coli* were the least sensitive to it, the combination of antibiotics with plant extract exhibited synergistic antibacterial activity particularly with Ciprofloxacin and Erythromycin against *Pseudomonas aeruginosa*, and *Staphylococcus aureus*, respectively. Combination of Ketoconazole and Fluconazole drugs with aqueous *Hibiscus sabdariffa* extract was very potent. Antifungal Nystatin exhibited increased activity when combined with plant extract studied the antimicrobial activity of acetone methanol and aqueous extracts of lichens of *C. furcata, P. caperata, P. pertusa, Hypogymnia physodes* and *Umbilicaria polyphylla* against gram-positive bacteria and gram-negative bacteria and fungal organisms viz. *A. flavus, A. fumigatus, Botrytis cinerea, Candida albicans, F. oxysporum, Mucor mucedo, Paecilomyces variotii, Penicillium purpurescences, Penicillium verrucosum* and *Trichoderma harzianum* by disc diffusion and MIC by broth tube dilution method. Acetone and methanol extracts of lichens *P. pertusa, H. physodes* and *U. polyphylla* suppressed growth of all tested microorganisms. Methanol extracts were most active in general against the test organisms; the minimum MIC value was found for acetone extract of species *C. furcata* - 0.39 mg/ml against the bacterium *Bacillus subtilis*. Water extracts of studied lichens were inactive against all tested organisms. determined the in vitro antimicrobial activity of aqueous and ethanol extracts of lichens *Peltigera polydactyla* and *Ramalina farinacea* against various bacterial species *Escherichia coli*, *Pseudomonas aeruginosa*, *Bacillus subtilis*, *Klebsiella pnuemoniae*, *Staphylococcus aureus* and *Staphylococcus epidermisdis* by MTT method and concluded that ethanol extracts had higher antimicrobial activity compared to aqueous extracts.

The crops are susceptible to criticism based on the etiology of disease due to pathogens such as fungi, mycoplasma, bacteria, and actinomycetes. The reasons are some specific fungal phytopathogens that cause some specific diseases in some specific plants. Hence, production of crops becomes decreased economically in the commercial sector. Chemically available preventers such as fungicides, bactericides etc., can be applied for disease reduction but application of chemical fungicides are not beneficial in various respects such as resistance breakdown, expense, residual issue and also non-target organism impact (Cown, and Poornimal and Sarathambal,). The bio-control activity of lichens P. tinctorum, P. grayanum and *P. praesorediosum* through food poisoning method against the diseases of anthracnose caused by phytopathogen Colletotrichum capsici and noted inhibition of the mycelial growth. The Parmotrema tinctorum showed excellent potential inhibitory activity. assessed fungicidal activity of acetone, methanol and chloroform extracts of foliose lichen; *F.carperata* against phytopathogenic fungi. *A. niger, A. flavus, F. oxysporum, F. solani*, using disc diffusion assay and

MIC determination proved that acetone and methanol extract showed greatest zones of inhibition at MIC 12.6mg/ml and 12.0mg/ml respectively. Again, evaluated fungicidal potential of acetone, methanol and chloroform extracts of foliose lichen *H. leucomelos* against phytopathogenic fungi A.niger, *A. flavus, F. oxysporum*, Using disc diffusion assay and MIC determination, acetone and methanol extract inhibited solani and Colletotrichum falcatum with the largest zone of inhibition at MIC 12.3mg/ml and 24.6mg/ml respectively. The in vitro antimicrobial properties of P. andinum extracts with varying solvents such as 2-propanol, methanol, petroleum ether, acetone and water against pathogenic fungi and bacteria were tested by disc diffusion technique and identified 2-propanol extract has good antibacterial activity against the *Cyanobacterium rubrum, S.typhimurium* and *P.aeruginosa* and also fungi *T. lignorum, A. niger and F.moniliforme*.

Conclusion

Lichens are a largely unexploited but pharmacologically diverse source of bioactive metabolites with vast potential in contemporary drug discovery. Their diverse secondary metabolites exhibit promising therapeutic activity against a variety of chronic and complex diseases. As medicine evolves toward precision and personalization, the combination of lichen metabolites with pharmacogenomic data creates new opportunities for personalized disease treatment. By synchronizing the therapeutic opportunity of lichens with genomics, systems biology, and personalized medicine advancements, this chapter highlights the importance of natural products in the context of precision medicine. However, conversion of lichen bioactives to clinical leads necessitates a multidisciplinary approach, including rigorous validation of bioactivity, safety profiling, and correlation with pharmacogenetics. The future should aim at bridging ethnobotanical information, molecular pharmacology, and genomic information to release the complete pharmaceutical potential of lichens inpatient- and target-directed therapy.

Reference

1. American Diabetes Association. "Economic Costs of Diabetes in the U.S. in 2023." *Diabetes Care*, vol. 47, no. 1, 2024, pp. 103-15.
2. Arumugam, G., et al. "A Review: Anti Diabetic Medicinal Plants Used for Diabetes Mellitus." *Journal of Acute Disease*, vol. 2, no. 3, 2013, pp. 196-200. https://doi.org/10.1016/S2221-6189(13)60126-2.
3. Babiah, P. S., et al. "Assessment of Fungicidal Potential of Lichen Heterodermia Leucomelos (L.)Poelt Against Pathogenic Fungi." *Current Research in Environmental and Applied Mycology*, vol. 5, no. 2, 2015, pp. 92-100.
4. Balaji, P., et al. "In Vitro Antimicrobial Activity of Rocella Montagnei Thallus Extract." *Journal of Tropography Medicinal Plants*, vol. 7, no. 2, 2006.

5. Boulton, A. J. M., et al. "Diabetic Neuropathy: A Review." *Journal of Diabetes Research*, 2023, Article ID 523456.
6. Fernandez-Moriano, C., et al. "Antioxidant Potential of Lichen Species and Their Secondary Metabolites. A Systematic Review." *Pharmaceutical Biology*, vol. 54, no. 1, 2016, pp. 1-17.
7. Nayaka, S. "Methods and Techniques in Collection, Preservation and Identification of Lichens." *Plant Taxonomy and Biosystematics: Classical and Modern Methods*, 2014, pp. 101-05.
8. Nayaka, S., and D. K. Upreti. "Status of Lichen Diversity in Western Ghats, India." *Sahyadri E-News, Western Ghats Biodiversity Information System - Issue XVI*, 2005. http://wgbis.ces.iisc.ernet.in/biodiversity/newsletter/issue16/main_index.htm.
9. Pandey, K. B., and S. I. Rizvi. "Plant Polyphenols as Dietary Antioxidants in Human Health and Disease." *Oxidative Medicine and Cellular Longevity*, vol. 2, 2009, pp. 270-78. https://doi.org/10.4161/oxim.2.5.9498.
10. Zhang, Y., et al. "An Investigation of the Anti-Diabetic Effects of an Extract from Cladonia Humilis." *Pakistan Journal of Pharmaceutical Sciences*, vol. 25, no. 3, 2012, pp. 509-12.

Edited Book Volume-1

"NEW APPROACHES IN BIOLOGICAL SCIENCES AND BIOTECHNOLOGY"

Dr. M. Thiruselvi
Dr. M. Santhoshkumar

ACTA CLASSIC
PUBLISHER